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Re´sume´ vulgarise´ pour le grand public
L’immense majorite´ des cellules de notre corps comporte la meˆme information ge´ne´tique, c’est a` dire l’ensemble
des instructions ne´cessaires a` leur fonctionnement. Selon le contexte — par exemple, le type de cellule, ou
encore les signaux que celle-ci rec¸oit — diffe´rentes unite´s d’information ge´ne´tique peuvent eˆtre lues. Les infor-
mations peuvent donc eˆtre interpre´te´es diffe´remment. Les facteurs responsables de cette lecture se´lective sont
des prote´ines appele´es facteurs de transcription. Dans cette the`se, je m’inte´resse a` une famille particulie`re
de ces facteurs: les prote´ines THAP, qui sont au nombre de 12 chez l’homme. Des e´tudes pre´ce´dentes ont
sugge´re´ que ces diffe´rentes prote´ines sont capables d’interpre´ter, en e´troite collaboration avec une prote´ine
partenaire appele´e HCF-1, l’information ge´ne´tique relie´e a` la prolife´ration cellulaire et au de´veloppement. De
plus, certaines de ces prote´ines sont implique´es dans diverses maladies comme notamment certains cancers,
une maladie neurode´ge´ne´rative et un trouble rare du me´tabolisme de la vitamine B12. Ceci rend donc la
compre´hension de leur mode d’action primordiale.
Ma the`se vise a` mieux comprendre les me´canismes qui permettent aux prote´ines THAP d’interpre´ter
l’information ge´ne´tique et ainsi de re´guler la prolife´ration cellulaire. Je montre que ces prote´ines sont des
facteurs essentiels pour la re´gulation de la prolife´ration cellulaire, chacune posse´dant des fonctions et car-
acte´ristiques a` la fois communes et spe´cifiques. En outre, je clarifie les me´canismes sous-jacents a` la maladie
ge´ne´tique lie´e au trouble du me´tabolisme de la vitamine B12. De fac¸on ge´ne´rale, une meilleure compre´hension
des me´canismes normaux et pathoge´niques lie´s a` ces prote´ines est un premier pas vers une meilleure prise en
charge des maladies associe´es.
5
6
Re´sume´
Les prote´ines THAP sont des facteurs de transcription caracte´rise´es par leur domaine THAP, un domaine
de liaison a` l’ADN a` doigt de zinc tre`s bien conserve´ dans les espe`ces animales. Un nombre croissant
d’e´tudes soulignent l’importance de ces prote´ines dans la re´gulation de la transcription et de la prolife´ration
cellulaire, et leur e´troite collaboration avec HCF-1, un co-re´gulateur de transcription. L’e´mergence de ces
prote´ines ainsi que leur association avec diverses maladies humaines — comme diffe´rents cancers, la mal-
adie neurode´ge´ne´rative “dystonia 6” ou un trouble du me´tabolisme de la cobalamine — rend leur e´tude
particulie`rement importante.
Dans ce travail de the`se, j’e´tudie comment les prote´ines THAP re´gulent la transcription des ge`nes et la
proliferation cellulaire. J’utilise une approche pluridisciplinaire combinant bioinformatique, biochimie et ap-
proches mole´culaires et cellulaires, ainsi que des techniques ge´ne´tiques et ge´nomiques de pointe. Je caracte´rise
pour commencer les diffe´rentes proteines THAP dans leur ensemble avant de concentrer progressivement mon
analyse sur un nombre re´duit de prote´ines THAP.
Tout d’abord, graˆce a` des outils bioinformatiques et aux banques de donne´es disponibles, je re´ve`le com-
ment ces prote´ines ont e´volue´ au sein dans les espe`ces animales, et caracte´rise les niveaux d’expression des
ge`nes THAP chez l’homme et la souris. Ensuite, je montre que les diffe´rentes prote´ines THAP humaines
posse`dent des capacite´s distinctes d’homo- et d’he´te´rodime´risation, ainsi que de liaison avec leur partenaire
suppose´ HCF-1. Ceci sugge`re l’existence d’un me´canisme complexe de re´gulation dans lequel les diffe´rentes
prote´ines THAP ont des fonctions a` la fois communes et particulie`res. Focalisant ensuite mon e´tude sur les
deux prote´ines THAP7 et THAP11, j’utilise des ligne´es cellulaires cre´e´es sur mesure pour de´montrer que
ces deux prote´ines re´gulent la prolife´ration cellulaire. Enfin, je concentre mes efforts sur l’unique prote´ine
THAP11 et montre qu’elle se lie a` l’ADN pour re´guler des ge`nes implique´s dans le de´velopement, la pro-
life´ration cellulaire et la transcription. En outre, je clarifie les me´canismes mole´culaires a` la base du trouble
cobalaminique associe´ a` une mutation du ge`ne THAP11.
Les re´sultats obtenus dans cette the`se caracte´risent les facteurs de transcription THAP comme d’importants
re´gulateurs de la prolife´ration cellulaire, chacun posse´dant des fonctions communes et spe´cifiques. Une
meilleure compre´hension des me´canismes normaux et pathoge´niques sous-jacents aux fonctions de ces prote´ines
est un pre´-requis pour une meilleure prise en charge des maladies associe´es.
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Abstract
THAP proteins are animal-specific transcription factors, which share the THAP domain, an evolutionary
conserved zinc-finger DNA-binding domain. Growing evidence implicates THAP proteins as broad transcrip-
tional and proliferation regulators, working hand in hand with the HCF-1 transcription co-regulator. The
emergence of THAP proteins and their association with diverse human diseases — such as several cancers,
the dystonia 6 neurodegenerative disorder or a subgroup of cobalamin disorder — make them ripe for detailed
exploration.
In this thesis work, I clarify how THAP proteins can regulate gene transcription and subsequent cell
proliferation. I use a multidisciplinary strategy combining bioinformatics, biochemistry, molecular and cellular
approaches, as well as state-of-the-art genetic and genomic techniques. I start by studying the whole set of
THAP proteins using bioinformatics tools and gradually concentrate my analysis to smaller subsets of human
THAP proteins for wet-lab experiments.
To begin with, using bioinformatics tools and available data, I shed light on the evolution of THAP
proteins among animal species, and unravel the pattern of expression of human and mouse THAP genes.
Then, I show that human THAP proteins possess differing potentials for homo- and heterodimer formation,
and for binding to their putative HCF-1 partner. This suggests possibilities for an intricate THAP-protein
regulatory network in which THAP proteins exhibit both shared and specific functions. Further focusing the
scope of my analysis on the THAP7 and THAP11 proteins, I demonstrate that both proteins regulate cell
proliferation using custom engineered THAP7 and THAP11 cell lines. Finally, I concentrate my efforts on
THAP11 and show that it associates to DNA to regulate genes involved in development, cell proliferation and
transcription. Particularly, I clarify the molecular mechanisms underlying the THAP11 cobalamin disorder-
associated mutation.
The results developed in this thesis implicate the THAP transcriptional factors as important regulators of
development and cell proliferation, each of them likely exhibiting shared and specific functions. Sheding light
on the normal and pathogenic mechanisms of the THAP proteins is therefore a first step towards managing
their associated diseases.
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Chapter 1
Introduction
This study explores some of the mechanisms of cell-proliferation regulation via the control of gene expression.
1.1 General principles
To better understand this research thesis, I review of some general principles of cell proliferation, gene
expression and genome organisation. The goal is not to be exhaustive but to illuminate some key points that
will be important for understanding the present study.
1.1.1 Cell proliferation in mammalian cells
Cell proliferation is a fundamental process by which cells reproduce themselves by growing and then dividing
into two daugther cells. This process is key in development by which multicellular organisms are generated
from a single cell. In addition, in adult organisms, cell proliferation is also essential as probably every organ
has the ability to regenerate (abeit to very different extents), either a normal state (e.g. the skin) or upon
damage (e.g. the liver).
Cells reproduce themselves by a series of highly conserved and coordinated events called the cell cycle,
which has been divided into four phases in eukaryotic cells (Figure 1.1). In the presence of growth signals,
resting cells can pass a “restriction point” late in the G1 phase, thereby becoming committed to progress
through the cell cycle. DNA duplication takes place in S phase (S for Synthesis), which typically requires
10 to 12 hours. In M phase, which is much shorter (about one hour), nuclear division first takes place with
chromosome segregation (mitosis), followed by cell division (cytokinesis). The two “gap phases”, named G1
and G2, have two majors functions. First, they allow sufficient time to synthesize the requisite proteins
and organelles for cell growth in G1. Second, they ensure the satisfaction of different checkpoints along the
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Figure 1.1: The eukaryotic cell cycle. [1]
progression through the cycle, to guarantee that the previous step have been performed properly and thus
that the conditions are favourable to pursue the cycle. Finally, cells in early G1 phase can either go into
another round of cell cycle, or exit the cell cycle and enter a resting state, called G0, in which they can stall
for hours, days or even a lifetime [1].
Cell-cycle progression is tightly regulated. Central proteins in this regulatory system are cyclins and
their partners, the cyclin-dependent kinases (CDKs). While CDK concentrations stay quite constant, cyclin
concentrations oscillate along the cell cycle as the result of the gene transcription and protein degradation.
More generally, control of the transcription of cell-cycle-related genes provides an important layer of regulation
of cell proliferation [1].
1.1.2 Regulation of transcription in eukaryotes
Most cells in our bodies possess an identical set of genetic information. Yet, different cell types exhibit
different patterns of gene expression to perform their specialized functions. A given cell can also alter the
expression of its genes depending on the conditions (e.g. nutrient availability, proliferation signals). To do so,
eukaryotes have acquired highly sophisticated regulatory mechanisms, in particular for gene transcription,
which is the first step of gene expression.
General aspects of gene-transcription regulation
Diverse classes of proteins interplay and positively or negatively impact transcription (Figure 1.2).
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Sequence-specific DNA-binding transcription factors directly bind DNA regulatory elements (e.g. en-
hancers, promoters) in a sequence-specific manner and can activate, or repress, the transcription of the
corresponding gene. They also recruit other proteins, named as transcription co-factors, that do not directly
bind DNA but further contribute to the activation or repression of transcription. Often, one transcription
(co-)factor can participate in either activating or repressing transcription depending on the other partners in
the regulatory complex.
In the nucleus, the DNA is highly compacted and the first level of compaction is the nucleosome, which is
an octamer of two of each histone protein H2A, H2B, H3 and H4, and DNA wrapped around them [2]. Such
a compaction of DNA could be an obstacle for DNA transcription, which requires the binding of numerous
factors to DNA, thus requiring accessibility to the DNA. Fortunately, chromatin is a highly dynamic structure:
it can be remodelled by displacing the nucleosomes along the DNA, removing nucleosomes, or modifying their
composition (e.g. incorporating histone variants instead of canonical ones). These modifications, mediated
by chromatin-remodeling complexes, can have various transcriptional outcomes. Indeed, it results in the
modification of the DNA accessibility by the transcription and regulatory machinery [3, 4]. In addition, the
N-terminal tails of histones can be post-translationally modified (e.g. lysine and arginine methylation, serine
and threonine phosphorylation, lysine acetylation). These modifications regulate gene transcription by locally
modifying the chromatin structure (for instance, histone acetylation loosens DNA-histone interactions) and
by recruiting or excluding non-histone proteins. Indeed, some proteins can “read” a so-called “histone code”.
These readers can in turn further influence the recruitment of additional factors — such as additional histone-
modifying enzymes or chromatin remodelers — and the regulation of transcription [3,4]. As an example, the
tri-methylation of the lysine 4 in histone H3 (H3K4me3) at promoters and close to the transcription start
sites is associated with high RNA polymerase II occupancy and active transcription [5,6]. As a downstream
consequence, this methylation mediates the recruitment of chromatin-remodeling machinery [6]. In contrast,
unmethylated H3K4 is perceived as a signal for DNA methylation, which generally represses transcription
when located at promoters and enhancers [5, 7].
Finally, scaffold proteins, which do not have a transcriptional activity per se, serve as binding platforms
to help different effectors to bind to each other (e.g. transcription factors and chromatin modifiers) and build
high-order protein complexes.
Transcription-factor dimerization as a regulatory strategy
Many eukaryotic transcription factors form dimers or higher-order oligomers. Regarding sequence-specific
DNA-binding transcription factors, dimerization has two major consequences. First, it both increases DNA-
binding affinity and specificity, as it simultaneously permits cooperative DNA binding and increases the length
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Figure 1.2: Simplistic view of gene-transcription regulation.
of the DNA-bound site [8]. Second, it increases the complexity of gene regulatory networks: as each monomer
can potentially have several binding partners, such that multiple different dimers can be formed, each having
a distinct DNA-binding specificity and transcriptional effect, and thus potentially different functions [9].
As an example, a functional E2F transcription factor is actually a heterodimer made of an E2F (E2F1-8)
protein and a DP (DP1-2) protein. Each individual subunit possesses a DNA-binding domain but their
DNA binding is mutually dependent. They thus regulate transcription in a synergistic manner, each subunit
potentiating the E2F transcription-factor activity. Indeed, depending on the E2F partner in the E2F-DP
complex, the transcriptional outcome will differ: for example, while the E2F1 member activates transcription,
E2F4 represses transcription [10,11]. Another good example is the group of Max, Myc and Mad transcription
factors. Max can interact with both Myc and Mad, whereas Myc and Mad are not able to bind each other.
When Max is bound to Myc, the resulting Myc-Max complex activates transcription. In contrast, the Mad-
Max heterodimer silences transcription [9].
1.1.3 Gene families and evolution
The study of genomes reveals that many genes belong to gene families, which are groups of genes coming
from a single common ancestor gene and retaining similar sequences and often related functions [12]. This
concept is used to describe genes belonging to the same genome — called paralogs. It is an efficient way
of increasing the genetic diversity [13]. Several models have been proposed to explain their appearance and
evolution. They all involve the concept of gene duplication within a single genome and subsequent evolution
— the difference being in the way the genes (or portions of gene) are duplicated and in the way the duplicated
segments evolve [14]. For instance, an intact “ancestor” gene can be duplicated, thus generating redundant
copies, each of them being able to independently diverge (“divergent evolution” model) [13,14]. On one hand,
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deleterious mutations can occur, resulting in non-functional (pseudo) genes. On the other hand, mutations
can give rise to distinct — yet related — genes. For instance, they can diverge in expression patterns
(e.g. tissue specificity) or in functions [12, 13]. As an example, the E2F transcription factors form such a
family of paralogs with opposing functions: while E2F1 activates transcription, E2F4 is a transcriptional
repressor [10, 11]. Of note, regarding transcription factors, the divergence of function can also be translated
into a divergence of DNA-binding specificity, and thus in a divergence of the genes regulated.
This gene duplication and divergence mechanism can result in both genetic redundancy and increased
complexity. While the paralogs have acquired specialized features (sub-functionalization), they often retain
at least part of their original common function and thus can be, to a certain extent, redundant. This
genetic redundancy can often complicate research to unravel the function of a specific protein. The resulting
complexity, however, allows an increased robustness of biological processes and promotes evolution [1].
Of note, an hypothesis suggests that, at very early stages of vertebrate evolution, the whole genome
successively underwent two rounds of duplication. Such duplications would have resulted in the creation of
four copies of every gene. Since then, evolution has led to the divergence of the different copies as well as to
the loss of some [1].
An excellent example of duplication in vertebrate evolution is the divergence and decay in the globin-gene
family. Indeed, present-day globin genes result from a single ancestor globin gene. This amplification and
evolution resulted in a four-chain globin molecule in modern vertebrates. This hemoglobin form is more
efficient than the ancestor single-chain one to transport oxygen in larger organsisms. In addition, it also
enabled the emergence of the fetal β chain in mammals, which allows the transfer of oxygen from the mother
to the fetus. Also, several duplicated globin genes have lost function along the course of evolution, giving
rise to pseudogenes [1].
1.2 HCF-1: a cell-cycle regulator which regulates gene transcrip-
tion
HCF-1 (for Host Cell Factor 1) has been initially discovered as a key cellular protein for the lytic phase
of the herpes simplex virus infection. Indeed, HCF-1 stabilizes the so-called “VP16-induced complex”, a
transcriptional regulatory complex formed by itself, another host protein named Oct-1, and the viral protein
VP16. This complex assembles on viral immediate-early promoters to promote their transcription and initiate
the lytic phase of the infection [15].
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1.2.1 The HCF-1 protein
In vertebrates, HCF-1 is synthesized as a large precursor protein that undergoes proteolytic maturation.
This generates non-covalently associated amino- and carboxy-terminal moieties, called HCF-1N and HCF-
1C , respectively [15] (Figure 1.3, top). This maturation occurs at centrally-located repeats, called HCF-1PRO
repeats, which are highly conserved among vertebrate species. Curiously, the processing is directly performed
by the OGT glycosyltransferase, which both O-GlcNAcylates and cleaves HCF-1 [16].
Additional notable features of the human HCF-1 proteins are [15] (Figure 1.3, top):
• a Kelch domain, arranged in a β-propeller structure, responsible for mediating the interaction with a
large number of HCF-1 partners;
• basic and acidic regions;
• two fibronectin type 3 (Fn3) repeats involved in the association of the HCF-1N and HCF-1C subunits;
• a C-teminal nuclear localization signal (NLS).
Interestingly, missense mutations in the HCFC1 gene encoding for the HCF-1 protein (located on the X
chromosome) have been associated with diseases: a mental retardation syndrome (non-syndromic intellectual
disability [17–20]) and neurological diseases associated with vitamin metabolism defects (X-linked cobalamin
disorder [18,21] and X-linked cobalamin disorder associated with multiple congenital abnormalities [22]).
1.2.2 HCF-1 regulates two phases of the cell cycle
It was early on suggested that HCF-1 plays a role in cell-cycle progression, as a single missense mutation
in HCF-1 in a baby-hamster kidney cell line results in a temperature-sensitive cell-cycle arrest [23]. Indeed,
both HCF-1 subunits ensure complementary roles in cell-cycle progression: while HCF-1N promotes G1-to-
S-phase transition, HCF-1C allows proper mitosis and cytokinesis during M phase [24] (Figure 1.3, bottom).
It has been shown that HCF-1 is required for proliferation in embryonic development and liver regeneration
after 2/3 partial hepatectomy [25, 26]. The early hypothesis was that HCF-1 controls cell proliferation by
regulating gene transcription [23,27].
1.2.3 HCF-1 is a broad and versatile regulator of transcription
HCF-1 regulates — positively or negatively — transcription by serving as a “scaffold protein” as described
in 1.1.2 [15]. It is an abundant chromatin-associated protein [27] that acts as a hub by connecting chromatin
modifiers to selected promoter-binding transcription factors (Figure 1.3, bottom). This results in a selective
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Figure 1.3: HCF-1 is an heterodimer, each of its subunits being required for a distinct phase of
the cell cycle. Top, schematic representation of the human HCF-1 precursor protein. Bottom, HCF-1 is
indirectly tethered to chromatin by interaction of its Kelch domain with HBM-bearing DNA-binding proteins,
and acts as a hub by connecting chromatin modifiers to selected transcription factors.
modification of chromatin structure at specific promoters, enabling either positive or negative transcription
outcomes, depending on the partners in the complex. For instance, in a cell-cycle dependent manner, HCF-
1 alternatively builds activating and repressing complexes by recruiting selected histone modifiers (histone
methyltransferase and histone deacetylase, respectively) to E2F-regulated promoters (E2F1 and E2F4, re-
spectively) [28].
Of note, HCF-1 has a paralog called HCF-2 which seems to have opposing cell-cycle and transcription func-
tions to HCF-1 (Gudkova and Herr, personal communication).
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1.2.4 HCF-1 acts as a member of a chromatin complex
As mentioned, HCF-1 regulates transcription as part of transcription-regulator complexes, but does not
bind DNA directly. Thus, to perform its functions, HCF-1 needs to associate with DNA-binding proteins. Of
note, the precise identity of the proteins responsible for HCF-1 recruitment to chromatin remains controversial
[28, 29].
Many different proteins, of diverse functions, can interact with HCF-1 (Figure 1.4). Even if it is not
the sole mode of interaction, its N-terminal Kelch domain mediates a large part of HCF-1 associations [30].
The latter recognizes a so-called HCF-1 Binding Motif (HBM; consensus sequence B/ZHxY, where B and
Z are aspartate/asparagine or glutamate/glutamine, respectively, and x denotes any amino-acid), which
is present in a large variety of DNA-binding proteins, from transcription factors to chromatin-modifying
enzymes [28,31–37].
Figure 1.4: Landscape of HCF-1-interacting proteins. Overview of proteins known to interact with
HCF-1, grouped by function. The ones bearing an HBM are in red.
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In addition, most of the THAP proteins, a recently-discovered family of transcription regulators, possess
an HBM sequence, and at the onset of my doctoral research three — THAP1, 3 and 11 — had been shown
to interact with HCF-1 in human extracts [38,39] (see Figure 1.4).
1.3 The THAP transcriptional regulators: a family of HCF-1 in-
teractors
The 12 human THAP proteins are encoded by a family of gene paralogs (Figure 1.5). These proteins are
defined by their N-terminal THAP (for THanatos — referring to the Greek God of Death — Associated
proteins) domain, an atypical zinc-finger domain.
1.3.1 Discovery of the THAP family of proteins
This family of proteins was uncovered 15 years ago [40]. The authors noticed that the N-terminal portion
of THAP1, a novel pro-apoptotic factor, shares some features with the N-terminal part of 11 other human
proteins, most of them being uncharacterized at the time. They were therefore called THAP2 to THAP11,
and the previously characterized p52rIPK protein was renamed as THAP0 [40].
1.3.2 Characteristics of THAP proteins
In addition to their THAP domain, the 12 human THAP proteins share several structural motifs, while some
also have unique characteristics (Figure 1.5).
The THAP domain The THAP domain is a sequence-specific zinc-dependent DNA-binding domain re-
stricted to the animal kingdom [40] (Figure 1.5, red box). It is characterized by its N-terminal location, its
size of around 80-90 amino acids, and the presence of several conserved features [40,46]:
• A “C2CH signature” (Figure 1.6A, red-highlighted residues), which forms an atypical zinc finger. Its
consensus sequence is Cys-X2−4-Cys-X35−50-Cys-X2-His, where X denotes any amino-acid. These 4
residues provide the ligands for the zinc coordination and are each individually required for DNA
binding of the THAP domain.
• Four key residues strictly conserved in the different THAP members (Figure 1.6A, blue-highlighted
residues), defined as the THAP1 amino-acids P26, W36, F58 and P78. Similarly to the 4 zinc-finger
amino-acids mentionned above, each of them is required for binding to DNA.
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Figure 1.5: The human family of THAP proteins. Schematic representation of the structures of the 12
human THAP proteins.
• A C-terminal “AVPTIF box” (Figure 1.6A, green box), suggested to be necessary for the proper folding
of the zinc finger.
• Several additional residues, abeit not strictly conserved, with particular physico-chemical properties.
Interestingly, the THAP domains of distinct proteins display similar three-dimentional structures (Figure
1.6B), while not recognizing the same DNA target sequence (Figure 1.6C). Thus, each THAP protein appears
to have its own DNA-binding specificity [41–45].
Similarities between the THAP domain and the DNA-binding domain of the Drosophila melanogaster
P-element transposase have been pointed out early on [40]. It has led to the hypothesis that the THAP
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Figure 1.6: The THAP domain. (A) Sequence alignment of the 12 human THAP proteins, with the
conserved features highlighted: red, “C2CH signature” of the zinc finger; blue, strictly conserved residues;
green box, “AVPTIF box”). (B) Cristal structure of the THAP domain of human THAP1 (left), human
THAP11 (middle), and comparaison of the structures of the THAP domains of human THAP1 and THAP2
displayed in the same orientations (right) [41, 42]. (C) DNA-binding motifs identified for some human
THAP proteins, by SELEX approach (THAP1 and THAP9), CASTing (Cyclic Amplification and Selection
of Targets) (THAP5) or ChIP-seq (THAP11) [43–45].
domain originated from the domestication of P-transposable elements [47], domestication being the change
from a parasitic element into a beneficial host gene [48]. Curiously, THAP9 was shown to be related to the
Drosophila melanogaster P-element transposase and suggested to retain the DNA-transposase activity [40,49].
Nevertheless, these two proteins are overall too different from each other to be considered as orthologs.
The coiled-coil domain The coiled-coil motif is a common structural domain involved in protein homo-
and heterodimerization. It is found on highly diverse classes of proteins and predictions have suggested that
around 2 to 3% of all protein residues are involved in a coiled-coil domain. In particular, many transcrip-
tion factors possess a coiled-coil domain, which is interesting regarding the role of protein dimerization in
transcription regulation (as seen in 1.1.2) [50].
Most of THAP proteins display such a motif. Indeed, 9 out of the 12 human THAP proteins have it
(Figure 1.5, blue box), which is of potential interest regarding their role as transcription factors (for more
details on the identification of the coiled-coil domain in THAP proteins, see section 3.3). And yet, so far,
only THAP0 [51], THAP1 [52,53] and THAP11 [54,55] have been shown to homodimerize.
The HBM sequence Several of these proteins additionally display an HBM sequence for potential HCF-1
association: 8 have a consensus HBM and THAP4 has 2 identical HBM-like sequences (Figure 1.5, grey
and dashed-grey lines, respectively). On the other hand, THAP0, 8 and 10 do not possess any evident HBM
sequence [38]. Of note, when both a coiled-coil domain and an HBM sequence are present in a THAP protein,
they are always positioned in the same orientation — the HBM being N-terminal to the coiled-coil — and
close to each other.
Heme-binding domain THAP4 has been shown to have a C-terminal heme-binding domain [56] (Figure
1.5, purple box) apparently able to catalyze the detoxification of peroxynitrite [57], connecting THAP4 with
metabolism.
Poly-glutamine tract THAP11 displays a poly-glutamine tract typically of 29 amino-acids (Figure 1.5,
orange box), but varying from 20 to 41 glutamine residues in different individuals. To date, it is not clear
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whether this polyQ tract could cause any disease [58,59].
Conservation in mouse Several, but not all THAP proteins have an ortholog in mouse. In the mouse
genome, there are only 7 Thap genes out of the 12 human ones [46] (Figure 1.5, green THAP names).
1.3.3 Importance of THAP proteins
At the time of their discovery, the THAP proteins were hypothesized to be DNA-binding proteins and to have
a role in gene transcription. But, it has so far only been shown explicitely for a subset of them: THAP1 [38,60],
THAP3 [38], THAP5 [45], THAP7 [61,62], THAP10 [63] and THAP11 [54]. Their mechanisms of action and
outcome on gene transcription are diverse, and THAP-protein and context dependent.
In the past decade, advances have shed some light on the cellular roles of several THAP members.
Importantly, they have often been involved in cell proliferation — both cell growth and cell-cycle progression
— and in development:
• THAP0 is a positive regulator of the Protein Kinase R (PKR), a cell growth suppressor [64];
• THAP1 positively regulates cell-cycle progression in endothelial cells by activating transcription of
many pRb/E2F cell-cycle target genes, including the RRM1 promoter, whose gene product, a subunit of
ribonucleotide-diphosphate reductase, is essential for S-phase DNA synthesis [60]. In addition, THAP1
is an essential factor for mouse embryonic stem cells (ESCs): whereas not required for maintenance
of the pluripotency, THAP1 loss promotes ESCs cell death and severely impairs cell proliferation by
blocking cells into S phase. It is also necessary for silencing pluripotency genes and subsequent neural
differentiation [65].
• THAP5 has been proposed to be a negative regulator of cell-cycle progression at the level of the G2-
to-M-phase transition [66];
• THAP7 has been suggested to control cell proliferation by interaction with the Histone Nuclear Factor
P (HiNF-P), a major activator of histone H4 gene transcription [67];
• THAP10 inhibits cell proliferation and promotes cell differentiation of acute myeloid leukemia cells
bearing the t(8;21) translocation [63];
• THAP11 has been extensively demonstrated to regulate cell proliferation, but whether it promotes or
represses cell proliferation has remained controversial [39, 54, 68, 69]. Nevertheless, THAP11 has been
repeatedly shown to bind numerous cell-growth (and metabolism) and cell-cycle-related genes promoters
[29,39,68–71]. In addition, numerous studies have highlighted its essential role in pluripotency [54,72,73]
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and in early vertebrate development of various organs: the retina [74], the heart [71], the brain [75,76]
and during hematopoiesis [77].
Of note, as their name indicates, several THAP proteins have also been implicated in apotosis: THAP0
[51,78], THAP1 [79] and THAP5 [45,66].
Finally, the importance of THAP proteins in humans is highlighted by their role in diverse human diseases.
First, THAP1 (also called DYT6) is associated with primary monogenic torsion dystonia, a neurodegenerative
movement disorder characterized by involuntary muscle contractions. Dystonia 6, the second most frequent
dystonia, is due to dominant mutations lying throughout the THAP1 gene, with a large majority of mutations
falling inside the THAP domain [80–82]. In addition, THAP5 -gene expression has been linked with heart
disease [66]. Also, as for HCF-1, THAP11 has been implicated in cobalamin disorder, an inborn vitamin
deficiency associated with neurodevelopmental abnormalities [75, 83]. Finally, many THAP genes have been
associated with cancer: THAP3 [84], THAP4 [85], THAP5 [45], THAP10 [63,86] and THAP11 [39,68,69,87,
88].
1.3.4 THAP proteins and HCF-1
As mentioned above (Figure 1.5), 9 out of the 12 human THAP proteins have an HBM or HBM-like sequence,
through which they could potentially interact with HCF-1. Mazars and colleagues showed, in a yeast two-
hybrid assay, that the HCF-1 Kelch domain binds to the human THAP proteins that bear an HBM or
HBM-like sequence but not to the three THAP members that are devoid of an HBM sequence [38]. As
mentioned above, the association of HCF-1 with THAP1 [38], THAP3 [38] and THAP11 [39] has also been
shown in human cell extracts.
Importantly, HCF-1 has been implicated in THAP-mediated functions:
• HCF-1 is critical for RRM1 promoter activation by THAP1 [38]. Also, dystonia-associated mutations
have been uncovered in the HBM of THAP1, suggesting the importance of binding with HCF-1 for
THAP1 activities. Also, it has been shown than HCF-1 is present at more than 90% of THAP1-
associated promoters, this recruitment being THAP1-dependent — and more precisely, THAP1-HBM
dependent [89].
• Likewise, THAP3 interaction with HCF-1 has also been shown to be required for THAP3-mediated
transcription regulation [38].
• HCF-1 has been extensively demonstrated to be a critical THAP11 partner for regulation of transcrip-
tion and cell proliferation, with THAP11 and HCF-1 binding and regulation of transcription to their
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common promoters being mutually dependent [29,39,43,54,70,71,75].
Consequently, HCF-1 seems to be an important co-factor in THAP-protein activities — an importance
that warrants further investigation.
1.4 Genetic methods: creating custom cell lines to investigate spe-
cific proteins
Genetics is often used to unravel the functions of genes and their associated encoded proteins. This process
is called reverse-genetics as it starts from the genotype to uncover the associated phenotype. To determine
the function of a specific gene, the most common approaches aim to study mutants (cells or organisms) that
either lack this gene, express an altered version of it, or otherwise over-express the gene of interest [1].
These past years, many technological advances allowed the development of easy and efficient techniques
to create such custom genetic tools and to decipher the function of genes.
1.4.1 The CRISPR/Cas9 technique of genome editing
Engineering specific mutations (either loss-of-function mutations, less drastic functional mutants, or disease-
associated mutations) in the laboratory gives the opportunity to assess their effect on the function of proteins,
then giving insights into their role and mechanism of action. The challenge is to alter the endogenous version
of the gene of interest, in a precise and efficient way, without affecting the rest of the genome. The so-called
CRISPR/Cas9 system, which arose this past decade and has become very popular, provides an extremely
satisfying solution.
Discovery
Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated sequences (Cas)
were initially discovered as part of the adaptive immune system of microbes. It allows bacteria and archaea
to defend against viruses and plasmids. By using single-strand RNA molecules, Cas nucleases are targeted
to foreign DNA in a sequence-specific manner. This results in the creation of a double-strand break (DSB)
at specific locations of the foreign DNA and its subsequent degradation [90,91].
Hijacking the CRISPR/Cas immune system for precise genome editing
This immune system has been diverted to precisely and efficiently edit genomes. Here, a human codon-
optimized Cas9 endonuclease is used in combination with a single-strand chimeric RNA in which the two
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RNA molecules traditionnally used by the Cas nuclease are fused. This latter RNA molecule, named guide
RNA (gRNA), will target the Cas9 endonuclease to a specific locus by direct base-pairing interaction of
its guide sequence of 20 nucleotides with the targeted DNA locus (Figure 1.7A). Thus, this system can be
designed to target virtually any location in a genome by adapting the 20-nucleotide guide sequence inside the
gRNA [90,92]. The single requirement is that the target sequence must be immediately followed, in the host,
by a so-called protospacer adjacent motif (PAM), necessary for Cas endonuclease activity (Figure 1.7A). The
PAM requirement differs depending on the Cas endonuclease ; in the case of Cas9, it is 5’- NGG [90].
Following cleavage of the DNA at the target location, DNA-damage repair pathways are activated [90]:
• By default, error-prone non-homologous end joining (NHEJ) takes place to repair the DSB, resulting
in the formation of indels. This can typically be used to create loss-of-function mutations, as indels can
lead to frameshifts and premature stop codons (Figure 1.7 B, left).
• Alternatively, a repair template can be used to activate the homology-directed repair (HDR) pathway.
Although occuring less frequently than NHEJ, HDR can be exploited to introduce precise modifications
of the targeted DNA sequence. This requires providing the system with a repair template for the
recombination, bearing the desired changes of the sequence (Figure 1.7B, right).
CRISPR/Cas9 procedure for cell lines in culture
First, a gRNA that fits ones goals needs to be designed. It consists in identifying the 20-nucleotides guide
sequence which will direct the Cas9 to the locus of interest (Figure 1.7 A, blue sequence). Again, this sequence
must be followed, on the genomic locus, by a 5’- NGG PAM (red line). Of note, Cas9 will cleave the target
sequence around 3 base pairs upstream of the PAM (red triangle). The guide sequence and a scaffold RNA
sequence (blue and red sequences, respectively) create the gRNA. This gRNA needs to be delivered to cells
together with a Cas9-expression construct and, if necessary, a DNA-repair template. One easy way to do
that is to create an expression plasmid encoding both the sgRNA and the Cas9 endonuclease, which can be
delivered to cells by transfection [90].
In case the objective is to create specific modifications of the locus, a repair template is also necessary
for HDR. An easy option is to use single-stranded DNA oligonucleotides (ssODNs), with homology arms of
40 to 80 nucleotides of each side, which are transfected into cells together with the gRNA-Cas9 expression
plasmid. In that case, the gRNA sequence needs to be chosen so that the desired modification (i.e., mutation)
of the locus is in close proximity of the DSB generated by Cas9 (around 10 nucleotides maximum for a good
efficiency) [90].
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Figure 1.7: Genome engineering using the CRISPR/Cas9 system. (A) The gRNA is composed of
the 20-nucleotides guide sequence (blue) fused with a scaffold (red). The guide sequence pairs with the DNA
target (bleu bar), which is immediatly followed by a 5’- NGG PAM. It subsequently mediates the cleavage
by Cas9 approximatively 3 base pairs upstream of the PAM (red triangle). (B) DSBs can be either repaired
by NHEJ, resulting in indels (left), or, providing a repair template, by HDR, allowing precise gene editing
(right). [90]
Following transfection, the cells can be clonally selected and eventually tested for the presence of indels
(if no ssODN) or for the presence of the desired mutation if a ssODN has been used.
Remarks
The design of the guide RNA sequence is particularly critical for the success of the technique. Among other
factors, one should try to minimize the off-target effects of the endonuclease. For this, an online CRISPR
Design tool (http://tools.genome-engineering.org) has been created which greatly helps with this problem.
Given an input sequence around the targeted site, it identifies suitable guide sequences (upstream of a 5’-
NGG PAM) minimizing the off-target activities, and provides a list of predicted off-target effects [90].
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Interestingly, the CRISPR/Cas9 system has been further used in a more general way, as a DNA targeting
platform, expanding the scope of this technology. As Cas9 DNA-docking ability does not depend on it
endonuclease activity, it has been possible to generate, by a single point mutation, a deactivated Cas9 enzyme
(dCas9). Together with a gRNA, this dCas9 can still be targeted to DNA, but without cleaving it. If directed
to a promoter region, binding of dCas9 can repress the transcription of the associated gene, by preventing
RNA polymerase binding or elongation, or the recruitment of necessary transcription factors. Alternatively,
dCas9 can be fused with any desired protein to generate a chimera protein, bearing the dCas9 site-specific
docking activity together with the function of the protein of interest. This could be exploited to modulate
gene expression in a more complex way, by fusing dCas9 with transcriptional activators, or repressors, or any
chromatin-remodelling complex, and subsequently targeting the resulting factor to a specific promoter region
with a gRNA. Thus, the CRISPR/Cas9 system can also be exploited to finely manipulate the expression of
virtually any endogenous gene [93,94].
Finally, the CRISPR/Cas9 genome editing allows multiplexing. Indeed, one can target mutiple genomic
locations simulatenously by introducing several distinct gRNAs together. This enables high-throughput
experiments with library-based approaches to perform screens [94].
1.4.2 The Flp-In
TM
T-Rex
TM
system to easily introduce an inducible gene con-
struct in the genome of targeted cells
In addition to altering the endogenous version of a particular gene of interest (GOI), it can be of interest
to introduce an ectopic gene contruct into cells. For instance, this can be used to complement the effect
of a particular mutation with the wild-type (WT) allele. Alternatively, it can allow the expression of non-
native genes, such as chimeras, or tagged genes (e.g. with GFP). Traditionally, this has been done by stable
transfection, providing the cells with a DNA plasmid and selecting the ones having successfully integrated
the foreign DNA into their genome. This integration event being very rare, however, the efficacy of this
technique is extremely low. In addition, the site of insertion and the number of gene copies inserted are
not controlled with this technique. The randomness of the insertion site is particularly problematic as the
insertion can disrupt a gene sequence, or regulatory regions of a gene.
Principles of the Flp-In
TM
system
The Flp-In
TM
system provides an interesting solution to allow integration and expression of a unique copy
of the GOI at a controlled genomic location [95]. It takes advantage of the Saccharomyces cerevisiae-DNA
recombination system. It uses the Flp recombinase to induce DNA recombination at specific sites called FRT
42
CHAPTER 1. INTRODUCTION
(for Flp Recombination Target) sites present in both the host cell genome and the GOI expression vector.
These sites are binding and cleavage sites for the recombinase. The Flp recombinase induces intermolecular
DNA homologous recombination, which does not require DNA synthesis, thereby limiting the introduction
of mutations.
Procedure for generating stable cell lines by Flp-mediated recombination
To create a Flp-In
TM
stable cell line, one has to go through the following steps (Figure 1.8) [95]:
• First, a host cell line containing an FRT site integrated into the genome, named as Flp-InTM host
cell line, has to be generated. This can be done in the laboratory for virtually any cell line, by stable
transfection of the appropriate plasmid. Alternatively, several Flp-In
TM
host cell lines have been
generated by Invitrogen for various mammalian species (HEK293 and Jurkat human cells, 3T3 mouse
cells, CV-1 monkey cells, CHO and BHK hamster cells), bearing a single FRT site into their genome at
a controlled location. Using these cell lines is therefore a appreciable gain of time as it tremendously
shorten and simplifies the creation of the Flp-In
TM
stable cell lines.
• Second, aforementioned host cells are co-transfected with a Flp recombinase-encoding plasmid (named
as pOG44) together with an expression vector (called pcDNA
TM
5/FRT) containing the GOI flanked
with an FRT site. Consequently, the expressed Flp recombinase mediates recombination between
the FRT sites present in the pcDNA
TM
5/FRT and in the host cell genome. This results into stable
integration of the GOI into the genome of the host cell.
• Third, cells with a stable integration at the FRT site can be selected using hygromycin resistance.
Indeed, the pcDNA
TM
5/FRT vector contains a degenerated hygromycin-resistance gene which is reca-
pitulated by a proper insertion event.
The previously-described system uses the pcDNA
TM
5/FRT vector, in which the GOI’s expression is con-
trolled by the human CMV promoter. Consequently, once integrated into host cells, the GOI is constitutively
expressed. In some instances, however, it can be of interest to turn on and off the expression of the GOI
in a reversible fashion. For this purpose, the Flp-In
TM
system has been further developed into a Flp-In
TM
T-Rex
TM
system, in which the expression of the GOI is under the positive control of tetracycline.
Adding a layer of complexity: tetracycline-regulated expression of the gene of interest
The Flp-In
TM
T-Rex
TM
system allows the generation of stable cells with a tetracycline-inducible GOI, using
the Tn10-encoded tetracycline (Tet)-resistance operon from E.Coli [96]. Unlike previously, the GOI will not
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Figure 1.8: Generation of stable cell lines using the Flp-In
TM
system. The pcDNA
TM
5/FRT
expression vector containing the gene of interest (GOI) is co-transfected with the Flp recombinase-encoding
vector (pOG44) into the Flp-In
TM
host cell line (top). The Flp recombinase mediates the recombination
between the two FRT sites (middle), resulting in the integration of the expression construct into the genome
of the host cell and expression of the GOI (bottom) [95].
be constitutively expressed, but rather constitutively repressed, due to the presence of 2 tandem copies of the
tet operator (TetO2) inserted into its CMV promoter, and the constitutive expression of Tet repressor by the
host cell. In the absence of tetracycline, the Tet repressor expressed by the host cell homodimerizes and is
recruited to the TetO2 sites, thereby repressing the expression of the GOI (Figure 1.9, top). Upon treatment
of the cells with tetracycline, tetracycline binds to the Tet homodimers (Figure 1.9, middle) and induces a
conformation change that results into dissociation from the TetO2 sites and removal of the transcriptional
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repression (Figure 1.9, bottom). In summary, in the absence of tetracycline, the GOI is transcriptionnally
repressed whereas, upon tetracycline treatment, it is expressed.
Figure 1.9: Principle of tetracycline-mediated regulation. The Tet repressor (tetR) constitutively
expressed from the host cell homodimerizes and binds to TetO2 sequences in the GOI promoter, resulting in
repression of its expression (top). When added, tetracycline (tet) binds to the tetR homodimers (middle).
This causes a conformational shift in the tetR homodimers and eventually their release from the TetO2
sequences, and subsequent derepression of the GOI (bottom) [96].
The following points are changed compared to the previously-described Flp-In
TM
system:
• The host cell line needs to be further modified to stably encode the Tet repressor. As before, this can
be made in virtually any cell line of interest, but the Flp-In
TM
T-Rex
TM
HEK-293 cell line has already
been developed by Invitrogen.
• The GOI needs to be cloned into the pcDNATM5/FRT/TO vector, which bears the two TetO2 sites in
the promoter controlling the expression of the GOI.
The rest of the procedure stays the same than previously described for the creation of Flp-In
TM
stable
cells.
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Additional remarks
Because tetracycline antibiotics inhibit protein synthesis in both human and bacterial cells, it has the potential
to kill the treated cells. But, the concentrations used to induce the expression of the GOI are usually too
low to be toxic of the cells. Nevertheless, one should keep in mind the potential toxic effect of the treatment
with tetracycline, especially if used at high concentrations. Classically, the tetracycline antibiotic used is
doxycycline as it is more stable.
Of note, most cells are kept in culture supplementing their medium with fetal serum. This latter serum,
however, often contains some tetracycline because it has been generated from animals fed with tetracycline-
containing diet. Consequently, the use of such serum in cell culture would lead to a basal GOI expression,
instead of a clean repression [96]. In case a cleaner repression of the GOI is needed (for instance, if it produces
a toxic compound), one should consider of using tetracycline-depleted serum that is commercially available.
1.5 Thesis content
By reviewing the literature at the onset of my doctoral studies, I noticed that the THAP family of proteins
had been barely studied as a whole, which I felt would provide an interesting research opportunity. Indeed,
I felt that a global analysis of these proteins as a family, and not as separate entities, had chances to reveal
interesting features. In addition, growing evidence implicates THAP proteins as broad regulators of gene
transcription and resulting cell proliferation, often working in collaboration with HCF-1. Nevertheless, even
at this writing, the importance of the THAP family is still emerging and most human THAP proteins remain
understudied. In particular, tools to study them are often lacking.
Thus, I aimed to establish experimental tools and to use them to probe the role of human THAP proteins
in the transcriptional control of cell proliferation alongside HCF-1, both by examining these proteins as a
complete set, and then by more carefully investigating some specific members.
The goals of this doctoral thesis are the following:
• Consider the THAP proteins as a family, thereby unraveling some of their shared and specific features.
The objective of Chapters 3 and 4 is to use bioinformatics and available data to respectively study
how THAP genes have evolved during evolution and to assay their expression. Also, in Chapter 5, I
describe biochemistry analyses performed on selected THAP proteins to examine how they interact,
both with themselves and with HCF-1.
• Create genetic tools to study specific THAP proteins.
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As mentioned above, very few tools are available so far to study the human THAP proteins, which
restrains the discoveries about their funtions. Chapter 6 describes how I have engineered cell lines
using recent genetic technologies, to question specific THAP proteins: THAP7 and THAP11.
• Probe the role of THAP7 and THAP11 in cell proliferation and gene transcription.
In Chapters 7 and 8, I describe the phenotypic analyses performed on the aforementioned cell lines.
Chapter 7 focuses on impacts on cell proliferation, and Chapter 8 explains how I have used genomic
approaches to probe the role of THAP7 and THAP11 in regulation of transcription.
This study sheds light on how THAP proteins, in collaboration with HCF-1, can regulate gene transcrip-
tion and subsequently cell proliferation. In addition, the established experiment tools can be beneficial for
other researchers to explore the function of THAP proteins.
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Materials and methods
Here, I describe the experimental procedures of the expriments presented in this thesis.
2.1 Plasmids and site-directed mutagenesis
Plasmids WT THAP open reading frames were purchased from OriGene and GeneCopoeia and then
cloned into the pcDNA
TM
5/FRT/TO vector (Invitrogen V6520-20) with an T7-Flag tag or an HA tag at
their C-termini. The pOG44 plasmid was from Invitrogen (V6005-20). The HCF-1-encoding plasmids are
made from the pCGN vector and encode N-terminally HA and c-myc-tagged HCF-1 versions. They come
from the Herr laboratory and have been deposited in the Addgene plasmid repository: pCGN-HCF-1FL,
pCGN-HCF-1N1011 (HA-HCF-1N ) and pCGN-HCF-1C600 (HA-HCF-1C).
Site-directed mutagenesis Partially overlapping primer pairs were designed as recommended [97]. A
polymerase chain reaction (PCR) was performed with 100 ng of the template plasmid, 0.2 µM of each forward
and reverse primer, 200 µM of dNTPs and 2.5 units of Pfu turbo Taq polymerase (Agilent 600250-52) in 1X
Pfu buffer supplemented with Quick Solution (Agilent 200516-51). The mix was incubated in the thermocycler
for the PCR, with an extension time of 1 minute per kilobase (kb) of template plasmid. At the end of the PCR
reaction, the mix was incubated with 20 units of DpnI enzyme (New England Biolabs R0176S) to digest the
(methylated) template plasmid. The mutagenesis mix was then used to transform competent bacteria under
carbenicillin selection (100 µg/µL, Carl Roth 6344.1). DNA was extracted from the bacteria and sequenced
to assess the presence of the desired mutation in the plasmid.
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2.2 Maintenance of cells in culture
Adherent cells were routinely maintained in DMEM medium (DMEM + 4.5g/L D-Glucose, L-Glutamine,
Pyruvate; Gibco 419666) supplemented with 10% of heat-inactivated fetal calf serum (FCS, BioConcept 2-
01F30) at 37 ◦C and 5% CO2 in humidified atmosphere. For some experiments, the latter serum was replaced
by tetracycline-free calf serum (FCS Tetracycline Free, BioConcept 2-01F28). In some proliferation assays,
cells are cultivated at 39.5 ◦C.
HeLa-S cells (S for spinner) were grown in suspension. They were cultivated in JMEM medium (JMEM
powder — MEM Joklik Modification with L-Glutamine without CaCl2 — BioConcept 1-29P02-W) supple-
mented with 10% of heat-inactivated fetal calf serum and 1% of Penicillin-Streptomycin mix (10 000 units/mL
Penicillin, 10000 µg/mL Streptomycin, Gibco 15140) at 37 ◦C and 5% CO2 in humidified atmosphere, under
constant agitation.
2.3 Cell transfection for biochemistry analyses
For THAP-protein interactions analyses as described in Chapter 5, cells were seeded in 10 cm dishes at 4×106
cells per dish 18 hours before transfection to allow their attachment. For the transfection, 6 µg of total DNA
(3 µg of each plasmid in case of two plasmids) was resuspended into 250 µL of serum-free Opti-MEM medium
(Gibco 31985). Separately, 10 µL of Lipofectamine R© 2000 (Invitrogen 11668-019) was diluted into 250 µL
of serum-free Opti-MEM medium. After 5 minutes incubation at room temperature, the Lipofectamine R©-
medium mix was added drop by drop to the DNA-medium mix. After incubating for 20 minutes at room
temperature, the DNA-Lipofectamine R© mix was added drop by drop onto the cells. The cells were then
further incubated for 28 hours before harvesting for analysis.
2.4 Co-immunoprecipitation
Cells were on-plate lyzed in 500 µL per plate of 0.5% NP40 lysis buffer (10 mM Tris pH 8.0, 150 mM NaCl,
5 mM MgCl2, 0.5% NP40, supplemented with one tablet of complete EDTA-free Protease Inhibitor Cocktail
(Roche 04693132001) per 50 mL). From the lysate, 40 µL was transferred into a fresh tube for the input
sample, mixed with 10 µL of 5X Laemmli buffer (250 mM Tris pH 6.8, 500 mM βmercaptoethanol, 50%
glycerol, 10% SDS, with bromophenol blue) and heated at 95 ◦C for 5 minutes. The rest of the lysate
was incubated overnight at 4 ◦C with 30 µL of monoclonal anti-HA (Sigma A2095) or monoclonal anti-Flag
(Sigma A2220) agarose beads. After 4 washes of the beads with the 0.5% NP40 lysis buffer, the beads were
resuspended in 20 µL of 5X Laemmli buffer, heated at 95 ◦C for 5 minutes and the supernatant was used for
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western blotting (IP sample).
2.5 Western blotting
The samples were separated by SDS-PAGE before being transferred onto a nitrocellulose membrane. For
samples after co-immunoprecipitation, an equal volume of input and IP samples were loaded (5 µL, then ratio
input over IP is 1/30). Membranes were blocked for 1 hour in 100% blocking buffer (LI-COR Bioscences
927-40000). Membranes were incubated overnight at 4 ◦C with the primary antibody diluted 1/1000 in a
mix of 50% PBS 0.5% Tween 20 and 50% blocking buffer. They were then washed with PBS 0.1% Tween 20
before being incubated with the appropriate secondary antibody during 1 hour at room temperature. Blots
were finally visualized with the Odyssey R© infra-red imaging system (LI-COR).
2.6 CRISPR/Cas9 mutagenesis
Design Using the online CRISPR Design tool (http://tools.genome-engineering.org), I selected for each
mutation a suitable gRNA fullfilling the following criteria:
• being immediatly followed by a 5’- NGG PAM sequence;
• being 20-nucleotides long if it already has a G at its 5’, or 21-nucleotides long adding an extra G
nucleotide at its 5’ if it does not have one;
• minimizing the off-target activities, meaning having a high score on the CRISPR Design tool output;
• close enough to the mutation site, more precisely the cutting site, which is 3 nucleotides upstream to
the 5’- NGG PAM sequence, should be not farer than 11 nucleotides away from the mutation site;
• the PAM sequence is disrupted by the mutation or, alternatively, can be disrupted by a silent mutation.
The different gRNAs used in this thesis are listed on the Table 2.1. Please note that the target gRNA can
be designed either on the sense or the antisense strand and that both forward and reverse sequences were
synthesized to create a double strand gRNA. Before synthesis, I added upstream to the forward sequence a
5’- CACC sequence and a 5’- AAAC upstream of the reverse one. The resulting forward and reverse gRNA
sequences, consequently partially overlapping, were synthesized by Microsynth. The extra nucleotides subse-
quently enable for cloning of the annealed gRNA sequences into the pSpCas9(BB)-2A-GFP backbone plasmid
(Addgene plasmid 48138) using the BsbI restriction enzyme. This gRNA-expression plasmid, designed by
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Table 2.1: List of gRNA used for CRISPR/Cas9 mutagenesis. Forward and reverse sequences designed
to create the double strand gRNA that was subsequently cloned into the pSpCas9(BB)-2A-GFP backbone
plasmid. Red, core guide sequence; Blue, 5’- G added if not already present in the 20-nucleotides guide
sequence; Green, extra nucleotides added for BsbI-mediated cloning into pSpCas9(BB)-2A-GFP.
Ran and colleagues [90], encodes the invariant gRNA scaffold and cloning sites for insertion of the guide
sequence, together with the Cas9 nuclease and a GFP cassette for selection purposes.
The repair templates were designed as followed: from the mutation sites, 80 nucleotides upstream and
downstream were taken to create an approximately 160-nucleotides long (depending on the number of nu-
cleotides mutated). Table 2.2 lists the different single-stranded DNA oligonucleotides (ssODNs) used, which
were synthesized by IDT.
Mutagenesis Cells were co-transfected with the pSpCas9(gRNA)-2A-GFP plasmid encoding for the gRNA,
the Cas9 nuclease and GFP together with the appropriate ssODN repair template. For this, low-passage
HEK-293 cells were seeded in 6 cm plates at 0.4 × 106 cells per plate, and incubated for 24 hours. The
following day, cells were transfected as follows: 500 ng of pSpCas9(gRNA)-2A-GFP plasmid and 1 µL of
the appropriate ssODN (10 µM) were diluted into 250 µL of serum-free Opti-MEM medium (Gibco 31985).
Separately, 4 µL of Lipofectamine R© 2000 (Invitrogen 11668-019) were diluted into 100 µL of serum-free Opti-
MEM medium. After 5 minutes of incubation at room temperature, the Lipofectamine R©-medium mix was
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Table 2.2: List of ssODN repair templates used for CRISPR/Cas9 mutagenesis. The mutated
residues are depicted in red in each sequence.
added drop by drop to the DNA-medium mix. After incubating for 20 minutes at room temperature, the
DNA-Lipofectamine R© mix was added drop by drop onto the cells and the cells were further incubated for 3
to 4 days.
Cells were then sorted using the FACS Aria II instrument to select for the transfected cells only, meaning
the GFP-expressing ones. At the exit of the cell sorter, cells were immediatly diluted at one cell per well in 3
96-well plates, to allow single-cell cloning. In addition, the remaining GFP-positive cells were collected and
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grown altogether for 2 to 3 days before being manually plated in 3 96-well plates at an average density of 0.5
cell per well. Also, the same procedure was done in parallel for GFP-negative cells as a control.
Screening Typically 3 weeks after the cell sorting and the single-cell seeding, the media of some wells starts
to turn yellow, indicating that the cell in this well has survived and is reaching confluency. Each well was
then splitted into two: two third of its content was used for DNA extraction and subsequent screening, while
the rest was maintained in culture. DNA was extracted as follows: cells were resuspended in 15 µL of basic
solution (25 mM NaOH, 0.2 mM EDTA, pH 12.0) and incubated in a thermocycler, first during 15 minutes
at 68 ◦C, second during 30 minutes at 98 ◦C and third cooled down at 4 ◦C. Finally, 12 µL of acid solution
(40 mM Tris, pH 5.0) was added and the extracted DNA was quantified.
The PCR was performed by mixing approximately 100 to 200 ng of the extracted DNA, with 0.4 µM of
each forward and reverse primers, 200 µM of dNTPs and 0.4 units of high fidelity Q5 DNA polymerase (New
England Biolabs M0491L) in 1X Q5 buffer. The PCR was done with appropriate annealing temperatures
and extension times, which were optimized for each primer pair. Table 2.3 lists the pairs of primers used for
these PCRs with their corresponding PCR conditions.
Following the PCR, half of the reaction mix was used for the enzymatic digestion with the appropriate
restriction enzyme. For this, half of the PCR mix was incubated with 4 units of the appropriate enzyme,
in 1X reaction buffer (which depends on the enzyme). Table 2.4 lists the different enzymes used for each
reaction, together with the incubation conditions (buffer, temperature and duration). Following the digestion,
PCR products and corresponding digestion products were loaded side by side on a 2% agarose gel. When a
clone displays the expected digestion pattern for the mutation, PCR products were extracted from the gel
by excising the gel portion and incubating it overnight in 40 µL of 1M Tris, pH 6.8. The following day, the
DNA released in the Tris buffer was submitted to sequencing using one of the forward or reverse primer to
confirm the presence of the mutation.
2.7 Stable cell lines
Transfection Flp-In
TM
T-Rex
TM
HEK-293 cells (Invitrogen R78007) were seeded in 10 cm dishes at 3×106
cells per dish 18 hours before transfection to allow their attachment. Cells were then transfected with the
THAP-T7-Flag pcDNA
TM
5/FRT/TO plasmid construct together with the pOG44 plasmid containing the
gene encoding for the Flp recombinase. Here, 3 µg of the pOG44 plasmid plus 0.313 µg of THAP-T7-Flag
pcDNA
TM
5/FRT/TO plasmid were transfected as described previously for the biochemistry analyses and
the cells were further incubated for 24 hours. Cells were then trypsinized and split to 3 new 10 cm dishes at
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Table 2.3: List of the PCR primer pairs used to screen the cell clones obtained after
CRISPR/Cas9 mutagenesis, and their specific working conditions. fwd, rvs: forward and reverse
primers, respectively.
the following dilutions: 1/4, 1/10 and 1/20. Cells were incubated for 24 hours to allow their attachment.
Antibiotic selection and generation of single-cell clones Cells were treated with the hygromycin-
B antibiotic to select for those having integrated the THAP gene construct. For this, the medium was
removed from the plate and replaced with fresh medium supplemented with hygromycin-B at 100 µg/ml
(LabForce HygroGold ant-hg-1). Cells were further incubated at 37 ◦C and the growth of colonies was
monitored regularly. During this time, medium was replaced twice a week by fresh medium supplemented
with 100 µg/ml of hygromycin. When the colonies are well formed, which typically took 10 to 12 days after
the first addition of hygromycin, 6 colonies were randomly picked from the plates to be further expanded and
eventually tested as described in the results. Cells were maintained under hygromycin selection at 100 µg/ml
when cultured outside experimental procedures, while antibiotic selection was removed during the course of
experiments.
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Table 2.4: Restriction enzymes used to screen the cell clones obtained after CRISPR/Cas9
mutagenesis, and their specific working conditions. O/N, overnight.
Doxycycline stimulation To stimulate the expression of the ectopic THAP construct, cells were treated
with doxycycline (doxycycline hyclate Sigma D9891-1G) at 1 µg/mL final, except otherwise specified, for 24
hours or longer. The doxycycline having been resuspended using dimethyl sulfoxide (DMSO) as solvent, the
same amount of DMSO was used to treat cells in parallel for the unstimulated-cell control.
2.8 Cell proliferation assays
Cells were seeded (day 0) in wells of 6-well plates at 25000 cells per well and incubated for 24 hours at 37 ◦C
to allow their attachment. For each condition, cells were plated in duplicate. After 24 hours (day 1), if
appropriate, cells were moved to temperature (39.5 ◦C) or treatment was performed (doxycycline, or DMSO
as control). Cells of two different well per condition were then counted on day 1, and every day from day 4
to day 8. Resuts were dispayed as the ratio between the mean cell number of the two replicates at the time
point (Nt), and the cell number initially seeded on day 0 (No).
2.9 Cell synchronization
For this experiment, I used Hela-S cells (S for spinner) which grow in suspension.
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Double thymidine block Cells were prepared as 0.3×106 cells/ml in 400 mL of medium and immediatly
blocked with 2 mM of thymidine (Sigma T1895) during 12 hours. After an 11-hour release in normal medium,
cells were blocked again for 12 hours with 2 mM of thymidine. They were subsequently released in normal
medium to let them progress synchronously through the cell cycle.
Flow cytometry for DNA-content analysis Time points were collected every two hours during 24
hours. Here, 0.5×106 cells were taken off from the pool of cycling cells and immediatly fixed by resuspending
them in 200 µL of ice-cold PBS 1X and adding drop by drop 800 µL of 100% ice-cold ethanol. Cells were
then stored at −20 ◦C for at least 12 hours before being analysed. The DNA of the fixed cells was stained
with propidium iodide (PI, Sigma P4864-10mL) by resuspending the cells in 250 µL of PI-staining buffer
(50 µg/mL of PI, 50 µg/mL of RNAse A (DNAse-free RNAse A, Roche 1119915), diluted in water) and
incubating them for 20 minutes at 4 ◦C in the dark. As control, cells from asynchronous cells as well as
unstained cells were also prepared. Cells were finally analyzed using the PE-A channel of a LSR II flow
cytometer (BD Biosciences). The results were visualized using the FACSDiva Version 6.1.1 software.
2.10 High throughput RNA sequencing (RNA-seq)
Preparation of cells For the analysis of stable cells, 0.25× 106 cells per well were seeded in 6-well plates
and treated 24 hours later with 1 µg/mL of doxycycline, or the same amout of DMSO, as control. Cells were
further incubated for 36 hours at 37 ◦C before being analyzed.
For the analysis of the mutant cells, 0.15× 106 cells per well were seeded in 6-well plates and incubated
at 37 ◦C for 24 hours. If necessary, some plates were switched to 39.5 ◦C. Cells were further incubated for
48 hours before being analyzed.
RNA extraction and sequencing Total RNA was extracted using the Qiagen RNeasy kit (Qiagen 74104)
according to the manufacturer protocol. The RNA was eventually eluted in water and quantified. The samples
were then entrusted to the UNIL Genomic Technology Facility (GTF) for quality control with a fragment
analyser. Ribosomal RNA was removed using the Ribo-zero rRNA removal kit (Illumina MRZH11124), then
libraries were prepared using the truSEQ stranded RNA LT kit (Illumina) and 50-nucleotides single-read
high-throughput sequencing was performed. The results were subsequently analyzed by Dr. Viviane Praz,
biotechnician in our laboratory.
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2.11 Chromatin immunoprecipitation followed by high-throughput
sequencing (ChiP-seq)
Chromatin preparation Cells were expanded at 37 ◦C and approximately 150 millions of cells were used
per IP. Cells were on-plate crosslinked with 1% of formaldehyde (Sigma F1635-500ml) during precisely 8
minutes, then 0.125 M of Glycine (Axonlab A1067.5000) was added to terminate the crosslinking reaction.
Cells were washed twice with cold PBS 1X and lyzed for 10 min on ice in 0.5% NP40 lysis buffer (5 mM PIPES
pH 8.0, 85 mM KCl, 0.5% NP40, supplemented with one tablet of complete EDTA-free Protease Inhibitor
Cocktail (Roche 04693132001) per 50 mL; 950 µL per 10 million of cells). The nuclei were recovered by
high-speed centrifugation (5 minutes at 3200 xg, at 4 ◦C), resuspended in nuclei lysis buffer (NLB, 50 mM
Tris-HCl pH 8.1, 10 mM EDTA pH 8.0, 1% SDS, supplemented with one tablet of complete EDTA-free
Protease Inhibitor Cocktail) and incubated for 20 minutes at 4 ◦C.
Chromatin was sonicated using a Bioruptor Pico (Diagenode) to obtain fragments of around 200 bp. Son-
icated chromatin was clarified by centrifugation and subsequently 1:2 diluted in 2X IP buffer (33.4 mM Tris
pH 8.1, 167 mM NaCl, 167 mM LiCl, 2.4 mM EDTA pH 8.0, 2.2% Triton X-100, 0.02% SDS, supplemented
with one tablet of complete EDTA-free Protease Inhibitor Cocktail) before being snap frozen in liquid ni-
trogen. A 50 µL aliquot was kept to analyze the chromatin quality and concentration. The frozen sonicated
chromatin was stored at −80 ◦C.
Chromatin immunoprecipitation The day prior to the chromatin immunoprecipitation, protein G
agarose beads (Roche 1243233) were washed with NLB:IP buffer (a mix of equal amounts of NLB and
2X IP buffer) and further incubated overnight under rotation at 4 ◦C) in NLB:IP buffer supplemented with
100 µg/mL of Bovine Serum Albumine (BSA, Sigma A8022-100).
The sonicated chromatin was thawed. A 60 µL aliquot was kept for the input sample, while, for each IP,
9 µg of chromatin (in a total volume of 1200 µL of NLB:IP buffer) was overnight incubated under rotation
at 4 ◦C with 2 µg of anti-THAP11 antibody. Samples were further incubated under rotation at room tem-
perature with 60 µL of the above washed and BSA-blocked protein G agarose beads. Immunoprecipitated
samples were washed twice with IPWB1 buffer (IP wash buffer 1: 20 mM Tris pH 8.1, 50 mM NaCl, 2 mM
EDTA pH 8.0, 1% Triton X-100 and 0.1% SDS). Each IP was performed 5 times in parallel as described and
subsequently pooled to form a single IP sample at this step, after the washes with IPWB1 buffer. Pooled IP
samples were then washed once with IPWB2 buffer (IP wash buffer 2: 10 mM Tris pH 8.1, 250 mM LiCl,
1 mM EDTA pH 8.0, 1% NP40 and 1% Na-deoxycholate) and finally twice with TE buffer (10 mM Tris pH
8.1, 1 mM EDTA pH 8.0). Two elutions with IPEB buffer (elution buffer: 100 mM NaHCO3, 1% SDS) were
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sequencially done (5 minutes at 37 ◦C under agitation) and pooled.
The input sample was thawed and supplemented with 190 µg of IPEB buffer. Eluates (IP) and input sam-
ples were decrosslinked by overnight incubation at 65 ◦C in presence of 20 µg/mL of RNAse A (DNAse-free
RNAse A, Roche 1119915) and 300 mM of NaCl. The samples were further incubated during 90 minutes at
45 ◦C with 350 µg/mL of proteinase K (Promega V3021). Samples were finally purified using the “Nucleospin
Gel and PCR clean-up” kit (Macherey-Nagel 740609) using the NTB buffer for SDS-containing samples. Sam-
ples were eluted with 50 µL of the pre-warmed (72 ◦C) buffer NE (from the kit), and subsequently re-eluted
using the previous eluate. DNA yield was quantifed using a Qubit spectrophotometer.
Library preparation and sequencing For each IP sample, two separate libraries were prepared and se-
quenced, using the same immunoprecipitated-DNA material. For this, 5 ng of purified DNA was used to pre-
pare paired-end sequencing libraries using the “MicroPlex Library Preparation” kit (Diagenode C05010014)
following the manufacturer instructions. Here, 8 PCR cycles were done for DNA amplification and the
DNA fragments were not size selected. Then, libraries were purified using AMPure R© XP magnetic beads
(Diagenode) and entrusted to the UNIL Genomic Technology Facility (GTF) for 100-nucleotide paired-end
high-throughput sequencing (Illumina, HiSeq 2100) with 3 samples per line (multiplexing). The results were
subsequently analyzed by Dr. Viviane Praz.
2.12 Antibodies
The antibodies used were: anti-HA (rat, Roche 10768600), anti-Flag (rabbit, Cell Signalling 2368S), anti-
HCF-1 (rabbit, H12, [98]), anti-OGT (rabbit, Santa Cruz Biotechnology sc-32921), anti-tubulin (mouse,
Sigma T0198) and anti-THAP11 (sheep, R & D Systems AF5727).
2.13 Bioinformatics
Analysis of THAP proteins The list of THAP proteins in the selected animal species was done by
combining the list from Clouaire et al. [46] and the Pfam database [99]. Duplicates, but with different
annotations, were identified by performing numerous Protein Blast analyses [100] and subsequently removed.
Each putative THAP protein was finally manually verified so it indeed contains a correct N-terminal THAP
domain as described in section 1.3.2.
The presence of an HBM sequence in the THAP proteins was assessed using Protein Patter Find [101],
providing a fasta file with the THAP protein sequences as a query, and looking at consensus HBM sequences
59
CHAPTER 2. MATERIALS AND METHODS
(B/ZHxY, where B and Z are aspartate/asparagine or glutamate/glutamine, respectively, and x denotes any
amino-acid) using the following search pattern: “[DNEQ]H.Y”.
The presence of a coiled-coil domain in the THAP proteins was assessed with two separate tools: COILS
[102] and PairCoil2 [103]. Fasta sequences of the THAP proteins were used as queries, with default parame-
ters, except for the p-score cut-off which was set to 0.05. Both tools gave identical results in terms of presence
or absence of a coiled-coil domain, even though precise coiled-coil domain boundaries may slightly differ.
Evolutionary trees were done using the Mobyle portal [104] to perform multiple alignment (Muscle align-
ment), by providing an input fasta file containing the sequences to be aligned. This was done either on the
full-length THAP proteins, or only on their THAP domains. The alignment was refined using the “protein
boostrap distance phylogeny (alignment)” option (random number seed = 3; random number seed for multi-
ple dataset = 7). The output of the alignment was subsequently uploaded on the iTOL (interactive Tree Of
Life) online tool [105,106] for visualization.
RNA-seq analysis The high-throughput RNA sequencing data were analyzed by Dr. Viviane Praz. Single
reads were mapped onto the Hg19 human genome annotation using STAR (Spliced Transcripts Alignment
to a Reference, [107]) and read counts and normalized RPKM (Reads Per Kilobase of transcript per Million
mapped reads) were calculated using RSEM [108, 109]. Genes with an RPKM value below 1.2 in all the
experiments were considered as not expressed and discarded of further analyses. Differential analyses were
performed with DESeq2 [110] (fold-change cutoff = 0.5, adjusted pvalue = 0.05). Resulting gene sets were
submitted to Gene Ontology (GO) enrichment analysis [111,112], summarized and visualized using REVIGO
[113]. PCAs were done with the prcomp function of the R software, with no scaling or normalization.
ChIP-seq analysis The data obtained from the high-throughput DNA sequencing following the chromatin
immunoprecipitation were analyzed by Dr. Viviane Praz. Paired-end reads were mapped onto the Hg19 human
genome annotation using STAR (Spliced Transcripts Alignment to a Reference) [107]. Each fragment end
was mapped individually allowing a maximum of 10 multiple genomic matches. Only the equivalent multiple
matches (in terms of match length and mismatch numbers) were kept. The sequencing pairs were then
reassembled with in-house scripts.
Peaks were detected using the Model-based Analysis of ChIP-Seq (MACS2) tool [114] (format = BEDPE,
qvalue cutoff = 1.00e-03, duplicates allowed = 3, Broad region calling = off) and tested using a custom method
developed by Dr. Viviane Praz, which identified enriched bins with a so-called “Origami method” [115]. Only
MACS-identified peaks intersecting with the Origami enriched bins were kept. Peaks were further classified
into 3 categories: (i) peaks present in both WT and THAP11F80L samples; (ii) peaks present only in the
60
CHAPTER 2. MATERIALS AND METHODS
WT sample; (iii) peaks present only in the THAP11F80L sample. Intersecting peaks in the different samples
were represented by a Venn diagram using the Meta-Chart website (https://www.meta-chart.com). A peak
was said close to a TSS if at least one nucleotide of its underlying DNA region locates within +/- 250 bp of
a Pol2 transcription start site.
Peak scores were calculated as follows: (i) peak fragments of the IP sample were summed on the whole
peak region, and normalized to total fragments in the sample and peak width (bringing all peaks width at a
standard 1 kb); (ii) the same procedure was done for the input sample; (iii) for each sample, the peak score
was calculated as the log2 of the normalized IP counts (done in (i)) minus the input normalized counts (done
in (ii)). For calculation purposes, one pseudocount was added to each of the IP and input normalized counts.
Sequence comparison with known motifs was done on regions expanding 500 bp on each side of the peak
middle using CentriMo [116].
The motifs under the THAP11 peaks were further analyzed to identify subtle differences in the consensus
sequences. First, the peaks were redefined by taking the peak summits (meaning, the highest position of the
peaks) as a reference (instead of the peak centers) and extending the positions 250 bp on each side. Second,
the ZNF143 consensus motif from Hocomoco (reference ZN143 HUMAN.H11MO.0.A, here 22-bp long) was
screened over the whole genome using the PWMTools web interface [117] to extract all the genomic positions
containing such motif, as well as the correponding 22-bp DNA sequence. Third, sequences intersecting
between the list of peaks and the genomic screen described (the latter having produced a list of more than
9 millions of sequences) were extracted. If more than one motif was identified for a given peak, only the
one closest to the peak center was considered. Fourth, a consensus sequence was generated using the list of
pre-aligned 22-bp long sequences and a logo was made. The number of THAP11-associated motifs per peak
was defined by counting, for each peak, the number of motifs in a region expanding 1000 bp on each side
of the peak maximum. The scores were defined as the difference of the IP and input log2 counts, scaled by
total tags in sample and peak width.
Peaks close to TSS (+/- 5 kb) were visualized with the UCSC genome browser [118] in which wiggle files
prepared by Dr. Viviane Praz were uploaded, all tracks being set with the same vertical viewing range (1 to
600).
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Evolution of THAP proteins in animal
species
When Roussigne and colleagues [40] reported the discovery of the THAP domain, they found THAP genes
in several animal species, but not in plants, yeast, fungi or bacteria. They therefore postulated that the
THAP domain is restricted to animals. Here, I use bioinformatics tools to dig inside the landscape of THAP
proteins in animal — and also potentially non-animal — species.
3.1 The THAP family within animal species
Here, I digged into the landscape of THAP proteins in selected animal model species.
3.1.1 THAP proteins in animal and non-animal species
Using the list provided by Clouaire and colleagues [46] and the Pfam database [99], I have counted all the
THAP proteins in selected animal model species (Figure 3.1): Homo sapiens (human, 12), Mus musculus
(mouse, 7), Gallus gallus (chicken, 7), Xenopus tropicalis (frog, 27), Danio rerio (zebrafish, 45), Drosophila
melanogaster (fruit fly, 12), Caenorhabditis elegans (round worm, 8). I only considered as putative THAP
proteins those having indeed an N-terminal THAP domain, with the appropriate characteristics (see section
1.3.2). In addition, I removed as much as possible redundant annotated sequences that are very likely to
belong to the same protein. I observed that, while in 5 out of the 7 species, the number of THAP proteins
remains in the same order of magnitude, this number has exploded in the zebrafish (almost 4-times more
THAP proteins compared to human) and, even to a lesser extent, in Xenopus tropicalis. In addition, the Pfam
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Figure 3.1: Number of THAP proteins in animal species.
database does not list any non-animal THAP proteins. Also, Protein Blast [100] on a a list of 122 animals,
99 protists and 48 plants, using the human THAP proteins as queries, did not reveal any non-annotated
THAP proteins in either animal or non-animal species. This also confirms the fact that the THAP domain
is animal specific.
3.1.2 Orthologs of human THAP proteins
Using the list of THAP proteins obtained and the gene annotations available, I investigated the presence of
orthologs of the human THAP proteins in the 6 other selected species.
First, the accuracy of each already-annotated ortholog was verified by performing Protein Blast on the
human-protein database using the annotated ortholog as a query, and on the selected-species protein database
using the human THAP protein as a query. This confirmed all of the orthologous relationships already
annotated. In addition, when there was not any ortholog for one particular THAP protein in a species, I
assessed whether it is due to a lack of annotation or to a real absence of ortholog. For this, I ran Protein
Blast on the selected-species protein database using the human THAP protein as a query. But, this analysis
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did not reveal any additional orthologs than the ones already annotated in the databases.
I exploited a complementary method to verify differently the orthologous relationships and identify new
ones. For this, I used the Mobyle portal (Mobyle@Pasteur) [104] and the iTOL (interactive Tree Of Life)
online tool [105,106] to build phylogenic trees. Each tree was made by mixing the human THAP proteins and
the THAP proteins from a single other species (data not shown). Again, it confirmed the already-annotated
orthologous relationships without revealing any new ones.
Table 3.1 summarizes the presence (green plus) or absence (red minus) of human THAP orthologs in the
selected animal species. To begin with, no ortholog of human THAP proteins has been detected in Drosophila
melanogaster and Caenorhabditis elegans. In addition, some human THAP proteins have been well conserved
from zebrafish to human, such as THAP0, 1, 4 and 7. In contrast, other human THAP proteins, such as
THAP8 and THAP10, seem to have appeared very recently in evolution. Some conservation patterns are
less easy to interprete, such as THAP2 and THAP6, because they appear in distant species but in not
proximal species on the evolutionary tree. An hypothesis is that the THAP orthologs would have appeared
independently in different species after speciation; it is, however, very unlikely due to the poor statistical
chances that it happens. Alternatively, the THAP gene may have been present in anscestor species, but
subsequently lost in some species after speciation, due to the divergence and decay phenomenon explained in
section 1.1.3. To test this hypothesis, one could look for related pseudogenes in the genome of the considered
species. Also, I noted that THAP11 is conserved in every species, but in the chicken (Gallus gallus). It is well
known that the Gallus gallus genome is poorly assembled. Consequently, the presence or absence of ortholgs
using genome sequences is poorly reliable in this species. Thankfully, another bird has been sequenced and
assembled with much better quality: the Tibetan ground tit (Pseudopodoces humilis, a bird from the Tibetan
plateau north of the Himalayas) [119]. I thus assessed the presence of human THAP orthologs in this species.
As in Gallus gallus, I found orthologs for human THAP0, 1, 4, 5, 7 and 9, and not of human THAP2, 3, 6, 8
and 10. But, unlike in Gallus gallus, I also found an ortholog of human THAP11. This suggests that there
is probably an ortholog of human THAP11 in birds, and that its absence in the Gallus gallus genome is due
to the poor genome assembly at this species. For the rest of this study, I therefore consider the THAP11
protein sequence from Pseudopodoces humilis as the avian model (Table 3.1, purple plus).
3.1.3 Relationships between human THAP proteins
I then analyzed the relationships between the 12 different human THAP paralogs.
First, while the THAP proteins form a family of structurally-related proteins, they are quite diverse.
Even the THAP domain, which gives them their identity, is less than 50% identical among each other.
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Table 3.1: Orthologs of human THAP proteins. Green, presence of an ortholog; red, no ortholog;
purple: probable ortholog found in another avian species (see text for details).
This divergence can explain why the different THAP domains do not recognize the same DNA sequences.
Considering the full-length proteins, this percentage drops to around 30-35% for most pairs of human THAP
proteins. This diversity can also be noted just when comparing the features of each THAP member, as seen
in Figure 1.5. This suggests that, despite sharing some features and perhaps some functions, each THAP
protein may have its own specifity.
Second, I produced an evolutionary tree as decribed above, to uncover the relationships between the
different proteins of the human THAP family. Figure 3.2 shows the 12 human THAP proteins, sorted by
sequence similarity of their THAP domain. It suggests the existence of protein couples, such as THAP2 and
10, THAP0 and 11, THAP1 and 3 or THAP5 and 8. Curiously, three of these four pairs associate an HBM-
containing protein with a non-HBM protein. This observation raises the intringing hypothesis of duplications
events and subsequent divergence which could have created such couples, one potentially interacting with
HCF-1, while the second not.
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Figure 3.2: Human THAP proteins. The 12 human THAP proteins are sorted by sequence similarity of
their THAP domain.
3.2 The HBM sequence in animal THAP proteins
I have previously explained that 9 of the 12 human THAP proteins display an HBM (i.e., HCF-1 Binding
Motif), and that HCF-1 seems to be an important co-factor in THAP-mediated activities (see 1.3.4). Also,
HCF-1 is conserved in metazoans (Gonzalez, Praz and Herr, personal communication). Thus, I globally
investigated the presence of the HBM sequence among animal THAP proteins.
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3.2.1 Conservation of the HBM sequence during the evolution of the THAP
proteins
The presence of the HBM sequence in each animal THAP protein listed in Figure 3.1 was explored using Pro-
tein Pattern Find [101]. Only consensus HBM sequences (B/ZHxY, where B and Z are aspartate/asparagine
or glutamate/glutamine, respectively, and x denotes any amino acid) were considered and the percentage
of HBM-displaying THAP proteins in each species has been calculated (Figure 3.3). This percentage is
pretty low in Caenorhabditis elegans (13%, 1 out of 8) and progressively increases in Drosophila melanogaster
and Danio rerio. Then, from Xenopus tropicalis to Homo sapiens, this percentage remains stable and high
(approximately 70%). This suggests that the interaction between HCF-1 and THAP proteins has changed
during evolution and is strenghtened in species closer to human.
Figure 3.3: Conservation of the HBM sequence during THAP-protein evolution. The percentage
of HBM-positive THAP proteins is displayed for each animal model species.
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3.2.2 Conservation of the HBM sequence among orthologs of human THAP
proteins
I then had a closer look at the conservation of the HBM sequence among the orthologs of human THAP
proteins, as seen on Table 3.2. I observed that, when there are orthologs of human THAP proteins, the HBM
presence or absence is well conserved. Indeed, when the HBM is present in the human proteins, it remains
present at least until Xenopus tropicalis, and most of the time until Danio rerio. This is also true for the 2
HBM-like sequences from human THAP4. Also, the HBM consensus sequence allows flexibility. I noted that,
while in some cases the HBM sequence is strictly conserved (e.g. THAP1 or 7), in other cases the 4 amino-
acid sequence has changed during evolution, yet still respecting the consensus sequence (e.g. THAP2 where
the first amino-acid position is a glutamic acid in Homo sapiens, and a aspartic acid in Xenopus tropicalis).
In addition, the only human HBM-negative THAP proteins having orthologs in the chosen model species
(THAP0) remains HBM negative in these species. More particularly, it is curious to realize that, among the
3 HBM-negative THAP proteins, a single one (THAP0) has orthologs in the chosen model species. It may
indicate that the HBM sequence is a selected element in evolution.
To conclude, the HBM sequence appears to be a critical element in THAP proteins that is very well
conserved during evolution, likely being the indication of a functional importance.
3.3 The coiled-coil domain of THAP proteins
The ability to form dimers is often important for the function of transcription factors, as mentionned in
section 1.1.2. Thus, the coiled-coil dimerization domain may have a particular functional relevance in THAP
proteins.
3.3.1 Presence of the coiled-coil domain in THAP proteins
Gervais and colleagues have published that all the 12 human THAP proteins display a coiled-coil domain [42].
I have used two independent bioinformatics tools to predict the presence and boundaries of coiled-coil domains
in proteins: COILS [102] and PairCoil2 [103]. Both prediction tools gave the same results: contrary to what
was suggested [42], not all human THAP proteins display a coiled-coil domain, as no such domain was
identified in THAP0, 9 and 10 (Figures 1.5 and 3.2, blue box). This suggests that the distinct THAP
proteins might not have the same ability to homo- or heterodimerize. In addition, the human family of
THAP proteins displays all the possibility of HBM/coiled-coil containing/lacking proteins. Thus, the HBM
and coiled-coil characteristics of each THAP protein may be particularly critical for its specific action.
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Table 3.2: The HBM sequence in human THAP-protein orthologs. Green text, HBM sequence
(consensus sequence B/ZHxY, where B and Z are aspartate/asparagine or glutamate/glutamine, respectively,
and x denotes any amino acid); green dot, no HBM in this ortholog; red minus, no ortholog. Italic, HBM-like
sequence. Please note that the THAP11 protein sequence from Pseudopodoces humilis was considered as the
avian (Gallus gallus) model (see text for details).
Contrary to what I demonstrated above for the HBM sequence, no particular conservation pattern of
the coiled-coil domain was observed when looking at the different orthologs of human THAP proteins (not
shown). To have a more global idea of the importance of the coiled-coil domain in THAP proteins, I plotted,
for each species I worked with, the percentage of coiled-coil domain-positive THAP proteins (Figure 3.4). It
shows that this percentage is slightly higher in Gallus gallus, Mus musculus and Homo sapiens compared
to other species. In Danio rerio and Xenopus tropicalis, the percentage drops. This can be explained, at
least, by the higher number of THAP proteins in these species and an expansion of non coiled-coil orthologs.
To conclude, the coiled-coil domain seems to be more conserved in species closer to humans, suggesting a
selection pressure in THAP proteins to possess such a domain.
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Figure 3.4: Frequency of coiled-coil domains in THAP proteins. The percentage of coiled-coil domain-
positive THAP proteins is displayed for each animal model species.
3.3.2 Coiled-coil domains and HBM sequences
Curiously, when both an HBM sequence and a coiled-coil domain are present in the same THAP protein,
they are in close proximity, the HBM being always just N-terminal (Figure 1.5). To investigate further the
possibility of a link between these two domains, I assessed the distance between these two features in HBM
and coiled-coil-positive THAP proteins, in all selected species (not shown). I realized that, in frog, chicken,
mouse and human, the relative position of the domains remains the same and the distance between them is
around 10 amino acids, even often less. But, in zebrafish, fly and worm, the distance slighlty increases. This
suggests that the HBM sequence and the coiled-coil domain might be functionally linked to each other, at
least in tetrapod species.
3.4 Discussion
In this chapter, I used bioinformatic tools to study features of the THAP proteins.
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First, I confirmed that the THAP domain is animal specific, and listed and verified all the THAP proteins
in 7 selected animal model species. One challenging problem was that, even though human and mouse
genomes are extremely well annotated, it is not as well done for other species. Consequently, in Gallus
gallus, Xenopus tropicalis, Danio rerio, Drosophila melanogaster and Caenorhabditis elegans, I obtained
many “uncharacterized” as well as “predicted” proteins. This complicated the analysis as some sequences
might be partial, or redundant with others, while corresponding to the same protein. Conversely, sequences
can be uncorrectly annotated. These drawbacks can mistakenly “create” or “miss” proteins. I tried as much
as possible to remove this bias, by carefully analyzing the sequences. In particular, I extensively performed
Protein Blast analyses to identify sequences that are likely to belong to the same protein, to remove as much
as possible artificial redundancy. I also verified the orthologous relationships already annotated with the
human THAP proteins and tried to uncover new ones. In particular, THAP11 was surprisingly absent from
the Gallus gallus annotations, but I showed that THAP11 is likely to be present in birds. The search for
additional non-annotated orthologous relationships using either Protein Blast searches or phylogenic trees
was unsuccessful. Nevertheless, these methods do not exclude the existence of yet-unnanotated orthologs
of human THAP proteins in other species. To have a more complete view of the presence or absence of
orthologs, one should also look at RNA-seq data and assess the presence of transcripts corresponding to
human THAP proteins.
Finally, I had a closer look at the human THAP proteins and realized that, despite sharing the THAP
domain and some additional features, the human THAP proteins sequences are pretty diverse. This can
suggest two non-exclusive hypotheses:
• Despite their weak sequence similarity, the THAP proteins could still have similar functional domains
and 3-dimentional structures, as we know it is already the case for the THAP domain, as seen in section
1.3.2. Thus, even being different at the amino-acid level, the 12 human THAP protein are likely to be
structurally and functionaly related.
• Alternatively, this divergence may have led to THAP proteins having their own identity and specificity.
As an example, the THAP domains of distinct human THAP proteins have similar 3-dimentional struc-
tures but recognize different DNA sequences (section 1.3.2). More generally, the sequence divergence
of THAP proteins probably has led to the appearance of specific functions and characteristics for par-
ticular THAP members (i.e., sub-functionalization). For instance, each THAP protein might have
the ability to interact with a different set of co-regulators, of which some might be shared with other
THAPs. Similarly, as distinct THAP proteins do not recognize the same DNA sequence, it is likely
that each one regulates a different set of genes, resulting in different regulatory outcomes.
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To conclude, the human family of THAP proteins displays similarities and differences, which can lead to
both shared and specialized partners, functions and outcomes.
I also had a closer look at the HBM sequence, which may be of particular relevance for THAP proteins.
Indeed, the HBM is present in most of human THAP members, and HCF-1 has been suggested to be a critical
partner for THAP-protein functions (section 1.3.4). By probing the presence of the HBM motif in each of
the listed animal THAP protein, I demonstrated that the percentage of HBM-containing THAP proteins has
changed during evolution and is higher in species closest to the human one. Also, I showed that, among
the orthologs of human THAP proteins, the presence or absence of the HBM sequence is relatively well
conserved. Thus, it is likely that the HBM is under positive selection pressure in THAP proteins, suggesting
its functional importance in this protein family. Together with the fact that both THAP and HCF-1 proteins
are restricted to metazoans, it raises the interesting possibility of their co-evolution.
Furthermore, I investigated the presence and conservation of the coiled-coil domain in THAP proteins,
as dimerization is of particular relevance in transcription factors (see section 1.1.2). I demonstrated that,
contrary to what has been published, some THAP proteins do not bear any evident coiled-coil domain. This
observation suggests that each THAP protein is likely to have a distinct capacity in dimerization, and also
different protein partners. The coiled-coil domain does not show any particular pattern of conservation among
human THAP orthologs, contrary to what has been shown with the HBM sequence. Nevertheless, looking
overall at all THAPs suggests that this domain is under positive selection pressure in THAP proteins as well.
Consequently, dimerization of THAP proteins might have a particular relevance for their functions. I also
identified a possible connection between the HBM sequence and the coiled-coil domain. Indeed, when both
are present in a single THAP protein, they are always close to each other, with the HBM being N-terminal
of the coiled-coil domain. This curious feature is conserved from human to frog, while less obvious in more
distant animals. This raises the intringing possibility of a functional link between these two domains and
further, between HCF-1 binding and protein dimerization. Thus, the THAP coiled-coil domains appear to
have an importance not only by themselves, but also in the context of an HCF-1 interaction.
It should be noted that this bioinformatics analysis was done at the beginning of my doctoral studies,
nearly 5 years ago. As mentionned above, the sequencing annotations of some species were far from complete.
But this is constantly improving and genome annotations are in permanent evolution. Consequently, some
annotations used in my analyses may have changed since then, and consequently the list of proteins, especially
for species other than human and mouse, may have also changed.
This in-silico analysis has revealed interesting features of THAP proteins, and raised attracting hypotheses
on their functions and characteristics. Biochemical and functional experiments are the next step to verify
these different hypotheses and uncover more precisely the relevance of the different domains, in particular the
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HBM sequence and the coiled-coil domain. Indeed, it would be of particular interest to investigate further the
functional role of these domains, which so far remains elusive, in future experiments. For instance, biochemical
experiments would unravel whether the different THAP proteins bind to HCF-1, as well as the importance
of the HBM sequence in the potential interaction. In addition, one could probe the potential of THAP
proteins to form (homo- and hetero-) dimers and the contribution of the coiled-coil domain to the possible
dimerization. Also, I suggested that each human THAP protein, although a member of a structurally-related
protein family, may have a particular combination of characteristics which makes it unique. To test this idea,
one could imagine to create THAP chimeras by combining portions of separate THAP proteins.
Another important aspect of proteins is to know their pattern of expression. Indeed, this can give insight
into their role. To assess the levels of proteins, one can either use publicly-available data, or experimentally
probe the protein or mRNA levels.
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Chapter 4
Expression of THAP genes
Here, I explain how I probed the expression of human THAP genes in normal tissues and in cultured cells,
as well as murine Thap genes in the regenerative liver.
4.1 Expression of human THAP genes in normal tissues
Here, I used available data to probe the expression of the different human THAP genes in normal tissues.
A former group from our department performed extensive RNA sequencing in different species for 6 organs:
brain, cerebellum, heart, kidney, liver and testis [120]. I took advantage of their data and analyzed the
normalized expression levels of the THAP genes in human, expressed in RPKM (Reads Per Kilobase of
transcript per Million mapped reads). In their analysis, only the genes displaying 1:1 orthology relationship
for each pair of selected primates species were considered. Consequently, the expression values of 9 out of
the 12 human THAP genes were available (THAP1, 2, 4, 6 to 11 ), while THAP0, 3 and 5 were not. For
brain, cerebellum, heart and kidney, one female and at least one male were analyzed; for liver and testis, two
males (but not female — naturally, for testis) were used.
First, I compared the expression values of each human THAP gene available between the two sexes. The
normalized expression values are similar between males and females in brain, heart and kidney, whereas in
the cerebellum, males and female seem to express differently some THAP genes (not shown).
I then plotted the mean of the normalized expression values from the male individuals for each available
human THAP gene and for the 6 organs. Choosing to concentrate on male individuals allowed me to probe
more organs and to determine variation between individuals, as several males were used but only one female.
As shown in Figure 4.1, some THAP genes are much more expressed than others, such as THAP4, 7 and
11. In addition, while some genes display a homogenous pattern of expression in the different organs (e.g.
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THAP11 ), some are differentially expressed according to the tissue (e.g. THAP1 ).
In conclusion, the differing expression patterns of human THAP genes suggest that each THAP member
possesses its unique regulatory mechanism, which can be ubiquitous or tissue specific.
Figure 4.1: Expression levels of THAP genes in human organs. Mean +/- standard deviation
of normalized RPKM expression values from males individuals. No standard deviation is shown for the
cerebellum as only one male individual was used. Note that THAP0, 3 and 5 are missing from the histogram.
4.2 In cultured cells, most human THAP genes are not differently
expressed along the cell cycle
Tissue-culture cells can be easily synchronized along their cell cycle using two rounds of thymidine block [121].
At the end of the second block, cells have accumulated at the G1-to-S phase transition. When released into
normal medium, they progress through the cell cycle in a synchronous manner. As a result, one can obtain
homogenous populations of cells at specific phases of the cell cycle.
4.2.1 The human THAP11 protein in synchronized cells
I was interested to probe the variation of THAP-protein levels during the cell cycle. The study of proteins,
however, is restricted by the availability of antibodies. Thus, I was only able to probe the levels of the
THAP11 protein, as it is the only THAP member for which I had a working antibody.
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I performed double-thymidine block on HeLa-S cells grown in suspension. From the release in normal
medium, I did a time course in which I analyzed every two hours the DNA content of the cells to assess
their cell-cycle status. Figure 4.2 A shows the flow cytometry profiles of cells, for which their DNA was
stained with propidium iodide. The P2 (left) and P4 (right) gates delimitate the diploid (2n) and tetraploid
(4n) cells, respectively. The P3 (middle) gate delimitates the cells in between which are synthesizing DNA.
Consequently, the P2, P3 and P4 gates contain the cells in G1, S and G2/M phases, respectively. The DNA
profile of non-synchronized cells (top left) exhibits 48% of cells in G1 (P2), 17% of cells in S phase (P3) and
34% of cells in G2/M phases (P4). The other profiles show that cells are efficiently synchronized at G1-to-S
transition prior release (86% of cells in P2), and then in S phase at 4 hours after release (67% of cells in P3),
in G2/M phase at 8-10 hours (74% and 71% of cells in P4, respectively), in G1-early (G1E) after 12 hours
(82% of cells in P2) and in G1-late (G1E) at 16 hours post relase (87% of cells in P2) [28, 121]. From 20
hours post release, the signal becomes blurred, indicating that the cells are losing their synchronization.
I also probed for the levels of cell-cycle protein markers: phospho-CDK1, cyclin A and cyclin B1. Their
respective levels confirmed the identified correspondance between the time points and the cell-cycle phases
(not shown).
At each time point post thymidine release, I probed for THAP11 protein. Figure 4.2 B shows the result.
The THAP11 protein levels were constant all along the course of the cell cycle, suggesting that its synthesis
is not cell-cycle regulated.
4.2.2 Human THAP genes in synchronized cells
To examine the expression of the THAP -gene family more broadly, I studied the THAP mRNA levels during
the course of the cell cycle, keeping in mind that mRNA and protein levels do not necessarily correlate.
Double-thymidine block was performed on HeLa-S cells grown in suspension as before. At different time
points post release in normal medium, RNA was extracted from the cells and subsequently submitted to high-
throughput sequencing (RNA-seq). This particular experiment was performed by Maykel Lopes, research
technician, and analyzed by Dr. Viviane Praz, a lab bioinformatician. Figure 4.3 shows the mRNA levels
of the corresponding THAP genes determined by the RNA-seq analysis, expressed in log2 of RPMK values.
Thus, a 1 unit change on the log2 RPKM Y-axis scale represents a 2-fold mRNA level change.
Among the 12 THAP genes, only THAP8 is not expressed in HeLa-S cells, as shown by the mRNA-level
curves below the cut-off (green bar). THAP2 and THAP3 are the only THAP genes that exhibit a notable
variation of mRNA levels during the progression through the cell cycle: THAP2 mRNA level progressively
decreases while cells are progressing along the cell cycle, while THAP3 mRNA level increases by almost 2.8
77
CHAPTER 4. EXPRESSION OF THAP GENES
78
CHAPTER 4. EXPRESSION OF THAP GENES
Figure 4.2: Levels of human THAP11 protein along the cell cycle of cultured cells. HeLa-S cells
grown in suspension were synchronized at G1-to-S phase by double thymidine block and analyzed at different
time points after release in normal medium. (A) Flow cytometry plots showing the DNA content of cells.
P2, G1-phase cells; P3, S-phase cells; P4, G2 and M-phase cells (see text for details). AS, asynchronous cells.
Blue circles, identification of the corresponding cell-cycle phases. (B) At each time point, the same amounts
of whole cell lysates were probed for THAP11 protein. The 12-hour time point has been done in duplicate
(12a and 12b).
fold (log2 RPKM change of 1.5) between 2 and 10 hours post release. The 9 other THAP genes, which are
expressed, are not markedly changing along the cell cycle.
In conclusion, among the human THAP genes expressed in HeLa-S cells, all but THAP2 and THAP3
seem quite constant along the cell cycle. In contrast, THAP2 and THAP3 show a notable change in mRNA
levels during the course of the cell cycle.
4.3 Expression of murine Thap genes during liver regeneration
Our laboratory has extensive experience with performing liver regeneration experiments [122,123]. Two-third
partial hepatectomy in the mouse induces a highly coordinated regeneration in which remaining hepatocytes
synchronously enter and progress through the cell cycle (Figure 4.4 A). This model is thus an excellent tool
to study, in vivo, the expression of genes along the cell cycle. Two-third partial hepatectomy was performed
on mice [122,123]. At different time points post surgery, mice were sacrified, RNA extracted from the livers
and submitted to high-throughput sequencing. In parallel, livers were used for ChIP-seq (Chromatin Im-
munoPrecipitation followed by high-throughput sequencing) against the Pol2 polymerase (Pol2), to correlate
the expression of genes with the presence of the polymerase at their promoter. This experiment was part of
Dr. Leonor Rib’s PhD thesis [123], who extracted for my purpose the expression levels of the murine Thap
genes and the presence of Pol2 at their promoters or in their gene bodies. Figure 4.4 B shows that the 7
murine Thap genes have a remarkable homogenous expression during the progression through the cell cy-
cle (yellow lines, mRNA levels). Similarly, the abundance of Pol2 at the gene promoter (brown lines, Pol2
promoter) and in the gene body (pink lines, Pol2 transcription unit) does not really vary either.
Thus, most of these results are consistent with the previous observation made in synchronized HeLa-S
cells. Indeed, mouse Thap0, 1, 4, 7 and 11 mRNA levels are not affected by the progession along the cell
cycle, similarly to human genes. By contrast, mouse Thap2 and 3 mRNA levels are not changed during the
cell cycle, while the corresponding human genes exhibit a decrease and an increase, respectively.
79
CHAPTER 4. EXPRESSION OF THAP GENES
Figure 4.3: Expression levels of human THAP genes along the cell cycle of cultured cells. HeLa-S
cells grown in suspension were synchronized at G1-to-S phase by double thymidine block and analyzed at
different time points after release into normal medium; the time points and the associated cell-cycle phases
are indicated below the THAP11 gene results. log2 of RPKM expression values (Y axis) are displayed for
each THAP gene. Red, replicate 1; orange, replicate 2; blue, mean of the 2 replicates; green, mRNA-level
cut-off.
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Figure 4.4: Transcription profiles of murine Thap genes during liver regeneration. Partial hepate-
ctomy was performed and the mice were sacrified at different time points post surgery, RNA extracted from
the liver and submitted to high-throughput sequencing. (A) Schematic showing the cell-cycle progression
following partial hepatectomy [122]. (B) Transcript levels and Pol2 occupancy are displayed for each Thap
gene. Orange, mRNA; brown, Pol2 at promoter; pink, Pol2 in the gene body.
4.4 Discussion
In this chapter, I have combined data of diverse sorts to probe the expression of the THAP genes: publicly-
available data, experimental results from colleagues, and my own experiments.
First, I took advantage of gene expression analyses that have been already published [120] and for which
the data are available online . This study assessed the gene expression levels in different human organs, in
several males and one female. From this, I was able to extract the levels of expression of the human THAP
genes. I observed that each THAP gene has a specific expression pattern, some being much more expressed
than others, and some having a tissue-specific expression pattern while other showing a more ubiquitous
pattern. These results suggest that at least some human THAP proteins may have tissue-specific functions.
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This result meets with the observations of the preceding chapter (Chapter 3) in which each THAP protein
was suggested to be unique, despite belonging to the same family. Indeed, I previously hypothesized that
each THAP protein would have specialized partners, functions and outcomes. This latter idea is strengthened
by the different patterns of expression of the diverse THAP members.
In addition, I probed the expression levels of THAP genes during the cell cycle. Indeed, as THAP
proteins have been suggested to be transcription factors implicated in the control of different phases of the
cell cycle, a possible level of regulation would be the modulation of their expression levels during cell-cycle
progression. To test this hypothesis, I used both synchonized human cultured cells and regenerating mouse
livers. The analysis of human THAP -gene expression shows that all but THAP2 and THAP3 genes remain
relatively constant along the cell cycle. By contrast, THAP2 and THAP3 mRNA levels change during the
cell cycle: they decrease, and increase, respectively, while the cell cycle progresses. The analysis of THAP11
protein levels is constistent with what has been shown at the mRNA level as the level of THAP11 protein in
synchronized cultured cells remains remarkably constant.
Also, the analysis of murine Thap mRNA levels during liver regeneration following partial hepatectomy
show both similar and different observations when compared to the human THAP genes. In a mouse liver
regeneration experiment, all 7 Thap mRNA levels remains relatively constant. The results are thus different
from what has been observed for human THAP2 and THAP3 genes.
Overall, the expression of most THAP genes do not appear to be particularly regulated along the cell cycle.
Two particular THAP genes, however, seem to have their expression affected during the cell-cycle course
in humans, but not in mice. The discrepancy between these two THAP genes and the rest of the THAP
family, as well as the discrepancy between human and mouse THAP2 and THAP3 genes, may be explained
differently for the two THAP genes. First, regarding THAP2, it has been shown to be downregulated in
the mouse placenta and developing brain following late-gestational hypoxia [124]. When growing HeLa-S
cells, we try as much as possible to keep them in suspension by cultivating them under constant agitation.
Nevertheless, these cells tend to aggregate. Then, in the course of an experiment in which cells are growing,
the increasing number of cells potentiates the tendency of HeLa-S cells to aggregate. When aggregated, the
cells are likely to have less locally-available oxygen, and thus to suffer from mild hypoxia. As this phenomenon
would tend to increase with the concentration of cells, it would thus increase while the experiment progresses.
This hypothesis would not only explain why THAP2 mRNA level was increasing in the cell-synchronization
experiment, but also account for the discrepancy between human and murine THAP2 mRNA levels in the two
different experiment. Second, with regard to THAP3, a recent study reported THAP3 mRNA upregulation
in human oligodendrogliomas and categorized this gene, together with others, as a gene candidate favoring
oligodendroglioma growth [84]. This hypothesis is coherent with the increase of THAP3 mRNA levels
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observed during the progression along the cell cycle. This does not explain, however, the fact that THAP3
mRNA levels are not decreasing at later time points in the synchonization experiment (from 16 hours post
release in normal media) to go back to the initial levels observed at time point 0 in order to start a new
cell cycle. Regarding the discrepancy between human and mouse THAP3 mRNA-level variation, one could
argue a species-specific mechanism. Alternatively, THAP3 gene expression may indeed be affected by the
double-thymidie block. This hypothesis why THAP3 mRNA level was changing during the first hours post
release in normal media, and then remaining constant. It would also explain why this phenomenon was not
observed in the mouse-liver regeneration experiment.
Thus, most cell-cycle specific action of THAP proteins is likely to be achieved by modulation of their
binding to promoters, rather than by modulating their levels. Nevertheless, except for THAP11, I cannot
exclude the possibility of a post-transcriptional regulation, which would modulate THAP-protein levels. To
test these possibilities, one should probe the binding of THAP proteins at promoters along the cell cycle.
ChIP-seq experiments against THAP proteins would need to be performed, either in synchronized human
cells, or in post-partial hepatectomy mouse livers.
4.5 Selection of THAP proteins for further study
Having largely considered the whole set of THAP proteins for the analyses done so far, I will know focus on
a smaller subset of THAP proteins. Indeed, while it is possible to investigate many proteins simultaneously
using bioinformatics tools, and in some high-throughput experiments, it would be highly inefficient to try
to deal with the complete set of human THAP proteins together for future experiments. I thus decided to
select a restricted number of THAP proteins to study further. The criteria I used to make a choice are the
following:
• To have the possibility to study endogenous proteins in vivo, I selected abundantly expressed ones. Even
though gene expression and protein levels are not systematically correlated, I nevertheless took into
account the expression levels of human THAP genes displayed in Figure 4.1, where the higher-expressed
ones are THAP4, 7 and 11.
• As I have a particular interest in the interplay between THAP proteins and HCF-1, I selected HBM-
bearing THAP proteins, but including an HBM-negative THAP protein to compare and contrast. The
HBM-negative protein selected was THAP8, as it is higher expressed than the 2 other non-HBM THAP
proteins (Figures 3.2 and 4.1). This led me to also include THAP5, which appears to be the closest
related THAP member to THAP8 (Figure 3.2).
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• It is essential to have the possibility to do validation studies in living organisms. Thus, I focused my
attention on THAP proteins having an ortholog in mouse (Figure 3.2).
• Also, it is of particular interest to work on proteins involved in human diseases, especially when specific
associated mutations have been uncovered. For this reason, I believe it would be extremely exciting to
study THAP1 and THAP11.
To summarize, I concentrated on the following six THAP proteins for deeper investigations: THAP1, 4,
5, 7, 8 and 11.
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Chapter 5
Biochemistry analysis of selected
THAP proteins
In this chapter, I describe how I performed biochemistry analyses to assess the ability of THAP proteins to
bind to themselves, to other members of the THAP family, or to HCF-1.
5.1 Dimerization of THAP proteins
As mentioned, most of the THAP proteins possess a putative coiled-coil dimerization domain (section 1.3.2),
and thus could potentially interact with other proteins possessing a coiled-coil domain. Also, dimerization
often being an important feature of transcription factors (section 1.1.2), it is of particular interest to study
whether THAP proteins can form dimers. Here, I describe the potential interaction of THAP proteins, both
with themselves as homodimers, and with each other as heterodimers.
5.1.1 THAP proteins can form homodimers
I first focused on the ability of THAP proteins to form homodimers. To start with, I verified the previously-
described THAP11-homodimer formation [54, 55] by co-transfecting HEK-293 cells together with HA- and
Flag-tagged THAP11 constructs (Figure 5.1 A) and immunoprecipitating the HA-tagged protein. As shown
in Figure 5.1 B, THAP11-Flag is recovered in the THAP11-HA immunoprecipitate (compare lane 6 with lane
8). Thus, the THAP11 protein can form homodimers.
In addition, I previously suggested that the HBM sequence and the coiled-coil domain might be somehow
functionally linked to one another (see section 3.3.2). I thus asked whether THAP11 homodimerization de-
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pends on the HBM sequence, meaning whether this homodimerization would be sensitive to HBM disruption.
I thus repeated the previous experiment using a THAP11 mutant construct in which the HBM sequence has
been disrupted by point mutation: DASA in THAP11HBMmut instead of DHSY in THAP11WT (Figure 5.1
A). Comparing lane 8 with lane 10 in Figure 5.1 B shows that THAP11HBMmut-Flag interacts as efficiently
as THAP11WT -Flag with THAP11WT -HA. This demonstrates that THAP11 homodimerizes independently
of the HBM sequence.
I performed similar experiments to assess the homodimerization ability of THAP7 and THAP8. I co-
transfected cells with both HA- and Flag-tagged THAP7 or THAP8 expressing constructs (Figure 5.1 A)
and immunoprecipitated the HA version. Figure 5.1 C shows that both THAP7 and THAP8 have the ability
to form homodimers (lanes 8 and 10, respectively). In addition, THAP7 homodimers seem to be stronger
than THAP8 ones, as the THAP8-Flag protein is recovered less efficiently than the THAP7-Flag one when
immunoprecipitating for THAP8-HA or THAP7-HA proteins, respectively (compare lanes 7-8 with lanes
9-10).
5.1.2 Selected pairs of THAP proteins form heterodimers
I then tested whether THAP proteins can form heterodimers. More precisely, I assessed whether THAP11
can bind other THAP proteins by co-transfecting THAP11-HA together with Flag-tagged THAP constructs,
and immunoprecipitating THAP11-HA (Figure 5.2 A). Figure 5.2 B shows that, while THAP8 is recovered in
the THAP11 immunprecipitate, THAP7 is not (lanes 10 and 8, respectively). A control experiment showed
that THAP8 was not recovered in the absence of HA-tagged THAP11 protein (data not shown). In addition,
THAP4 is not recovered by THAP11 co-immunoprecipitation (Figure 5.2 C, lane 6). Thus, THAP11 can
form heterodimers with THAP8, but not with THAP4 and THAP7.
5.1.3 Conclusions
I have shown here that the three THAP proteins tested (THAP7, 8 and 11) form homodimers. Notably,
the disruption of the HBM sequence does not impair THAP11 homodimerization. In addition, one forms
heterodimers with THAP11 (THAP8), whereas the others tested do not (THAP4 and 7). In conclusion, the
distinct THAP proteins interestingly possess different potentials for homo- and heterodimer formation.
5.2 Interactions between THAP proteins and HCF-1
Assessing the HBM presence among THAP proteins in evolution suggested that there is a selective pressure
towards its presence and maintenance in THAP proteins, likely being evidence of a functional relevance
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Figure 5.1: Formation of homodimers within the THAP family. HEK-293 cells were co-transfected
with Flag- and HA-tagged THAP constructs (A) and whole cell lysates were then subjected to HA immuno-
precipitation and analyzed by immunoblot (B and C). (B) THAP11 forms homodimers independently of
its HBM sequence. (C) THAP7 and THAP8 form homodimers. HBM-positive THAP proteins are depicted
in green whereas HBM-negative ones are in red. * non-specific band (antibody heavy chain). wlc, whole cell
lysate; IP, immunoprecipitate.
(section 3.2.1). I thus investigated the ability of several human THAP proteins to interact with HCF-1 in
human-cell extracts. To present the results, I have grouped the THAP proteins by similarity of their HCF-1
interaction. First, I present two HBM-containing THAP proteins that indeed interact with HCF-1. Second,
I show two THAP proteins that do not bind HCF-1 and yet contain an HBM sequence. Third, I introduce
an HBM-lacking THAP protein that nevertheless interacts with HCF-1.
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Figure 5.2: Selected pairs of THAP proteins form heterodimers. HEK-293 cells were co-transfected
with THAP11-HA and a Flag-tagged THAP construct (A) and whole cell lysates were then subjected to HA
immunoprecipitation and analyzed by immunoblot (B and C). (B) THAP8, but not THAP7, heterodimer-
izes with THAP11. (C) THAP4 does not form heterodimers with THAP11. * non-specific band (antibody
heavy chain). wlc, whole cell lysate; IP, immunoprecipitate.
5.2.1 HBM-containing THAP7 and THAP11 bind HCF-1
As previously mentioned, the interaction of THAP11 with HCF-1 has been documented in human cell extracts
[39]. I thus intended to reproduce the result.
First, I probed the interaction of endogenous THAP11 with exogenous HCF-1 fragments. For this,
human HEK-293 cells were transfected with one of the following HCF-1 constructs (Figure 5.3 A) before
being immunprecipitated:
• HCF-1FL representing the wild-type and full-length protein;
• HCF-1N representing the N-terminal subunit;
• HCF-1C representing the C-terminal part.
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Figure 5.3 B shows that THAP11 is recovered in the HCF-1FL and HCF-1N immunoprecipitates (lower
band, lanes 8 and 6, respectively), but not in the control and HCF-1C samples (lanes 2 and 4). As a positive
control, the presence of the OGT enzyme was probed, as OGT associates with the HCF-1PRO repeats, thus
with the full-length HCF-1, and not with its processed forms [16]. Indeed, OGT is co-immunoprecipitated
by HCF-1FL (lane 8) but not present in the control, HCF-1C or HCF-1N immunoprecipitates (lanes 2, 4
and 6 , respectively). This experiment thus demonstrates that exogenous HCF-1 interacts with endogenous
THAP11, and that this interaction is mediated by the HCF-1 N-terminal subunit.
As THAP11 possesses an HBM sequence, it is likely that the described interaction is mediated by the
HCF-1 Kelch domain and the THAP11 HBM sequence. To test this idea, I used an HCF-1 Kelch mutant
bearing the P134S mutation, known to disrupt the HCF-1 Kelch:HBM interaction, and exogenous Flag-tagged
THAP11 constructs, either WT or with a disrupted HBM sequence (DASA instead of DHSY) (Figure 5.3 A).
Comparing lanes 2 and 4 in Figure 5.3 C shows that THAP11 efficiently binds HCF-1N . Lanes 6 and 10 show
that using a THAP11 HBM mutant or an HCF-1 P134S mutant strongly decreases the interaction, which is
essentially abolished by the combination of both mutants (lane 12). Consequently, THAP11 interacts with
HCF-1 in a Kelch:HBM-mediated manner.
Similarly, I have assessed the interaction of THAP7 with HCF-1, and the effect of the HBM and P134S
mutations. Figure 5.4 demonstrates that THAP7 interacts with the N-terminal HCF-1 subunit (compare
lanes 2 and 4), but that this interaction is impaired by the use of HBM and P134S mutants (lanes 6 and
10, respectively), the effect being even more pronounced when the two mutants are used together (lane 12).
Thus, THAP7 binds to HCF-1 via their respective HBM and Kelch domains.
5.2.2 THAP4 and THAP5 do not interact with HCF-1, although containing an
HBM or HBM-like sequence
A similar experiment was performed to determine whether THAP4, which has two identical, yet non-
canonical, HBM sequences, can interact with HCF-1N . Indeed, THAP4 HBM-like sequences have a leucine
instead of a glutamate, glutamine, aspartate or asparagine in the first position of the HBM motif (Table 3.2).
Figure 5.5 shows that THAP4WT and its different HBM mutants (Figure 5.5 A) are unable to bind HCF-1N
nor the HCF-1P134S Kelch mutant.
For technical reasons, THAP5 interaction with HCF-1 has been investigated in a slightly different manner.
In this experiment, THAP5 was transfected alone into HEK-293 cells and subsequently immunoprecipitated,
to assess the recovery of the endogenous HCF-1 protein. HCF-1 was barely recovered (Figure 5.6, compare
lanes 2 and 4), suggesting that THAP5 possesses a very weak interaction, if any, with endogenous HCF-1.
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Figure 5.3: THAP11 binds HCF-1 in a Kelch:HBM-dependent manner. HEK-293 cells were trans-
fected with different HA-HCF-1 constructs (A) and whole cell lysates were then subjected to HA immunopre-
cipitation and analyzed by immunoblot (B). Alternatively, HEK-293 cells were co-transfected with THAP11-
Flag and HA-HCF-1 constructs (A), and whole cell lysates were then subjected to Flag immunoprecipitation
and analyzed by immunoblot (C). HBM-positive THAP proteins are depicted in green whereas HBM-negative
ones are in red. * non-specific band (antibody heavy chain). wlc, whole cell lysate; IP, immunoprecipitate.
Curiously, THAP5 has an identical HBM to THAP7 (Table 3.2), the latter interacting very efficiently with
co-transfected HCF-1 in an HBM-dependent manner, as shown in Figure 5.4. I ruled out the possibility
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Figure 5.4: THAP7 interacts with HCF-1 via their respective HBM and Kelch domains. HEK-293
cells were co-transfected with THAP7-Flag and HA-HCF-1 constructs (A), and whole cell lysates were then
subjected to Flag immunoprecipitation and analyzed by immunoblot (B). HBM-positive THAP proteins are
depicted in green whereas HBM-negative ones are in red. wlc, whole cell lysate; IP, immunoprecipitate.
that this discrepancy is due to the two different experimental systems used for THAP5 and THAP7, by
reproducing with THAP7 the same experimental approach of interaction with endogenous HCF-1 as for
THAP5. Comparing Figures 5.6 A and B shows that THAP5 and THAP7, yet displaying identical HBM
sequences, have a very different ability to bind HCF-1. Thus, more than the HBM sequence influences the
interaction of THAP proteins with HCF-1.
5.2.3 An HBM-lacking THAP protein binds HCF-1: THAP8
Finally. I assessed whether THAP8, which does not display any HBM sequence, interacts with HCF-1.
The same experimental set-up described above for THAP11-HCF-1 interaction revealed that, surprisingly,
THAP8 interacts with HCF-1N (data not shown).
To verify if THAP8 indeed interacts with the Kelch domain of HCF-1N , I co-transfected a THAP8-
Flag construct with an HA-tagged HCF-1 Kelch domain-only construct (HCF-1Kelch, Figure 5.7 A). Figure
5.7 B shows that THAP8WT co-immunoprecipitates with HCF-1Kelch WT (compare lanes 2 and 4). To
further investigate this HBM-independent binding, I introduced an HBM into the THAP8 sequence by
point mutations to determine if it strenghtens, or modifies, the interaction. The HBM was introduced at
a similar location to where it is located in HBM-positive THAP proteins, meaning just N-terminal of the
coiled-coil domain (Figure 5.7 A). I also used the P134S HCF-1 Kelch mutant to determine if it disrupts the
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Figure 5.5: THAP4 does not interact with HCF-1. HEK-293 cells were co-transfected with THAP4-Flag
and HA-HCF-1 constructs (A), and whole cell lysates were then subjected to HA immunoprecipitation and
analyzed by immunoblot (B). HBM-positive THAP proteins are depicted in green whereas HBM-negative
ones are in red. wlc, whole cell lysate; IP, immunoprecipitate.
interaction (Figure 5.7 A). None of these mutants, however, shows a substantial effect on THAP8-HCF-1
interaction(compare lanes 5, 6 and 7 with lane 4 in Figure 5.7 B). I thus conclude that THAP8 interacts with
the Kelch domain of HCF-1 via an unknown mechanim that does not involve the well-known Kelch:HBM
mode of interaction.
5.2.4 Conclusions
Here, I show that the THAP proteins have different abilities to bind HCF-1, which surprisingly do not
correlate with the presence or absence of an HBM sequence:
• THAP7 and THAP11 interact with HCF-1N in a Kelch:HBM-mediated manner. This was expected as
both THAP proteins display an HBM sequence.
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Figure 5.6: THAP5 barely binds to endogenous HCF-1. HEK-293 cells were co-transfected with
THAP5-Flag (A) or THAP7-Flag (B) constructs, and whole cell lysates were then subjected to Flag im-
munoprecipitation and analyzed by immunoblot. HBM-positive THAP proteins are depicted in green whereas
HBM-negative ones are in red. wlc, whole cell lysate; IP, immunoprecipitate.
• THAP4 contains two identical HBM-like sequences. Nevertheless, it does not bind HCF-1.
• THAP5 has an HBM sequence identical to THAP7, the latter efficiently interacting with HCF-1. But,
THAP5 displays a very weak interaction, if any, with HCF-1.
• Conversely, THAP8, which lacks an HBM sequence, binds to HCF-1Kelch. The interaction mechanism
is unknown, but is independent from the well-known Kelch:HBM interaction.
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Figure 5.7: THAP8 does interacts with HCF-1. HEK-293 cells were co-transfected with THAP8-Flag
and HA-HCF-1 constructs (A), and whole cell lysates were then subjected to HA immunoprecipitation and
analyzed by immunoblot (B). HBM-positive THAP proteins are depicted in green whereas HBM-negative
ones are in red. * non-specific band (antibody heavy chain). wlc, whole cell lysate; IP, immunoprecipitate.
5.3 THAP7 is phosphorylated
5.3.1 THAP7 immunoblotting reveals its phosphorylation
Figure 5.4 has shown that THAP7 appears as a series of bands on immunoblotting. First, I ruled out the
possibility that this pattern is due to the anti-Flag antibody used. Indeed, three different antibodies (the
anti-Flag, and two anti-THAP7) reveal ectopically-expressed THAP7 as a series of bands on immunoblot
(data not shown). Actually, the precise number of bands remains difficult to establish with certainty as they
are very close to each other: there are at least 3 bands with the middle one, or/and the lower one possibly
being composed of two different bands, thus resulting in 4 or even 5 bands in total. This result is not specific
to ectopically-expressed THAP7 as endogenous THAP7, although barely visible with available antibodies,
also appears with the same pattern of bands (data not shown).
I then investigated whether these different bands are due to different forms of THAP7 protein, in par-
ticular different post-translational modifications. PhosphoSitePlus R©, a comprehensive database of post-
translational modifications (mainly from mass-spectometry experiments) [125], reveals 7 phosphorylation
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sites as well as one acetylation site (Figure 5.8 A, green and pink residues, respectively). I then investigated
whether THAP7 phosphorylation is responsible for the multi-band pattern. For this, a THAP7-Flag construct
was transfected into HEK-293 cells, immunoprecipitated and then treated with the CIP alkaline phosphatase
(Calf Intestinal Phosphatase). Comparing lanes 3 and 5 in Figure 5.8 B shows that the phosphatase treat-
ment of THAP7 leaves only the lower THAP7 band, making the slower migrating species disappear. As a
negative control, an inactivated phosphatase does not impact the pattern of THAP7 bands (Figure 5.8 B,
lane 4). The treatment of the whole cell lysate with the CIP phosphatase similarly impacts the pattern of
THAP7 bands, although in a less dramatic way (Figure 5.8 B, lanes 1 and 2). This result is not surprinsing
as the phosphatase treatment is less efficient on non-purified material. To conclude, I have shown that the
different bands of THAP7 appearing on immunoblots are due to phosphorylated forms of the protein, but
these experiments did not address the functional significance of this interaction.
5.3.2 Impact of THAP7 phosphorylation on its interactions
Thus, I was interested in the possible consequences of the phosphorylation of THAP7, particularly on the
previously shown interactions.
First, I have shown that THAP7 homodimerizes (Figure 5.1 C). Comparing lanes 7 and 8 shows that the
lower bands of THAP7-Flag are better recovered after co-immunprecipitation of THAP7-HA. This suggests
that the different forms of THAP7 have distinct capacities to form homodimers, thus the phosphorylation of
THAP7 modulates its ability to dimerize.
Also, I studied whether THAP7 phosphorylation might impact its interaction with HCF-1. For this, I
co-transfected HEK-293 cells with HA-tagged HCF-1N and THAP7-Flag constructs. But, in contrast to
Figure 5.4, I performed an HA-immunoprecipitation to pull down HCF-1. Figure 5.9 shows that the different
THAP7 bands are not equally co-immunoprecipitated with HCF-1, the middle band being recovered more
effectively (compare wcl and IP rows in lane 5). Thus, the interaction of THAP7 with HCF-1 is likely to be
modulated by THAP7 phosphorylation.
5.4 Discussion
In this chapter, I have described some elements of how THAP proteins interact with each other and with
HCF-1. Table 5.1 summarizes the different interactions presented here.
First, I have probed the ability of some THAP members to form homodimers and heterodimers with
THAP11. This has revealed that distinct THAP proteins have differing capacities for homo- and heterodimer-
ization:
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Figure 5.8: THAP7 undergoes phosphorylation. (A) THAP7 post-translational modifications, modified
from PhosphoSitePlus R©. (B) HEK-293 cells were transfected with THAP7-Flag and either directly treated
with the CIP phosphatase (lane 2) or subjected to Flag immunoprecipitation before being treated with the
CIP phosphatase (lanes 4 and 5). in. CIP, heat-inactivated CIP. wlc, whole cell lysate; IP, immunoprecipitate.
• THAP7, 8 and 11 form homodimers. This confirms the previously-published THAP11 homodimeriza-
tion [54, 55] and adds two new THAP proteins to the list of the ones forming homodimers, already
composed of THAP0 [51], THAP1 [52,53] and THAP11 [54,55].
• THAP8 heterodimerizes with THAP11, while THAP4 and 7 do not. This latter finding was unexpected
as Dejosez and colleagues [54] showed an interaction between the mouse THAP7 and THAP11 (Ronin)
orthologs. Surprisingly, this paper was suggesting an interaction between THAP7 and Ronin via the
N-terminal half of Ronin, which does not contain the coiled-coil domain.
Thus, each THAP protein has its own ability to form dimers among the THAP family. This result is of
particular interest regarding their role in transcription. Indeed, it suggests possibilities for an intricate
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Figure 5.9: THAP7 phosphorylation modulates its interaction with HCF-1. HEK-293 cells were
co-transfected with THAP7-Flag and HA-HCF-1 constructs (A), and whole cell lysates were then subjected
to HA immunoprecipitation and analyzed by immunoblot (B). HBM-positive THAP proteins are depicted
in green whereas HBM-negative ones are in red. wlc, whole cell lysate; IP, immunoprecipitate.
THAP-protein regulatory network in which their dimerization can modulate their DNA-binding affinity and
specificity, further diversifying their gene targets and functions. Additional experiments would be useful to
better understand how THAP proteins bind each other. Now, 5 out of 12 THAP members have been shown
to form homodimers; also, to my knowledge, no study so far has reported that a specific THAP protein
does not homodimerize. This tends to suggest that homodimerization is an ability shared by most THAP
proteins, but additional experiments are required to confirm this hypothesis. In addition, it is likely that
the THAP proteins dimerize through their coiled-coil motif, but it remains to be formally investigated by
creating THAP-mutant proteins lacking this domain or alternatively, bearing point mutations that disrupt
it.
Second, I have assessed the differing abilities of selected THAP proteins to interact with HCF-1 in
human cell extracts. Mazars and colleagues [38] have previously demonstrated, in a yeast two-hybrid assay,
that all HBM-containing THAP proteins bind HCF-1, but not the HBM-negative ones. I indeed showed a
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Table 5.1: Summary of THAP dimerization and interaction with HCF-1. Green plus, interaction;
red minus, no interaction; (-), very weak, if any, interaction; grey dot, not tested.
Kelch:HBM-mediated interaction between HCF-1 and THAP7 or 11. But, I do not reproduce their results for
THAP4, 5 and 8. Regarding THAP4 and THAP5, it is possible that the interaction is not strong enough to
be detected in human cell extracts, particularly for THAP4, as it displays a non-canonical form of the HBM.
On the other hand, it makes more sense to assess the interaction of proteins in their native environment,
such as human cells, rather than in an artificial system such as the yeast two-hybrid one. Thus, in my hands,
some but not all THAP members bind to HCF-1, and it does not correlate with the fact that they display, or
not, an HBM sequence. Together with the fact that THAP5 and THAP7 bind to a very different extend to
HCF-1, yet having identical HBM sequences, suggests that the HBM sequence is not the only determinant
for THAP-protein binding to HCF-1. Several additional experiments would be needed to unravel in more
detail how THAP proteins bind to HCF-1:
• My results suggest that the non-canonical HBM sequences of THAP4 are not sufficient to interact with
HCF-1. Thus, it would be interesting to mutate these HBM-like sequences into canonical ones to probe
whether it creates an interaction with HCF-1.
• To understand the discrepancy between THAP5 and THAP7, one could create swap mutants between
THAP5 and THAP7 HBM-adjacent sequences. It would allow one to unravel the non-HBM determi-
nants of binding with HCF-1.
• I showed the interaction between the HCF-1 Kelch domain and THAP8, but how they interact remains
to be clarified. Binding assays between THAP8 deletion mutants and HCF-1Kelch mutants available in
the Herr laboratory would reveal which portions of each protein are responsible for the interaction.
In addition to the results presented here, I also tried to probe the interaction between THAP1 and HCF-1.
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But, while I used the exact same procedure as for the other THAP proteins, I repeatedly had problems with
excessive background in the negative controls. Consequently, I decided to focus on the THAP protein that
were giving me interpretable results, and to remove THAP1 from the list of studied THAP proteins.
I previously suggested a putative interconnexion between the HBM sequence and the coiled-coil domain,
in other words between the interaction with HCF-1 and THAP dimerization. I showed here that the ability
of THAP11 to homodimerize is HBMindependent. This result does not mean, however, that the dimerization
of THAP proteins and their interaction with HCF-1 are independent. Notably, I have shown that the HBM
and the coiled-coil domain are in close proximity in human proteins (for instance, there are 9 amino-acids
between these 2 motifs in THAP11). Consequently, the dimerization of THAP proteins through their coiled-
coil domain and their binding to HCF-1 via their HBM are likely to influence each other, at least simply
because of sterical reasons. Indeed, THAP dimerization and HCF-1-interaction are likely to be two non-
simultaneous events. Thus, it would be interesting to probe whether THAP proteins can dimerize in the
context of an HCF-1 interaction, and vice versa, whether THAP proteins can interact with HCF-1 once they
have formed an hetero- or homodimer. For instance, one can imagine to probe whether THAP proteins could
simultanenously dimerize and interact with HCF-1, by performing sequencial co-immunoprecipitation. If this
hypothesis of non-simultaneous binding is correct, it would be interesting to understand in which contexts
THAP proteins choose to dimerize, or interact with HCF-1, respectively.
Finally, I demonstrated that THAP7 undergoes phosphorylation and that this phosphorylation appears
to modulate THAP7’s ability to form dimers with THAP11 and to bind HCF-1. Thus, the phosphorylation
of THAP7 is likely to have a regulatory role for its interactions and functions. So far, 7 THAP7 residues
— 6 serine and one threonine — have been identified as phosphorylated in mass-spectrometry experiments
(PhosphoSitePlus R©, [125]). Interestingly, none of these residues lies within the HBM sequence or the coiled-
coil domain, which are responsible — or suspected to be — for the THAP:HCF-1 and THAP:THAP inter-
actions. Point mutations of these residues, either in alanine or in a phosphomimetic residue (e.g. aspartate
instead of a putative phospho-serine), would reveal which ones are responsible for the mobility shifts observed
and allow one to attribute the different immunoblot bands to different THAP7 phosphorylated versions.
I should point out the fact that the biochemical analyses presented in this chapter are dealing with
ectopically-expressed proteins in human cells, which is quite an artificial system. Results should thus be
confirmed using endogenous proteins. Working with endogenous proteins necessitates sensitive-enough anti-
bodies to detect the endogenous version of the proteins — the latter being often expressed at a much lower
level than the exogenous one. Also, the protein needs to be actually present in the working system (here,
human cell lines). I tested several commercial antibodies against THAP proteins in a collection of human cell
lines (HeLa-S, U2OS, HEK293, DLD-1, IMR90). Although most of them recognized the exogenous THAP
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proteins, only THAP1 and THAP11 antibodies were able to detect the endogenous proteins. Gene expression
data of HEK293 and HeLa-S cells (not shown and Figure 4.3, respectively) available in the Herr laboratory
suggested that, abeit different levels of expression, THAP genes are expressed in these cells, abeit at different
levels. Gene expression and protein level, however, do not necessarily correlate. Consequently, I cannot
completely rule out the possibility that the corresponding proteins are not expressed, explaining the absence
of detection by the antibody.
During the course of this study, I ordered the generation of a peptide-based THAP7 custom antibody
from a biotech company (Covalab). The antibody was generated using chicken as a host, because the human
THAP7 sequence was too well conserved in other available species (rabbit, mouse, rat) to lead to an efficient
immunization. Also, peptides were chosen carefully to avoid any cross-reactivity with other THAP proteins
(e.g. outside of the THAP domain). Unfortunately, whereas the resulting purified antibody gave excellent
results when tested in ELISA against the peptides, it was very disappointing when tested in western blotting.
Indeed, it was barely able to recognize the ectopically-overexpressed THAP7 protein in western blotting, and
generated a large number of non-specific bands, making it unusable for immunoblotting. Also, when tested
in chromatin immunoprecipitation, it did not allow for any enrichment. In summary, THAP11 is the only
studied THAP member for which I have a sufficiently-good antibody, thus the only one for which I can study
the endogeous protein.
After having removed THAP1 from the list of THAP proteins that I am focusing on, the subset of studied
THAP proteins was reduced to 5 members. To concentrate my efforts, I decided to focus on only two THAP
proteins to study in more depth their cellular roles, particularly in cell proliferation and gene transcription. I
chose the following two THAP members, in the context of a study centered on the interplay between THAPs
and HCF-1:
• THAP11 as its already-suggested HCF-1-dependent involvement in transcription and proliferation is
extremely exciting, while requiring further investigation. Also, I confirmed that THAP11 interacts
with HCF-1, using the well characterized Kelch:HBM mode of interaction. Importantly, I have a
good antibody for it, thus I have the possibility to work on the endogenous protein, which is extremely
valuable. Furthermore, a human disease-associated mutation have been identified in THAP11 (p.F80L),
which makes this protein even more interesting.
• THAP7 as its role in transcription was previously suggested, and as I clearly demonstrated its Kelch
and HBM-dependent interaction with HCF-1.
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Creation of custom cell lines to
investigate the cellular roles of
THAP7 and THAP11
In this chapter, I describe how I exploited recent genetic technologies to engineer specific mutant THAP7 and
THAP11 cell lines. First, I used CRISPR/Cas9 genome-editing technology to perform reverse genetics and
alter the THAP7 or THAP11 endogenous genes. Second, I created cells stably synthesizing ectopic THAP7
or THAP11 proteins.
6.1 CRISPR/Cas9 engineered mutant cells
I used the CRISPR/Cas9 genome-editing system to engineer specific point mutations in the endogenous
THAP7 and THAP11 genes. The mutations I introduced were of two types: functional (reverse-genetic
strategy) and human-disease associated. I should mention here that I have benefited from priceless help from
Philippe Lhoˆte, cell-culture technician, in the creation and screening of these cell lines.
6.1.1 Point mutations in a human host cell line
As described in the introduction (section 1.4), the CRISPR/Cas9 system allows one to precisely modify the
genome of specific cells. When properly designed, the gRNA and the repair template can target the Cas9-
mediated cleavage at the desired genomic location and introduce specific DNA modifications, respectively.
This technology can be applied on virtually any cell type. Because of the following reasons, I decided to use
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human embryonic kidney HEK-293 cells as parental cells:
• At the time at which I intented to use this technology, the CRISPR/Cas9 technique had already been
well established in the Herr laboratory by Laura Sposito, a PhD student, in HEK-293 cells;
• HEK-293 cells are easy to maintain in culture and synthesize high levels of proteins;
• HEK-293 cells are easy to transfect, which is of great importance as cells need to be transfected with
the different components of the CRISPR/Cas9 system;
• Even if HEK-293 cells are not genetically normal, they have been transformed from primary cells, as
opposed to cell lines derived from tumors, and may be genetically more reliable.
The details about the CRISPR/Cas9 mutagenesis protocol are explained in Chapter 2. Briefly, cells
transfected with the CRISPR/Cas9 components and a repair template were clonally selected. Each clone
was then analyzed by PCR and subsequent digestion with a restriction enzyme. Indeed, each mutagenesis
strategy has been designed so the mutation created, or disrupted, a specific restriction site.
Figure 6.1 summarizes the 7 different mutants that I set out to obtain. For each of THAP7 and THAP11,
I intended to create the following functional mutants:
• THAPnull mutants. One very classical approach of reverse genetics is to assess the effect of the gene
loss. Thus, I aimed to create cells in which the THAP gene has been disrupted. For this, my strategy
was to introduce two stop codons in a row near the very beginning of the THAP coding sequence. This
should result in the synthesis of an extremely truncated THAP protein with only few amino acids left,
likely being non-functional.
• THAPHBM mutants. I have a particular interest in the role of HCF-1 in THAP-mediated activities,
and I demonstrated that THAP7 and THAP11 proteins interact with HCF-1 via their HBM sequence.
Thus, I wished to investigate what is happening when a given THAP protein has lost its ability to
bind HCF-1, by precisely mutating its HBM sequence — as previously done in ectopically-expressed
proteins (Chapter 5).
• THAP∆CC mutants devoid of the coiled-coil domain. The ability of THAP proteins to form dimers
probably being critical for their functions and the coiled-coil domain likely being responsible for their
dimerization, I had an interest in probing the effects of the lack of this domain in THAP proteins. As
in THAP proteins, the coiled-coil domain is the most C-terminal feature (Figure 1.5), the truncation
can be achieved by introducing two stop codons in a row at the beginning of the coiled-coil domain.
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This would result in a truncated THAP protein devoid of its coiled-coil domain, but still retaining its
HBM sequence.
Also, a disease-associated mutation has been identified in THAP11 (p.F80L), resulting in a cobalamin
disorder [75, 83], but so far its mechanism of action remains unclear. It would thus be extremely interesting
to introduce this point mutation into cells, to create a cellular model and study the altered mechanisms of
this mutation.
Figure 6.1: THAP7 and THAP11 point mutants. HEK-293 cells are subjected to CRISPR/Cas9-
mediated genome editing in the aim of obtaining these 7 different mutants.
To rule out clone-specific observations and off-targets effects, I tried to obtain for each mutant, if possible,
two independent clones from two different transfection experiments.
6.1.2 Generation of THAP7null and THAP11null cell lines
To create THAP7null and THAP11null mutants as described, I had to create two successive stop codons by
point mutagenesis at the very beginning of the THAP coding sequence. To increase the efficiency of the
mutagenesis, I minimized the number of nucleotides to be mutated. Also, the mutations should be around
10 nucleotides from the cleavage site, the latter being determined by a PAM sequence on the target gene.
Considering these restrictions, the selected position of the stop codons would result in the generation of
truncated THAP7 and THAP11 proteins of 12 and 17 amino-acids, respectively. These truncated THAP
proteins would only retain the two first cysteines of the THAP domain “C2CH signature”. Consequently,
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the THAP zinc fingers would be incomplete and the resulting truncated THAP proteins would be likely
non-functional.
THAP7null mutant cell lines
The introduction of the two selected stop codons described above required the mutation of 4 distinct nu-
cleotides (Figure 6.2 A). As the mutations created a NlaIII restriction site that is absent in the WT sequence
(Figure 6.2 B), the cell clones were screened by the ability of the NlaIII enzyme to digest the DNA at the
site of the mutations.
The first mutagenesis attempt gave us 59 clones to test, from which we were able to identify one clone
with the desired homozygous mutations (# 29). A second independent attempt provided us with 101 clones,
from which two had the desired mutations in a homozygous state (# 32 and # 44). Figures 6.2 B and C
show the pattern of NlaIII digestion of these 3 clones compared to WT, and their sequencing chromatograms,
respectively. Because it comes from a separate transfection, clone # 29 is independent from the clones # 32
and # 44.
THAP11null mutant cell lines
Despite having screened 139 clones from two separate transfection experiments, we were not able to find a
single cell clone with the desired 4-nucleotide mutation as depicted in Figure 6.3. We were thus unable to
obtain a cell line devoid of the THAP11 protein.
6.1.3 THAP7 and THAP11 HBM-mutant cell lines
As seen in Chapter 5, mutating the second and last positions of the 4 amino-acid HBM sequence into alanine
residues is sufficient to disrupt the HBM sequence and prevent THAP7 and THAP11 from interacting with
HCF-1. T thus designed CRISPR/Cas9 mutagenesis strategies to create such mutations in HEK-293 cells.
THAP7HBM mutant cell lines
Mutation of the THAP7 EHSY HBM sequence into EASA disrupts an AluI restriction site (Figures 6.4 A and
B). From the 80 clones tested, 2 have the homozygous desired mutation (clones # 34 and # 76). In addition,
clone # 50 is unclear: its sequencing chromatogram — which has been confirmed by a second sequencing —
suggested the presence of the mutations, but still displays residual signals for the WT nucleotides (C, A, T
and A). Thus, the homo- or heterozygous status of this clone remains uncertain. Curiously, the clone # 42 is
heterozygous at the two first nucleotide positions, while being homozygous at the two last ones (Figures 6.4
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Figure 6.2: THAP7null mutant cells. Two successive stop codons were created by mutating 4 nucleotides at
the beginning of the THAP7 coding sequence (A), and cell clones were subsequently screened with the NlaIII
enzyme, as the mutation creates one restriction site (orange triangle) (B). (C) NlaIII digestion patterns of
WT and mutant cell clones, compared to the theoretical ones. (D) Sequencing chromatograms of the mutant
cell clones, compared to the WT and the expected mutant sequences, the mutated residues deing depicted
in red. U, undigested PCR fragment; D, NlaIII digested fragment.
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Figure 6.3: Strategy for THAP11null mutagenesis. Four mutations were designed to create two succes-
sive stop codons at the beginning of the THAP11 coding sequence.
C and D). As clones # 42 and # 50 are odd, I did not include them in future analyses and instead focused
on the clear homozygous mutant clones # 34 and # 76.
THAP11HBM mutant cell lines
Figures 6.5 A and B show that the suppression of the THAP11 HBM sequence by mutation of 4 nucleotides
disrupts a CviQI restriction site originally present in the WT sequence. Unfortunately, we did not identify any
THAP11HBM mutant cells on the first attempt of mutagenesis, in which we screened 87 clones. In a second
attempt, we suprisingly obtained only 12 clones. While we still did not obtain any homozygous mutant clone,
we found an heterozygous THAP11HBM mutant (clone # 1, Figures 6.5 C and D). These cells, however,
failed to survive as, despite the great attention we provided them, they ultimately died. These results suggest
that the THAP11 HBM mutation is detrimental to HEK-293 cell growth even in a heterozygous state.
6.1.4 Coiled-coil truncated THAP7 and THAP11 mutant cell lines
Thanks to the fact that the coiled-coil domain is the most C-terminal feature of THAP proteins, introducing
stop codons at the very beginning of this domain will result in a truncated protein devoid of the coiled-coil
domain, but still retaining its other features — particularly, its THAP domain and HBM sequence. Here, I
introduced two successive stop codons to completely delete the coiled-coil domain, leaving only one amino-
acid from the original coiled-coil domain of THAP7, and not any for THAP11. Consequently, the HBM is
left intact and located 9 amino-acids from the C-terminus of both truncated proteins.
THAP7∆CC cell lines
Figure 6.6 A shows the nucleotides mutated to create two stop codons at the very beginning of the THAP7
coiled-coil domain. The resulting cell clones were tested using the AciI enzyme, as the mutations disrupt
an AciI restriction site originally present in the WT sequence (Figure 6.6 B). From the 79 clones tested, we
obtained 6 homozygous for the desired 3-nucleotide mutation: clones # 7, # 22, # 27, # 36, # 40 and # 58
(Figures 6.6 C and D). Clones # 22 and # 58, however, had trouble proliferating, making them difficult to
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Figure 6.4: THAP7HBM mutant cells. The THAP7 EHSY HBM sequence was changed into EASA by
mutating 4 nucleotides (A), and cell clones were subsequently screened with the AluI enzyme, as the mutation
disrupts one restriction site (orange triangle) (B). (C) AluI digestion patterns of WT and mutant cell clones,
compared to the theoretical ones. (D) Sequencing chromatograms of the mutant cell clones, compared to
the WT and the expected mutant sequences, the mutated residues being depicted in red. U, undigested PCR
fragment; D, AluI digested fragment.
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Figure 6.5: THAP11HBM mutant cells. The THAP11 DHSY HBM sequence was changed into DASA
by mutating 4 nucleotides (A), and cell clones were subsequently screened with the CviQI enzyme, as the
mutation disrupts one restriction site (orange triangle) (B). (C) CviQI digestion patterns of WT and the
mutant cell clone, compared to the theoretical ones. (D) Sequencing chromatograms of the mutant cell clone,
compared to the WT and the expected mutant sequences, the mutated residues being depicted in red. U,
undigested PCR fragment; D, CviQI digested fragment.
keep in culture. Cells were nevertheless expanded sufficiently to be frozen, but they were consequently not
analyzed further as I concentrated my efforts on the 4 other clones obtained.
THAP11∆CC cell lines
For construction of the THAP11∆CC cell line, a first experiment gave us 91 single-cell clones to test. We
were not able, however, to find any clone bearing the desired 2-nucleotide mutations depicted in Figure 6.7.
The repetition of the experiment resulted in only 30 clones and unfortunately, none of them was positive for
the mutations as well. Thus, we were unable to obtain any THAP11∆CC cell clone, indicating that loss of
the THAP11 coiled-coil domain is deleterious to HEK-293-cell growth and/or viability. .
108
CHAPTER 6. CREATION OF CUSTOM CELL LINES
109
CHAPTER 6. CREATION OF CUSTOM CELL LINES
Figure 6.6: THAP7∆CC mutant cells. Two successive stop codons were created by mutating 3 nucleotides
at the very beginning of the THAP7 coiled-coil domain (A), and cell clones were subsequently screened
with the AciI enzyme, as the mutation disrupts one restriction site (orange triangle) (B). (C) AciI digestion
patterns of WT and mutant cell clones, compared to the theoretical ones. (D) Sequencing chromatograms
of the mutant cell clones, compared to the WT and the expected mutant sequences, the mutated residues
being depicted in red. U, undigested PCR fragment; D, AciI digested fragment.
Figure 6.7: Strategy for THAP11∆CC mutagenesis. Two nucleotides were mutated to create two
successive stop codons at the beginning of the THAP11 coiled-coil domain.
6.1.5 Creation of a cell line bearing a human THAP11 disease-associated mu-
tation
I also aimed to create a cell line bearing the recently uncovered THAP11 disease-associated p.F80L mutation
(THAP11F80L, [75]).
The F80L THAP11 mutation associated with cobalamin disorder
Cobalamin disorders refer to a group of disorders of intracellular cobalamin (vitamin B12) metabolism as-
sociated with neurodevelopmental abnormalities. An X-linked subgroup, named cblX, is due to a variety
of recessive HCF-1 mutations [126]. HCF-1, together with THAP11, transcriptionaly regulate cobalamin
metabolism by regulating the expression of MMACHC, whose gene product is a key enzyme in the cobalamin
metabolic pathway. In cblX patients, however, mutant HCF-1 fails to activate MMACHC expression, result-
ing in a pronounced decrease of MMACHC mRNA and protein levels, likely being the cause of the cobalamin
deficiency [75,126]. Recently, Quintana and colleagues [75] have reported a patient with cblX -like phenotypic
characteristics, but without any MMACHC or HCF-1 mutation. Instead, this patient had an homozygous
missense mutation in the THAP11 gene (n.C240G) resulting in the change of a phenylalanine into a leucine
at the end of its THAP domain (p.F80L) [75]. This phenylalanine amino acid is highly conserved across
vertebrate species [75] and also among the different human THAP proteins. Indeed, it is the last position
of the THAP domain “AVPTIF box” which has been suggested to be necessary for the proper folding of
the zinc finger (Figure 6.1, see also section 1.3.2 and Figure 1.6 A, green box). Thus, the mutation likely
affects the folding and then the stability of the THAP11 protein. Similarly to cblX patients with HCF-1
mutations, the THAP11F80L patient exhibited a drastic reduction in MMACHC expression [75]. To further
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clarify the pathology of the THAP11F80L mutation, I translated it into a cellular model by precisely mutating
the endogenous THAP11 gene in HEK-293 cells.
Translating a human disease into a cell-culture model: the THAP11F80L cell line
I exploited once more the CRISPR/Cas9 genome-editing strategy to introduce the p.F80L mutation depicted
in Figure 6.8 A in HEK-293 cells. In a first transfection experiment, we were able to obtain 88 clones to test
with the FauI enzyme, as the corresponding n.C240G mutation disrupts a FauI restriction site (Figure 6.8 B).
From these 88 clones, sequencing chromatograms revealed that clone # 8 is homozygous for the mutation,
while clone # 20 is heterozygous (Figures 6.8 C and D). We repeated the experiment to obtain a second
independent homozygous mutant, but unfortunately, none of the 128 tested clones bore the desired mutation.
Impact of the F80L mutation on the THAP11 protein
To assess the effect of the p.F80L mutation on the THAP11 protein, a western blot was performed using
lysates of WT and THAP11F80L mutant cells. With the help of Maykel Lopes, equal amount of proteins
from the two lysates were separated and visualized with the anti-THAP11 antibody. Figure 6.9 A reveals
that the band corresponding to the WT protein is barely visible in the THAP11F80L mutant cells compared
to the WT cells (lanes 2 and 1, respectively). It is unlikely that the F80L mutation causes a change in the
migration pattern of the THAP11 protein, as there is not any new band appearing in the THAP11F80L cell
lysate. Consequently, this observation demonstrates that the THAP11F80L cells have lower THAP11 protein
levels compared to WT cells. To more accurately estimate the amount of THAP11F80L mutant protein
compared to the THAP11WT one, Maykel Lopes sequentially diluted the lysate of the WT cells by 2 fold.
Figure 6.9 B indicates, however, a non-linear esponse of the detection assay. Thus, the THAP11 protein level
is reduced in the THAP11F80L cells compared to WT ones, but the assay did not allow me to quantify this
decrease.
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Figure 6.8: THAP11F80L mutant cells. The cell clones bearing the n.C240G, p.F80L mutation (A) were
screened with the FauI enzyme, as the mutation disrupts one restriction site (orange triangle) (B). (C)
FauI digestion patterns of WT and mutant cell clones, compared to the theoretical ones. (D) Sequencing
chromatograms of the mutant cell clones, compared to the WT and the expected mutant sequences, the
mutated residues being depicted in red. U, undigested PCR fragment; D, FauI digested fragment.
6.1.6 Discussion of the generation of CRISPR/Cas9-designed mutant THAP7
and THAP11 HEK-293-based cell lines
Table 6.1 summarizes the different homozygous and heterozygous cell clones obtained.
I was able to obtain the 3 THAP7 functional mutant cells that I set out to obtain. I obtained 3 THAP7null
cell clones from 2 separate transfection experiments. Thus, THAP7null clones # 29 can be considered as
independent from clones # 32 and # 44. I also obtained 2 homozygous THAP7HBM mutant cell clones
— as well as two others that are likely heterozygous. These two homozygous clones come from a single
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Figure 6.9: Comparison of THAP11WT and THAP11F80L protein levels. Whole cell lysates of the
WT and THAP11F80L, clone #8 cell lines were analyzed by immunoblot. (A) Equal amount of proteins
were loaded and the whole gel picture is depicted. (B) Serial dilution of the WT cell lysate were performed,
the dilution ratio being expressed relative to the undiluted lysates. α-tubulin was used as loading control.
transfection experiment, so they are not necessarily independent. Nevertheless, cells were cultured for only 3
days between the transfection and single-cell clonal selection was carried out immediatly after. Consequently,
there are very few chances that the different clones originally come from the same transfected cell and thus
they are likely to be independent too, even though it cannot be formally concluded as such. Finally, I got
6 different homozygous THAP7∆CC cell clones. Again, these different clones have been generated from the
same transfection experiment and thus cannot be formally considered as independent — even though they
are likely to be so. Among these 6 clones, 2 of them have critically impaired cell survival and/or proliferation,
making them difficult to keep in culture. As I was lucky enough to get 4 additional homozygous clones, I
decided to not deal with these two impaired clones and to focus on the 4 remaining ones. Nevertheless,
it would have been extremely interesting to understand the reasons of the different behavior of these two
specific cell clones. These cells may have off-target effects in cell survival and/or proliferation-related genes.
Comparing the genomic sequence of these cell clones with the genomes of the other THAP7∆CC clones and of
the WT cells would possibly unravel any underlying off-target mutated genes. To not lose focus of this PhD-
thesis project, I did not do pursue this question, but still kept them frozen for possible future investigation
by others.
Regarding THAP11, Table 6.1 immediately reveals that very few mutagenesis experiments were successful.
No single THAP11null or THAP11∆CC clones, and only an heterozygous THAP11HBM one, were obtained,
although the experiment was conducted twice for the two latter mutations. A tempting hypothesis to explain
these results is that the homozygous alteration of THAP11 (the loss of either the entire protein, its coiled-
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Table 6.1: Summary of THAP7 and THAP11 mutant cell clones obtained by CRISPR/Cas9
genome editing. Independent clones coming from separate transfection experiments are placed in separated
columns. Red, homozygous mutants; blue, heterozygous mutants. †, non-viable cell clones (see text for
details).
coil domain or its HCF-1 interaction) is lethal for the cells, which would explain the failure of obtaining
such mutant clones. Notably, the complete loss of mouse Thap11 (Ronin) is embryonically lethal [54]. In
addition, the heterozygous THAP11HBM mutant cells were extremely unhappy in culture and ultimately
died even before we were able to freeze some, despite all the good care we provided them. This result raises
the intringing hypothesis that the THAP11HBM mutant protein is dominant negative, impairing the WT
protein’s functions. To test this, I could imagine to assess the effect of the stable synthesis of an ectopic
THAP11HBM mutant protein in WT cells. Finally, I succeeded in getting two THAP11F80L cell clones,
one homozygous and one heterozygous. Unfortunately, I was not able to obtain any additional independent
homozygous THAP11F80L mutant clones in a second transfection experiment. Consequently, the results
obtained further with the homozygous THAP11F80L clones will have to be interpreted cautiously, as I will
not be able to rule out any clone-specific effects. From now on and for the rest of this study, these homo-
and heterozygous mutant cells will be referred as THAP11F80L/F80L and THAP11F80L/+ cells, respectively.
Please note that this designation is not meant to mean that the cells are diploid of the locus.
Interestingly, I demonstrated that THAP11F80L/F80L cells express significantly lower THAP11 protein
levels compared to WT cells. This difference is not due to an altered recognition of the mutant protein
by the antibody, as this antibody recognizes the last 85 amino acids of the THAP11 (amino-acids 226 to
314) while the mutation is at position 80 (p.F80L). In addition, the western blotting has been performed
in denaturating conditions, thus a different conformation of the mutant protein would neither affect its
recognition by the antibody. Thus, the difference observed truly reveals a difference in protein levels in
the different cell lines, which can either result from a decrease in protein synthesis (transcription and/or
translation) or from an increase in protein degradation. Considering the fact that the mutated amino-acid is
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part of the THAP-domain “AVPTIF box” suggested to be necessary for the proper folding of the zinc finger,
the F80L mutation is likely to impair the folding of the THAP11 protein, thereby leading to an increased
degradation of the mutant THAP11F80L protein. This result is in accordance with a published abstract [83]
(the corresponding paper being in the writing process) also suggesting that the THAP11F80L corresponding
protein is unstable. I cannot rule out the possibility, however, that the THAP11F80L mutant protein is
simply synthesized less. An hypothesis here is that, as THAP11 is a transcription factor, it may activate its
own transcription — the F80L mutation preventing it from doing so. I will demonstrate in a future chapter,
however, that the THAP11 p.F80L mutation does not impact THAP11 binding to its own promoter neither
the THAP11 mRNA levels in THAP11F80L/F80L cells (Chapter 8).
THAP7null and THAP7∆CC mutants were engineered by creating stop codons at the beginning of the
THAP7 coding sequence or the coiled-coil domain, respectively. I cannot, however, exclude the possibility
of a read-through of the stop codons, even though I inserted two successive — and different, in the case
of THAP7null mutant — ones to avoid this phenomenon. The effectiveness of the stop codons should thus
be verified in western blotting by the absence of the full-length protein for THAP7null cells, and by the
generation of a truncated THAP7 protein in THAP7∆CC cells. Unfortunately, the lack of a good THAP7
antibody able to detect the endogenous protein prevents me from doing such a control.
Interestingly, the ploidy of HEK-293 cells is still debated, from near-tetraploid to hypo- and hyper-
triploidy [127]. Consequently, obtaining the aforementioned mutations in a homozygous state would mean
to have mutated the 3 or 4 gene copies in these cells. Alternatively, observing an heterozygous clone such
as THAP11HBM clone # 1 or THAP11
F80L/+ one, where the peaks of the WT and mutated nucleotides
are of similar height on the sequencing chromatograms (Figures 6.5 D and 6.8 D) suggests that equivalent
number of gene copies are WT and mutated. Relative to HEK-293 ploidy, it likely means that the cells are
tetraploid (or alternatively, diploid) at the THAP11 locus. The HEK-293 cell ploidy could also explain what
was observed for THAP7HBM clone # 50, where the peaks of the WT nucleotides were much lower than the
mutant ones on the sequencing chromatogram (Figure 6.4 D). Indeed, one can imagine that a single THAP7
gene copy remains WT while the other ones — 2 or 3, depending the ploidy at this specific locus — are
mutated, which would explain a much higher signal of the mutated residues in the sequencing. Finally, the
fact that the CRISPR/Cas9 genome editing enabled me to create, in a single mutagenesis step, homozygous
mutants at triploid or tetraploid locus highlights the power and efficiency of this technique.
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6.2 Stable cell lines containing an inducible THAP11 or THAP7
gene construct
Complementary to the mutations of the endogenous THAP7 and THAP11 genes described above, I created
stable cell lines containing an ectopic THAP -gene expression construct. In parallel, I suspected some of
the CRISPR/Cas9-mediated mutations to be potentially lethal for the cells. I thus envisioned the use of
THAP-inducible cells lines as host cells, so I could benefit from the presence of the exogenous THAP protein
to keep the cells alive, and suppress its synthesis to perform experiments. Consequently, the generation of
cell lines with inducible THAP constructs would both enable me to probe the effect of the forced synthesis
of the THAP proteins of interest and increase the chances of success of the CRISPR/Cas9 mutagenesis at
the same time.
6.2.1 Integration of ectopic and inducible gene constructs into human host cells
To generate such inducible cell lines, I took advantage of the Flp-In
TM
T-Rex
TM
technology described in the
introduction (section 1.4). I decided to use HEK-293-based host cells as it would allow me to compare the
stable cells with the CRISPR/Cas9 mutant ones, the latter being generated in HEK-293 cells.
In addition to the generation of cells containing inducible THAP11WT or THAP7WT constructs — to
probe the effects of THAP11 or THAP7 forced synthesis — I also created cells with an inducible THAP11HBM
mutant construct to determine whether the THAP11HBM mutant protein has a dominant-negative effect.
Indeed, the only THAP11HBM mutant cell clone that I obtained with CRISPR/Cas9 was heterozygous and
died almost immediately. This result has led to the hypothesis that the THAP11HBM mutant protein has
a dominant deleterious effect on cells. To test this hypothesis, I thus suggested to assess the effects of the
introduction of a THAP11HBM version into WT cells containing the endogenous THAP11WT protein.
The protocol to generate Flp-In
TM
T-Rex
TM
stable cells is detailed in Chapter 2. Briefly, cells were
transfected together with the Flp recombinase-encoding vector (pOG44) and the pcDNA
TM
5/FRT/TO con-
taining a THAP11WT , THAP11HBM or THAP7WT -Flag construct. After hygromycin selection of the cells
having the appropriate stable integration, cells were clonally selected before being subsequently tested. The
three different THAP constructs were Flag-tagged to be easily detected on immunoblots.
As explained, I had initially intended to mutate the endogenous THAP7 or THAP11 gene with the
CRISPR/Cas9 system in the stable THAP7WT or THAP11WT cells, respectively, and to benefit in parallel
from the presence of the WT exogenous construct. Thus, the latter construct has to be Cas9 resistant so that
the CRISPR/Cas9 systemb will selectively affect the endogenous THAP gene. This can be achieved by silently
116
CHAPTER 6. CREATION OF CUSTOM CELL LINES
mutating the PAM sequence of the exogenous THAP construct used in the design of the CRISPR/Cas9
mutagenesis. These stable cell lines, however, were finally not used to generate the CRISPR/Cas9-mediated
mutant cells, for reasons that I will explain later. Nevertheless, the Flp-In
TM
T-Rex
TM
THAP7WT and
THAP11WT cells were engineered before this decision, thus with Cas9-resistant THAP7WT and THAP11WT
constructs.
6.2.2 Creation of Flp-In
TM
T-Rex
TM
THAP11WT cells
I started by creating the stable cells containing the THAP11WT gene construct. After hygromycin selection
of the transfected cells — to select for the cells having properly integrated the construct at the FRT site —
single-cell cloning was carried out. From all the clones obtained, 6 were randomly selected for further testing.
To begin with, I probed the level of the ectopic THAP11WT -Flag protein under stimulation with a tetracy-
cline antibiotic, here doxycycline. Figure 6.10 A shows that the six cell clones exhibit a high THAP11WT -Flag
level after 3 days of treatment with doxycycline. Also, in every clone, the level of ectopic THAP11WT -Flag
protein is much higher than the level of the endogenous THAP11 protein. Interestingly, the level of endoge-
nous THAP11 protein does not seem to be affected by the forced synthesis of the ectopic THAP11WT -Flag
counterpart (compare lanes 5 and 6 with lane 1, in which the confluency of the cells were similar).
As the six clones behaved similarly, two were randomly chosen for further characterization: clones # 13 and
# 14. To assess whether the expression of the THAP11WT -Flag construct is properly repressed in the absence
of doxycycline, cells were treated for 28 hours with, or without, doxycycline. Normal FBS, used to supplement
the cell medium, is likely to contain some tetracycline, which would then lead to a basal THAP11WT -Flag
level, even in the absence of doxycycline treatment. I thus cultivated cells either in medium supplemented with
normal FBS (normal medium) or switched them two days prior to the experiment into medium supplemented
with tetracycline-free FBS (tet-free medium). In the absence of doxycycline, THAP11WT -Flag is expressed
at a very low, but still detectable level in clone # 13, while significantly expressed in clone # 14 (Figure
6.10 B, lower panel, compare lanes 3 and 5 and lanes 7 and 9, respectively). Importantly, the use of tet-free
medium does not suppress the basal THAP11WT -Flag synthesis in the absence of doxycycline stimulation
(lane 3 versus 5, and lane 7 versus 9). To rule out the possibility that the cells were not treated for long
enough in tet-free medium to have completely washed tetracycline out of the cells, and thus still contain
some tetracycline at the time of the experiment, I repeated the previous experiment, but cultivating the
cells for an entire week in tet-free medium before analysis. But again, the tet-free medium does not enable
the suppression of the basal THAP11WT -Flag synthesis in unstimulated cells (not shown). To conclude, the
tet-free medium does not have the expected effect and I was not able to totally avoid a basal expression of the
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Figure 6.10: Flp-In
TM
T-Rex
TM
THAP11WT cells. (A) The 6 selected cell clones were treated during
3 days with 1 µg/ml of doxycycline and whole cell lysates were analyzed by immunoblot. The cell confluency
at the time of the cell lysis is depicted. (B) Clones # 13 and # 14 cultured in normal or tet-free medium
were treated during 28 hours with 1 µg/ml of doxycycline (+) or with DMSO as control (—), and whole
cell lysates were analyzed by immunoblot. Top pannel, anti-Flag antibody; bottom 2 pannels, anti-THAP11
antibody. P, parental cells. L, low exposure; H, high exposure.
ectopic THAP11WT -Flag construct. Curiously, the basal level of THAP11WT -Flag synthesis in the absence
of doxycycline varies in the differing clones. As it is lower in clone # 13 than in clone # 14, I worked with
clone # 13 in future experiments. In addition, I only used normal medium, as the use of tet-free one has no
evident effect.
I was also interested to determine whether I could manipulate the inducible system more finely than a
simple on-off expression. For this, I probed whether using different doses of doxycycline would allow different
levels of THAP11WT -Flag synthesis. The standard doxycycline concentration to induce ectopic-construct
expression is 1 µg/ml. Doxycycline titration with concentrations ranging from 0.01 to 10 µg/ml did not
allow any modulation in THAP11WT -Flag synthesis level, which is very high in all conditions (Figure 6.11
A). Thus, doxycycline is in large excess at the standard 1 µg/ml concentration, where the system is already
saturated. I repeated the experiment with doxycline concentrations a thousand times lower, ranging from
0.01 to 10 ng/ml. Figure 6.11 B shows that low doxycycline concentrations induce lower THAP11WT -Flag
118
CHAPTER 6. CREATION OF CUSTOM CELL LINES
Figure 6.11: Doxycycline dose response in Flp-In
TM
T-Rex
TM
THAP11WT cells. Cells were treated
with different doxycycline concentrations for 28 hours and whole cell lysates were analyzed by immunoblot.
Doxycycline concentrations ranged from 0.01 to 10 µg/ml (A) or from 0.01 to 10 ng/ml (B). Top 2 pannels,
anti-Flag antibody; bottom 2 pannels, anti-THAP11 antibody. L, low exposure; H, high exposure.
synthesis, and thus the level of ectopic THAP11WT -Flag protein can indeed be manipulated using different
doxycycline concentrations. Notably, the use of doxycycline at 0.3 ng/ml (lane 5) allows for an interesting
intermediate between the leaky and the very high THAP11WT -Flag synthesis (lane 9). As a remark, I
observed that doxycycline at 10 µg/ml starts to be toxic for the cells, as cell death was notably higher at
this concentration than at lower ones. Indeed, doxycycline being an antibiotic, its use is potentially toxic
for the cells. While the 10 µg/ml concentration appears to be toxic, I observed no obvious difference in cell
viability at the lower concentrations, in both short-term and long-term experiments (see below), compared
to the control DMSO treatment. Thus, except for the 10 µg/ml concentration, the other ones are not toxic
— particularly, the 1 µg/ml used routinely.
So far, I only performed short term doxycycline treatments (3 days or 28 hours). I thus assessed the
effect of a long-term treatment with doxycycline, on both the ectopic THAP11WT -Flag and the endogenous
THAP11 proteins. Figure 6.12 demonstrates that cells treated for 5 weeks, twice a week, with doxycycline
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Figure 6.12: Effect of prolonged doxycycline treatment on Flp-In
TM
T-Rex
TM
THAP11WT cells.
Cells were treated with 1 µg/ml of doxycycline for 28 hours (28h) or during 5 weeks (5w), twice a week, or
treated with DMSO as control (—) and whole cell lysates were analyzed by immunoblot. The cell confluency
at the time of the cell lysis is depicted. Top 2 pannels, anti-Flag antibody; bottom 2 pannels, anti-THAP11
antibody. P, parental cells. L, low exposure; H, high exposure.
express a lower level of THAP11WT -Flag protein compared to cells treated for only 28 hours with the same
concentration of doxycycline (compare lanes 3 and 4, taking into account the respective confluency of cells
depicted below the figure). The prolonged treatement, however, does not affect the endogenous THAP11
protein, as seen by comparing lane 2 with lane 3. Please note that the endogenous THAP11 protein is barely
detected in the 28-hours sample (lane 4), but this is likely due to the low confluency of cells, thus a low
amount of total material.
Finally, it is interesting to note that the THAP11WT -Flag protein level in the absence of doxycycline is
generally comparable — or slightly lower depending the experiment and the cell clone used — to the level of
endogenous THAP11 (e.g. Figure 6.11 A and B, lanes 1 or Figure 6.12, lane 2).
6.2.3 Creation of Flp-In
TM
T-Rex
TM
THAP11HBM cells
Similarly, cells containing a THAP11HBM -Flag construct, in which the HBM has been disrupted, were
generated. Interestingly, I did not have more trouble in obtaining these cells than in obtaining the Flp-In
TM
T-Rex
TM
THAP11WT ones. After hygromycin selection and single-cell cloning, 6 clones were randomly
selected and tested for the synthesis of the THAP11HBM -Flag under stimulation, or not, with doxycycline.
Figure 6.13 A reveals that the six clones strongly express THAP11HBM -Flag after 28 hours of treatment
with doxycycline, the leaky synthesis of the ectopic construct differing between the clones. All of the 6
cell clones survived well in culture and did not display any obvious defect, suggesting that the presence of
the THAP11HBM -Flag protein does not severely impact the survival of these cells. For future experiments,
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clone # 21 was used (a random selection). Interestingly, the level of the endogenous THAP11 protein is not
affected by the synthesis of the THAP11HBM -Flag mutant protein, the latter being lowly (no doxycyline) or
strongly (with doxycycline) expressed (Figure 6.13 B for clone # 21, and not shown for the 5 other clones).
Figure 6.13: Flp-In
TM
T-Rex
TM
THAP11HBM cells. (A) The 6 selected cell clones were treated during
28 hours with 1 µg/ml of doxycycline (+), or with DMSO as control (—), and whole cell lysates were analyzed
by immunoblot with an anti-Flag antibody. (B) Cells from clone # 21 or parental cells were treated for 6
days with 1 µg/ml of doxycycline, or with DMSO as control (—), and whole cell lysates were analyzed by
immunoblot. Top pannel, anti-Flag antibody; bottom 2 pannel, anti-THAP11 antibody. Please note that
this immunoblot comes from the experiment described in Figure 7.5. P, parental cells. L, low exposure; H,
high exposure.
6.2.4 Creation of Flp-In
TM
T-Rex
TM
THAP7WT cells
With the same approach, Flp-In
TM
T-Rex
TM
THAP7WT cells were created, and 6 clones were randomly
selected. Figure 6.14 shows that the 6 clones express high levels of the THAP7WT -Flag protein after 3 days
of doxycycline treatment. Due to the lack of a THAP7 antibody, I was unfortunately not able to probe the
effect of the ectopic THAP7WT -Flag protein on the endogenous THAP7 one. By random selection, future
studies were done using clone # 14.
6.2.5 Discussion of the generation of stable cell lines containing an inducible
THAP11 or THAP7 gene construct
Using the Flp-In
TM
T-Rex
TM
system, I was able to engineer stable cell lines synthesizing, under the control
of tetracycline (here, doxycycline), one of the following Flag-tagged ectopic THAP proteins: THAP11WT ,
THAP11HBM or THAP7WT . The generation of such cells worked very well, and I obtained for each type
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Figure 6.14: Flp-In
TM
T-Rex
TM
THAP7WT cells. The 6 selected cell clones were treated during 3 days
with 1 µg/ml of doxycycline and whole cell lysates were analyzed by immunoblot. P, parental cells.
many cell clones, among which the 6 randomly tested expressed high levels of the ectopic THAP protein
when treated with doxycycline. In the absence of doxycycline, the cells nevertheless possess low levels of the
ectopic proteins, which vary depending on the cell clone. This low level being likely due to the presence of
tetracycline in the serum used to supplement the cell culture medium, I tested the use of tetracycline-free
serum. This did not, however, suppress the basal expression of the ectopic THAP constructs in the absence
of doxycycline. Thus, the inducible aspect of these cells does not work perfectly, as I am not able to cleanly
suppress the expression of the ectopic contruct in the absence of doxycycline treatment. Because of this leaky
expression, these cells were not used as hosts for CRISPR/Cas9-mediated mutagenesis, as the key point was
to be able to completely suppress the synthesis of the ectopic THAP construct. I can nevertheless make the
best of this drawback by exploiting the leaky synthesis, particularly as this level is comparable to the one of
the endogenous THAP protein (at least for THAP11; THAP7 was not tested for this due to the absence of a
THAP7 antibody). These cells can thus be used in two ways: with no doxycycline, they express the ectopic
THAP protein, at a low level similar to the endogenous THAP one, while upon treatment with doxycycline,
the ectopic THAP is strongly expressed. Also, I showed that the use of different doxycycline concentrations
enables me to modulate the expression level of the ectopic construct. Thus, the leaky expression and the
use of different doxycycline concentration can be exploited to obtain intermediate levels of synthesis of the
ectopic THAP protein (between very low to very high synthesis), which might be less artificial than the high
forced synthesis.
Curiously, I observed that the THAP11WT -Flag level is lower after a prolonged doxycycline treatment
than after a short treatment (1 to 3 days). I can hypothesize that a compensatory mechanism takes place to
reduce the expression of the ectopic THAP construct when it is overexpressed for a certain length of time.
Alternatively, it can be the sign that some of the cells may not have the inserted THAP construct — either
they have lost it, or they never had it — and that the treatment with doxycycline somehow positively favors
these cells at the expense of the Flp-In
TM
T-Rex
TM
THAP11WT stable cells.
Interestingly, using Flp-In
TM
T-Rex
TM
THAP11WT cells, I demonstrated that the endogenous THAP11
protein is not affected by the presence of the exogenous THAP11-Flag one, the latter being WT or HBM
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mutant, highly or lowly expressed (i.e., treated, or not, with doxycycline), briefly or continuously expressed
(i.e., treated for a short, or a long, period with doxycycline). Thus, the THAP11 protein may not regulate
the expression of its own gene.
Finally, I succeeded in creating Flp-In
TM
T-Rex
TM
THAP11HBM cells, and I did not encounter more
difficulties with the THAP11HBM construct than with the WT one. Contrary to what I suggested earlier, the
THAP11HBM protein might not have such a deleterious effet on cells, the WT version of the protein being
present. This cell line needs to be further tested to probe whether it behaves differently than the Flp-In
TM
T-Rex
TM
THAP11WT one.
6.3 Conclusion
In this chapter, I have created a collection of cellular models to investigate the role of THAP7 and THAP11
proteins. THAP7 functional mutants and a THAP11 disease-associated mutant were created in the en-
dogenous genes of HEK-293 cells: THAP7null, THAP7HBM , THAP7∆CC and THAP11F80L. In addition, I
obtained cell lines stably expressing THAP11WT , THAP11HBM or THAP7WT at a low basal state, and at
a high level upon treatment with doxycycline. I exploited these cell lines to probe the effect of THAP7 and
THAP11 proteins on cell proliferation and gene transcription, and to decipher their mechanism of action.
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Chapter 7
Cell proliferation roles of THAP7 and
THAP11
In the following chapter, I describe how I used the previously generated cell lines to probe the role of THAP7
and THAP11 in cell proliferation. With the help of Philippe Lhoˆte, I performed proliferation experiments in
which we followed the cells for 8 days.
7.1 THAP7null and THAP7∆CC mutations retard cell proliferation
To test cell proliferation rates, HEK-293 WT and THAP7null cells from clones # 29, # 32 and # 44 were
seeded at the same density on day 0 and cell proliferation was followed during a week from day 1 by counting
cells from two duplicate plates every 24 hours (except on days 2 and 3). Figure 7.1 displays for each time
point the mean of the cell count between the two replicates (Nt), relative to the initial cell number on day 0
(No). All of these three THAP7null cell lines (orange, grey and yellow lines), which are homozygous, have a
delay in cell proliferation compared to WT cells (blue line). The three mutant cells are able to proliferate,
but at a lower rate than the WT ones. Thus, the disruption of the THAP7 gene impairs HEK-293-cell
proliferation.
Growth curves using THAP7HBM and THAP7∆CC cells were done similarly. Figure 7.2 shows that the
two homozygous THAP7HBM mutant clones have different behaviors regarding cell proliferation: whereas
clone # 76 cells (grey line) grow similarly to the WT cells (blue line), cells from clone # 34 (orange line)
display a marked impairment in cell proliferation. Indeed, almost half as many clone # 34 cells were counted
on day 8 compared to WT or clone # 76 cells. Due to the discrepancy between the two mutant cell clones,
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it is difficult to draw any conclusions regarding the impact of the HBM mutation in THAP7.
Figure 7.1: Proliferation assays of HEK-293 WT and THAP7null cells. Cells were seeded at the same
density on day 0, and 2 plates of each cell line were counted every 24 hours from day 1 (except on days 2
and 3). The ratio of the mean cell count between the two replicates (Nt) and the initial cell number (No) is
displayed, +/- the standard deviation.
Figure 7.2: Proliferation assays of HEK-293 WT and THAP7HBM cells. Cells were seeded at the
same density on day 0, and 2 plates of each cell line were counted every 24 hours from day 1 (except on days
2 and 3). The ratio of the mean cell count between the two replicates (Nt) and the initial cell number (No)
is displayed, +/- the standard deviation.
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Regarding THAP7∆CC cells, Figure 7.3 reveals that the 4 homozygous clones (orange, grey, yellow and
green lines) consistently exhibit a slow down in cell proliferation compared to WT cells (blue line). Remark-
ably, the absence of the coiled-coil domain in THAP7 has the same effect as the total loss of the protein, as
it slows down cell proliferation to the same extent than the THAP7null mutation (compare with Figure 7.1).
Figure 7.3: Proliferation assays of HEK-293 WT and THAP7CC cells. Cells were seeded at the same
density on day 0, and 2 plates of each cell line were counted every 24 hours from day 1 (except on days 2
and 3). The ratio of the mean cell count between the two replicates (Nt) and the initial cell number (No) is
displayed, +/- the standard deviation.
In conclusion, both the total loss of THAP7 protein and the truncation of its coiled-coil domain retard
cell proliferation, while effect of the THAP7 HBM mutation cannot be interpreted.
7.2 Cell proliferation is moderately affected by the forced synthe-
sis of the THAP7WT protein
In the same manner, I assessed the effect of the reinforced synthesis of the THAP7WT protein. For this, I used
the Flp-In
TM
T-Rex
TM
THAP7WT cells created in Chapter 6, which can express very low or high levels of the
ectopic THAP7WT -Flag protein, depending on the treatment. I then compared the proliferation of cells with
no (parental cells), very low levels (DMSO-treated) or high levels (doxycycline-treated) of THAP7WT -Flag
protein (Figure 7.4 A). The same number of cells were plated for each condition, and treated 24 hours later
(day 1) with doxycycline (DOX, dashed lines), or DMSO (solid lines) as control. Comparing parental cells
treated with DMSO and doxycyline (Figure 7.4 B, solid and dashed blue lines, respectively) demonstrates
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that doxycycline treatment by itself does not affect cell proliferation. The leaky synthesis of THAP7WT -Flag
(DMSO-treated cells, solid orange line) slightly slows down cell proliferation compared to parental cells, the
effect being more pronounced when THAP7WT -Flag is highly expressed by stimulation with doxycycline
(dashed orange line). Consequently, the ectopic synthesis of THAP7 moderatly slows down cell proliferation,
the effect being THAP7WT -Flag-dose dependent.
Figure 7.4: Proliferation assays of Flp-In
TM
T-Rex
TM
THAP7WT cells. Cells were seeded at the
same density on day 0, and treated 24 hours later with 1 µg/ml of doxycycline (DOX, dashed line), or DMSO
as control (solid line). From day 1, 2 plates of each cell line were counted every 24 hours (except on days 2
and 3). (A) Equal amounts of proteins from whole cell lysates of day 7 cells were analyzed by immunoblot.
P, parental cells. (B) The ratio of the mean cell count between the two replicates (Nt) and the initial cell
number (No) is displayed, +/- the standard deviation.
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7.3 The forced synthesis of an ectopic THAP11 protein impairs
cell proliferation
Similarly, I probed the effect of the reinforced synthesis of THAP11 on cell proliferation, using the Flp-
In
TM
T-Rex
TM
THAP11WT cells (Chapter 6). While the leaky synthesis of THAP11WT -Flag in the absence
of doxycycline (DMSO treatment) is at a level comparable to the endogenous THAP11 protein one, using
doxycycline allows to strongly induce THAP11WT -Flag resulting in a large excess of the ectopic protein
(Figure 7.5 A, lanes 3 and 4, respectively). The low synthesis of THAP11WT -Flag (DMSO treatment) slows
down cell proliferation when compared to parental cells (Figure 7.5 B, compare the solid orange line with
the blue lines). In addition, the impairment in cell proliferation is more pronounced when the synthesis of
THAP11WT -Flag is reinforced by stimulation with doxycycline (dashed orange line).
In addition, the absence of an HBM sequence in the ectopic THAP11 protein (THAP11HBM cells) also
slows down cell proliferation compared to parental cells (Figure 7.5 C, compare the solid green line with
the blue lines). Again, the increased synthesis of the ectopic THAP11HBM -Flag protein due to doxycycline
treatment (Figure 7.5 A, lanes 5 and 6) further slows down cell proliferation (compare the solid and dashed
green lines). Curiously, the ectopic THAP11HBM -Flag protein is here expressed in large excess compared to
the endogenous protein, even in the absence of doxycycline stimulation.
To conclude, the forced synthesis of both THAP11WT and THAP11HBM impairs cell proliferation, the
decrease of proliferation rate being correlated with their respective levels.
7.4 The THAP11 cobalamin-disorder mutation impairs cell pro-
liferation
Similarly, cell proliferation was followed for the cells bearing the cobalamin-disorder associated mutation.
Growth curves were done for both the homozygous THAP11F80L/F80L and heterozygous THAP11F80L/+
cells. As the stability of the THAP11 protein is affected by the p.F80L mutation (see section 6.1.5), the
resulting mutant protein may be particularly sensitive to temperature change. Indeed, an increase of temper-
ature may then destabilize even more the THAP11F80L mutant protein. To test this hypothesis, proliferation
assays were performed at both 37 ◦C and 39.5 ◦C. For this, cells were seeded on day 0 at the same density
and incubated at 37 ◦C. Then, 24 hours later (day 1), half of the cells were transferred at 39.5 ◦C for the
following 7 days. Figure 7.6 shows that temperature has an effect on WT cells: as expected, cells grown
at 39.5 ◦C proliferate slower than the ones grown at 37 ◦C (dashed and solid blue lines, respectively). In
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Figure 7.5: Proliferation assays of Flp-In
TM
T-Rex
TM
THAP11WT and THAP11HBMcells. Cells
were seeded at the same density on day 0, and treated 24 hours later with 1 µg/ml of doxycycline (DOX,
dashed line), or DMSO as control (solid line). From day 1, 2 plates of each cell line were counted every 24
hours (except on days 2 and 3). (A) Equal amounts of proteins from whole cell lysates of day 7 cells were
analyzed by immunoblot. P, parental cells. (B) and (C) The ratio of the mean cell count between the two
replicates (Nt) and the initial cell number (No) is displayed, +/- the standard deviation.
Figure 7.6: Proliferation assays of HEK-293 WT and homozygous THAP11F80L/F80L cells. Cells
were seeded at the same density on day 0, and half of the cells were transferred at 39.5 ◦C on the following
day (dashed lines) while the rest of the cells stayed at 37 ◦C (solid lines). From day 1, 2 plates of each cell
line were counted every 24 hours (except on days 2 and 3). The ratio of the mean cell count between the two
replicates (Nt) and the initial cell number (No) is displayed, +/- the standard deviation.
addition, homozygous THAP11F80L/F80L cells display a marked impairment in cell proliferation when com-
pared to WT cells, which is worsened by the increase of temperature. At 37 ◦C, we counted less than half
THAP11F80L/F80L cells compared to WT cells (compare solid orange and blue lanes, respectively), and al-
most four times less when the cells have been switched at 39.5 ◦C (compare dashed orange and blue lanes,
respectively).
Regarding the heterozygous THAP11F80L/+ cells, Figure 7.7 shows that they have an intermediate phe-
notype. When grown at 37 ◦C, THAP11F80L/+ cells have a smaller cell count in days 6 and 7 compared
to WT cells, but finally catch up on day 8 (compare solid orange and blue lines, respectively). In contrast,
heterozygous mutant cells cultivated at 39.5 ◦C retain their defect in cell proliferation until day 8, where
there were more than three times less THAP11F80L/+ cells than WT cells (dashed orange and blue lanes,
respectively).
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Figure 7.7: Proliferation assays of HEK-293 WT and heterozygous THAP11F80L/+ cells. Cells
were seeded at the same density on day 0, and half of the cells were transferred at 39.5 ◦C on the following
day (dashed lines) while the rest of the cells stayed at 37 ◦C (solid lines). From day 1, 2 plates of each cell
line were counted every 24 hours (except on days 2 and 3). The ratio of the mean cell count between the two
replicates (Nt) and the initial cell number (No) is displayed, +/- the standard deviation.
Thus, the p.F80L mutation in THAP11 impairs cell proliferation at both temperatures, the effect being
more pronounced when cells are grown at 39.5 ◦C. In addition, cells bearing the homozygous mutation have
a more pronounced phenotype than the heterozygous ones.
7.5 Discussion
In this chapter, I have probed, with the help of Philippe Lhoˆte, the role of THAP7 and THAP11 proteins in
cell proliferation.
I demonstrated that THAP7 is an important factor for HEK-293-cell proliferation. First, its absence in
the CRISPR/Cas9 THAP7null cells slows down cell proliferation. Second, the lack of its coiled-coil domain in
THAP7∆CC cells also markedly reduces the rate of proliferation, and its absence has a similar effect. Thus, its
ability to dimerize is likely to be necessary to control cell proliferation. The role of its interaction with HCF-1,
however, remains uncertain, as the two different THAP7HBM homozygous clones behave very differently. To
conclude, THAP7 appears to be important, though not essential — as cells carry on proliferating even when
it is missing — for HEK-293-cell proliferation, and its mechanism of action likely involves its dimerization.
In Chapter 5, I showed that THAP7 homodimerizes, but does not form heterodimers with THAP11. Also,
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homodimerization is often important for transcription-factor activies, as explained in section 1.1.2. It is thus
likely that THAP7 homodimerizes to regulate gene expression and subsequent cell proliferation.
In addition, the increased THAP7 synthesis in the Flp-In
TM
T-Rex
TM
THAP7WT cells also slows down
cell proliferation, albeit its forced synthesis has a weaker effect than its absence. Interestingly, in the latter
stable cells, the reduction of cell proliferation is proportional to the level of the THAP7 forced synthesis.
Thus, a precise level of THAP7 protein appears to be critical for its effect on cell proliferation, as any
manipulation of its level impairs cell proliferation. Importantly, stable increased synthesis of a protein into
cells is a very artificial experiment, which can be quite difficult to interprete. For instance, an hypothesis
would be that THAP7 negatively regulates its own synthesis, directly or indirectly. It would explain the
similar effect of the overexpression and knock-out experiments, as the forced synthesis of THAP7 would then
result in a negative feedback to decrease THAP7 (endogenous) levels. Although mRNA and protein levels
do not necessarily correlate, this hypothesis could be tested by probing, on western blotting, the level of the
endogenous THAP7 protein in Flp-In
TM
T-Rex
TM
THAP7WT cells — stimulated or not with doxycycline.
Alternatively, one can imagine doing THAP7 ChIP-seq and to assess whether THAP7 protein is present on
the THAP7 regulatory regions, which would be an indication of its possible direct auto-regulation. These
experiments are, however, not possible here as I do not possess any good THAP7 antibody.
Otherwise, increasing THAP7 protein concentration could result in diluting out the critical THAP7
partners (e.g. HCF-1). One can imagine that having too many THAP7 molecules results in a whole set of
THAP7 proteins in excess and not bound by their usual partners, which would thus be less or non functional.
Thus THAP7 in excess would retain the ability to bind DNA and thus compete with other THAP7 molecules
that are bound by their usual partners. More generally, the increased synthesis of any protein has the potential
to result in an impaired function of the protein, by a dominant-negative mechanism. It would also explain
why the phenotype is dose-dependent, as increasing the synthesis of the ectopic protein would enhance
the dilution of THAP7 partners. This highlights how cautious the interpretation of an forced-synthesis
experiment should be. Overall, these different results tend to show that THAP7 is a positive regulator of cell
proliferation in HEK-293 cells. This conclusion, however, is in contradition with a previous study suggesting
that THAP7 would repress cell proliferation as it inhibits Histone Nuclear Factor P (HiNF-P)-mediated
histone H4 transcription, necessary for G1-to-S phase transition and S-phase progression [67]
For THAP11, the impossibility to obtain any THAP11null cell clones (Chapter 6) suggested that THAP11
is an essential protein for cell survival and/or proliferation, at least in HEK-293 cells. The results obtained
here with the THAP11F80L/F80L and THAP11F80L/+ mutant cells point in the same direction. In Chapter 6, I
demonstrated that the homozygous p.F80L mutation results in a marked decrease in protein level, likely being
the consequence of protein destabilization and subsequent degradation. In these THAP11F80L/F80L mutant
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cells, the homozygous mutation severely hampers cell proliferation, which suggests that THAP11 positively
regulates cell proliferation. This result is in accordance with clinical manifestations of the X-linked cobalamin
disorder which include neurodevelopment defects (developmental delay, microcephaly, brain malformations)
[126]. Indeed, the mutation in THAP11F80L is then likely to prevent THAP11 from positively regulating
cell proliferation and subsequent development, leading to the aforementioned developmental impairments. In
agreement with this, several recent studies have suggested that THAP11 (or Ronin, in mice), is involved not
only in cell proliferation, but more largely in early vertebrate development of several organs, by controling the
proliferation and differentiation fates of the cells [71,72,74–77,83]. In addition, heterozygous THAP11F80L/+
mutant cells initially display a delay in cell proliferation compared to the WT cells, before catching up in
the later time points. This result suggests that the cells are able to adapt and to compensate for the partial
loss of the THAP11WT protein. This explains why the THAP11F80L mutation causing the cblX -like disease
has only been identified as an homozygous state, as the heterozygous one would not probably cause any
symptoms.
Interestingly, increasing the cell-growth temperature worsened the effect of the p.F80L mutation on cell
proliferation. Indeed, the homozygous THAP11F80L/F80L mutant cells barely proliferate when they are
switched to 39.5 ◦C. The mutant protein is likely to be even more destabilized at elevated temperature, which
would explain the more severe phenotype 39.5 ◦C. In addition, heterozygous cells for the cobalamin-disorder
mutation, which are not severely affected at 37 ◦C, exhibit a defect in cell proliferation at 39.5 ◦C almost as
pronounced as the one of the homozygous mutant cells. Consequently, at this temperature, the WT THAP11
version seems unable to compensate for the heterozygous mutation. Thus, THAP11F80L mutation probably
has an incomplete penetrance at 37 ◦C, while a complete penetrance at 39.5 ◦C. An hypothesis would be
that the mutated THAP11F80L protein is not completely lost and probably still retains some function at
37 ◦C, while being more destabilized and likely non functional at 39.5 ◦C. More precisely, the decrease of
THAP11 protein level in heterozygous cells (likely due to a degradation of the mutant THAP11 protein
version) probably does not lead to a strong-enough reduction of total (WT and mutant) THAP11 protein
level. When grown at 39.5 ◦C, the THAP11F80L mutant protein is likely to be even more unstable, thus
even more degradaded. The resulting more severe decrease in THAP11 level may then be important enough
to impact THAP11 function. It would thus be interesting to compare the THAP11 protein level in both the
homozygous THAP11F80L/F80L and heterozygous THAP11F80L/+ mutant cells at 37 ◦C and 39.5 ◦C. Also,
it likely means that a single functional allele of THAP11 is not sufficient for THAP11 functions. Clinically
speaking, the heterozygous mutation should then not cause any defect as our body is normally maintained
at 37 ◦C. Also, THAP11 seems to mainly impact development, and to have minor effects in adult organisms.
Nevertheless, one could theoretically imagine that a fetus heterozygous for the THAP11F80L mutation could
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have developmental impairments in case of a prenatal (in-utero) exposure to fever, the latter happening when
the mother suffers from fever.
In addition, I showed that the reinforced synthesis of THAP11WT also hampers cell proliferation in HEK-
293 cells, the magnitude of the effect being proportional to the level of synthesis. Similarly to THAP7, I
thus demonstrated that the increased synthesis of THAP11 as a similar effect, although weaker, than its
(probable) loss of function due to the p.F80L mutation. Similarly to what I explained above, THAP11
enhanced synthesis is likely to result in a dominant-negative effect. HCF-1 has been shown to be a critical
THAP11 partner for regulation of transcription and cell proliferation [29,39,43,54,70,71,75], thus THAP11
increased level could dilute out the HCF-1 molecules, leaving numerous THAP11 molecules unbound to
HCF-1 and consequently non functional. The latter unbound THAP11 protein are unlikely to bind DNA by
themselves, as THAP11 and HCF-1 binding to their common promoters has been suggested to be mutually
dependent. THAP11, however, has the ability to form homodimers (Chapter 5, Figure 5.1 B), which is likely
to be important for its DNA binding and subsequent regulation of transcription. Thus, an excess of THAP11
protein may result in formation of THAP11 homodimers bound by a single HCF-1 molecule, instead of two,
which may not be sufficient for their synergistic transcription regulation.
Furthermore, I demonstrated that the forced synthesis of an HBM-depleted THAP11 protein — thus
unable to bind HCF-1 (as shown in Chapter 5, Figure 5.1 B) — slows down cell proliferation with a dose-
dependent effect. The overexpressed THAP11HBM protein being in such large excess compared to the
endogenous THAP11WT one, two sorts of THAP11 dimers can be formed : either endogenous THAP11WT
with ectopic THAP11HBM mutant heterodimers, or ectopic THAP11HBM mutant homodimers. The latter
being unable to bind any HCF-1 molecule, they are likely not bound to DNA and non functional. The
former heterodimer, however, would have the ability, through the endogenous THAP11WT moiety, to recruit
a single HCF-1 protein and to bind DNA. Nevertheless, the recruitment of a single HCF-1 molecule to the
THAP11 dimer may not be sufficient for their synergistic regulation of transcription. Consequently, the forced
synthesis of the HBM mutant THAP11 protein is likely to also have a dominant negative effect by saturating
the endogenous WT protein. This result can be linked to the fact that the heterozygous CRISPR/Cas9-
mediated THAP11HBM mutant cell line obtained in Chapter 6 ultimately died. Indeed, the death of these
cells suggested a possible dominant-negative effect of the HBM mutant protein and motivated the creation
of stable cells expressing the THAP11HBM protein. It is suprising, however, that the effect in the mutant
cells, likely expressing similar levels of THAP11WT and THAP11HBM protein, would be stronger than the
one observed in the stable cells, in which the THAP11HBM protein is expressed at a much higher level than
the WT version, even without doxycycline stimulation.
Most of the time, the experiments we performed show very similar results for different clones of the same
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mutation. This is the case, for example, for THAP7null and THAP7∆CC clones. Thus, the results obtained
there are very strong and I can be very confident. Regarding THAP11F80L/F80L cells, I had only one ho-
mozygous clone which theoritically does not give as much confidence in the results obtained. I demonstrated,
however, that the heterozygous cells have an intermediate behavior between the WT and THAP11F80L/F80L
homozygous cells. It then gives quite some confidence in the results obtained with the single clone. For the
stable cells, however, we used a single mutant for each type of cell to perform the proliferation experiments.
The results obtained should then be considered cautiously, even though the different clones of each cell type
behave similarly when routinely maintained in culture. Unfortunately, in the case of THAP7HBM mutant
cells, the two clones we used behave very differently, making any interpretation difficult. It is consequently
necessary to obtain additional THAP7HBM cell clones to conclude on the role of the HCF-1 interaction on
THAP7-mediated proliferation effect. In addition, it is likely that the two clones have different off-target
effects due to the CRISPR/Cas9 mutagenesis. It would be interesting to understand the underlying differ-
ences which would explain their different behaviors. For this, one could sequence and compare their genome
to identify specific off-target mutations on each clone.
Here, I note that although most of my custom cell lines have exhibited an impaired cell proliferation
compared to WT cells, none of the mutation or over-synthesis experiments resulted in a complete suppres-
sion of cell proliferation, or even in cell death. This was actually expected, as the process of the cell line
creation had necessarily selected cells able to proliferate to a certain extent. Indeed, both the CRISPR/Cas9
mutagenesis and the creation of stable cells involved a step of clonal selection, in which cells have to survive
and proliferate at least to a certain extent, to be able to be selected and tested. It then automatically gets
rid of the non-proliferating and dying cells. It is thus important to keep this in mind as it can be responsible
from a bias in the cell line clones selected and the results I obtained using them.
Overall, these different results demonstrate that THAP7 and THAP11 are, at least in HEK-293 cells,
positive regulators of cell proliferation that need to be expressed at a precise level. Their respective mecha-
nisms of action, however, remain largely unclear. For instance, previous studies suggested that both THAP
proteins regulate G1-to-S phase transition and S-phase progression during the cell cycle [29,67,74]. To probe
this, one could compare the cell-cycle progression of WT and CRISPR/Cas9 mutant cells — particularly,
THAP7null and THAP11
F80L/F80L cells — using flow cytometry as described in Chapter 4 for synchronized
cells. In addition, it would be interesting to assess the proliferative role of THAP7 and THAP11 in other cell
types, to verify that the latter conclusions are not specific to HEK-293 cells.
In the rest of this study, however, I more globally examined the transcriptional role of THAP7 and
THAP11, which is likely to underly their proliferation effects.
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Role of THAP11 on gene transcription
Using the aforementioned stable and mutant cell lines, genomic analyses were performed to decipher how
THAP7 and THAP11 regulate gene transcription and subsequent cell proliferation. Here, I described the
analysis of the data related to the THAP11 protein.
In this chapter, I thus describe the state-of-the-art high-throughput RNA sequencing (RNA-seq) per-
formed on the THAP11F80L/F80L and THAP11F80L/+ mutant cells as well as the Flp-In
TM
T-Rex
TM
THAP11WT and THAP11HBM stable cells. Also, I present the chromatin immunoprecipitation followed
by high-throughput sequencing (ChIP-seq) executed on the WT and THAP11F80L/F80L mutant cells. Im-
portantly, I was lucky enough to benefit from the valuable help from Philippe Lhoˆte and Maykel Lopes,
two lab technicians, for the experimental part. The subsequent sequencings were executed by the Lausanne
Genomic Technologies Facility (LGTF). Also, the computational data analysis was performed by Dr. Viviane
Praz, our lab bioinformatician.
8.1 Transcriptomic analysis of THAP11 stable cells supports the
involvment of THAP11 in cell proliferation and development
To begin with, we performed a large scale transcriptomic analysis on the Flp-In
TM
T-Rex
TM
cell lines
expressing THAP11WT and THAP11HBM . A single clone per cell type (the same as used in Chapter 3)
was used, but technical duplicates were done for each of them. Parental Flp-In
TM
T-Rex
TM
cells were used
in parallel as a reference. Cells were grown and treated for 36 hours at 37 ◦C with DMSO (all cells) or
doxycycline (all but Flp-In
TM
T-Rex
TM
THAP11HBM cells). Total RNA was then extracted, the ribosomal
RNA removed and the resulting RNA was subjected to single-read high-throughput sequencing.
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Dr. Viviane Praz started by summarizing the normalized RNA-seq data using a principal component
analysis (PCA). Indeed, PCA allows a simplification of the complexity of high-dimensional data, which is
the case for large-scale experiments such as RNA-seq. By transforming the data, PCA summarizes the
large number of correlated variables into a smaller number of new, uncorrelated variables. The latter are
named principal components (PC1, PC2, . . . ). The first principal component accounts for the largest possible
variability within the data, and each of the following principal components accounts for the largest possible
part of the remaining variability. As a result, PCA allows one to identify patterns within the data and to
highlight similarities and differences. In addition, it allows a graphical representation of such high-dimensional
data, in other words it enables to visually see how the data look like.
The PCA plot in Figure 8.1 shows the mean of the 2 technical replicates (square) with the dashed-line
circle representing the two standard errors for each principal component. The first principal component
(PC1), represented on the X-axis and accounting for 28% of the variance, mainly segregates the different
cell lines. Curiously, the THAP11WT and THAP11HBM -expressing cells segregate on opposite sides of the
parental cells: while the Flp-In
TM
T-Rex
TM
THAP11WT cells are on the right of the parental ones, the
Flp-In
TM
T-Rex
TM
THAP11HBM are on the left.
The second principal component (PC2), on the Y axis and responsible for 12% of the remaining variance,
mainly differentiates between the treatments (DMSO versus doxycycline). Curiously, the treatment seems to
have opposite effects regarding the PC2 component for the parental and THAP11WT -expressing cells. Indeed,
doxycycline treatment induces a marked displacement along the PC2 (Y) axis towards to top in the parental
cells, while this displacement is very small and towards the bottom for Flp-In
TM
T-Rex
TM
THAP11WT cells.
Interestingly, the standard-error circle is elongated along the Y-axis for each sample, suggesting that the two
replicates segregate along the Y axis. Thus, the PC2 component may also account for the difference between
the replicates, meaning, the technical and sequencing variability.
Dr. Viviane Praz also did several differential analyses between the different cell lines and conditions, fol-
lowed by Gene Ontology (GO) analyses. First, when analyzing the effect of the treatment on the parental
cells, only one gene, ZACN, is differentially expressed between parental cells treated with DMSO or doxy-
cycline. This gene is also upregulated in the doxycycline-treated Flp-In
TM
T-Rex
TM
THAP11WT sample
compared to the DMSO-treated one. Thus, doxycycline treatment at the concentration used is likely to have
a negligible adverse effect besides the activation of the ectopic protein, as it is limited to the upregulation of
the sole ZACN gene.
Second, we compared the gene expression of parental and Flp-In
TM
T-Rex
TM
THAP11WT cells, in both
treatment conditions. When treated with DMSO, 374 genes were upregulated and 564 were downregulated in
the Flp-In
TM
T-Rex
TM
THAP11WT cells compared to the parental ones. Upon doxycycline treatment, 358
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Figure 8.1: Principal component analysis of RNA-seq data from THAP11 stable cell lines.
PCA1 and 2 resulting from RNA-seq data of Flp-In
TM
T-Rex
TM
parental (red), THAP11WT (blue) and
THAP11HBM cells (purple), treated during 36 hours with 1 µg/ml of doxycycline (DOX, dark colors) or
with DMSO (light colors) as control. The squares represent the mean of the 2 technical replicates with the
dashed-line circle representing the standard error.
genes are upregulated and 1043 are downregulated in the Flp-In
TM
T-Rex
TM
THAP11WT cells compared
to the parental ones. These numbers immediately suggest that the treatment with doxycycline strenghtens
the effects of THAP11WT ectopic synthesis, which is what has already been observed when assaying the
proliferation of such cells. Indeed, I observed that Flp-In
TM
T-Rex
TM
THAP11WT cells proliferate slower
than parental ones, the effect being more pronounced upon treatment with doxycycline (see Chapter 7).
Dr. Viviane Praz submitted the list of differentially expressed genes to Gene Ontology (GO) analysis. The
results for cells treated with DMSO or doxycycline were very similar, the ones obtained with doxycycline-
treated cells being even stronger (Supplemental Tables S1, S2, S3 and S4). This was actually expected as the
doxycycline treatment increases the ectopic THAP11WT -Flag synthesis and reinforces the phenotypic effects
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as seen in Chapter 7. Upregulated genes in the Flp-In
TM
T-Rex
TM
THAP11WT cells reveal pathways mainly
related to development (purple), cell proliferation (blue), and also in transcription (orange) (Figure 8.2 A
for doxycycline-treated cells, showing a visual summary of GO terms associated to downregulated genes, and
Supplemental Tables S1 and S3 for the full lists of GO terms obtained for DMSO and doxycycline-treated
cells, respectively). Alternatively, genes downregulated in the Flp-In
TM
T-Rex
TM
THAP11WT cells are
associated to mitochondria (GO cellular composents: mitochondrion, mitochondrial matrix, mitochondrial
inner membrane; green dots) (Supplemental Tables S2 and S4 for the full lists of GO terms obtained for
DMSO and doxycycline-treated cells, respectively). These analyses again support the idea that THAP11 is
involved in gene transcription, cell proliferation and development. They also make sense with what has been
observed in the proliferation assays, meaning that THAP11 is involved in cell proliferation, with an increased
phenotype when it is more highly overexpressed (doxycycline treatment) (Chapter 7).
Of note, many fewer genes are differentially expressed between Flp-In
TM
T-Rex
TM
THAP11WT cells
treated with DMSO and doxycycline (27 upregulated and 66 downregulated) and the GO analyses did not
identify any relevant pathway affected (Supplemental Table S5). Together with the proliferation experiments
(Chapter 7), the latter results strenghten the idea that most of the effect due to the ectopic THAP11 protein
is already triggered by its leaky synthesis. The reinforced THAP11 synthesis due to doxycycline treatment
only enhances the phenotype slightly.
Third, we analyzed the gene expression of the Flp-In
TM
T-Rex
TM
THAP11HBM cells to probe whether
the HBM sequence is necessary for the role of THAP11 on gene transcription. Comparing parental and
Flp-In
TM
T-Rex
TM
THAP11HBM cells treated with DMSO, a small number of genes were differentially
expressed. Indeed, only 68 genes were upregulated and 167 downregulated upon forced synthesis of the
ectopic THAP11HBM protein. In addition, GO analyses did not reveal any significant pathway affected
(Supplemental Table S6). Thus, gene expression does not seem to be severely affected by the forced synthesis
of the THAP11HBM ectopic protein. In addition, 479 genes were upregulated and 577 downregulated in
the Flp-In
TM
T-Rex
TM
THAP11WT cells compared to the Flp-In
TM
T-Rex
TM
THAP11HBM ones (DMSO
treatment). When submitting these lists of genes to GO analysis, it revealed an association with mitochondria
for downregulated genes (green dots) and pathways linked to development, proliferation and transcription
for upregulated genes (purple, blue and orange, respectively; Figure 8.2 B for a visual summary of GO
terms associated to downregulated genes, and Supplemental Tables S7 and S8 for the full lists of GO terms).
The results are actually the same than what was obtained when comparing the parental and THAP11WT -
expressing cells (see above). Consequently, the THAP11 HBM sequence appears to be necessary for THAP11
to alter gene transcription.
To conclude, transcriptomic analyses using THAP11 stable cells demonstrated that THAP11 is implicated,
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Figure 8.2: Visual summary of Gene-Ontology analyses of RNA-seq data from THAP11 stable
cell lines. List of upregulated and downregulated genes in the interesting sample comparisons were separately
submitted for Gene-Ontology analysis and visualized using REVIGO and the interactive graph tool. GO
biological processes from (A) genes upregulated in the Flp-In
TM
T-Rex
TM
THAP11WT cells compared to
WT cells, treated with doxycycline and (B) genes upregulated in the Flp-In
TM
T-Rex
TM
THAP11WT cells
compared to Flp-In
TM
T-Rex
TM
THAP11HBM cells, treated with DMSO. The size of each GO term is
proportional to its associated p value resulting from the GO analysis output.
in an HBM-dependent manner, in the regulation of transcription, development and cell proliferation. In
addition, its function appears to be tightly linked to mitochondria.
8.2 Genomic analyses of the cobalamin-disorder associated THAP11
mutation
Previous analyses of the THAP11F80L/F80L and THAP11F80L/+ cell lines showed a severe proliferation
impairment of these cells compared to WT ones. To decipher the mechanism underlying the THAP11
cobalamin-disorder mutation, we used two complementary approaches on the mutant cells:
• a genome-wide analysis of THAP11 DNA association in WT and mutant cells, using ChIP-seq against
the THAP11 protein in the homozygous THAP11F80L/F80L cells;
• a transcriptomic analysis using RNA-seq, to compare the gene expression profiles between WT,
THAP11F80L/F80L and THAP11F80L/+ cells.
8.2.1 THAP11 DNA association is selectively disrupted at a subset of DNA
sites by the p.F80L mutation
As explained, the THAP11 p.F80L mutation affects the last amino acid of the “AVPTIF” box of the THAP
domain, which has been suggested to be involved in the proper folding of the THAP domain. The THAP
domain being responsible for DNA association, the resulting mutant protein could have an impaired ability
to bind to DNA. Also, previously published studies [75,83], as well as my own experiments described above,
suggest that the resulting mutant protein is likely less stable than the WT protein.
To probe the effect of the THAP11 p.F80L mutation on THAP11 DNA binding, Maykel Lopes per-
formed a chromatin immunoprecipitation against the THAP11 protein, followed by high-throughput se-
quencing, in both the WT and the homozygous THAP11F80L/F80L cells. Crosslinked chromatin from these
cells was sonicated and immunoprecipitated by an antibody directed to the C-terminus of THAP11, thus
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not competing with its DNA binding. The recovered chromatin and the input — the total, meaning non-
immunoprecipitated, chromatin — were decrosslinked and submitted to paired-end sequencing. The data
were analyzed by Dr. Viviane Praz. After mapping the reads onto the human genome, peaks were detected
in each sample. Each of THAP11 ChIP, in the two different cell lines, was sequenced in duplicate (two
different libraries were prepared from the same immunoprecipitated chromatin and sequenced). Comparing
the intersection of peaks between the replicate samples, we observed that 72 to 90% of the peaks in one of the
two replicate are found in the other one, depending the relative comparison made (data not shown). Also,
Figure 8.3 shows the two pairs of sequencing duplicates for 3 peak examples, and demonstrates how similar
the data are inside each replicate pair. Consequently, the sequencing data are extremely robusts. For future
visualization of peaks, a single replicate per sample is shown (replicate (a) for each sample). Also, for each
cell line, the sum of the peaks found in the duplicates will be considered. Naturally, when a peak is present
in both replicates, it is only counted once. If needed to choose between the peak data coming from one or
the other replicate, sample (a) was used. When later quantifiying the peaks, the mean between the replicates
was considered.
Figures 8.4 A and C show that 2341 peaks were detected in the WT cells, and only 1473 in the
THAP11F80L/F80L cells, with about half of the peaks being located close to an annotated transcription
start site (TSS; 250 bp on each side).
These peaks were classified into three categories: (i) peaks present in both the WT and the
THAP11F80L/F80L samples (“common”); (ii) peaks present only in the WT sample (“WT specific”); (iii)
peaks present exclusively in the THAP11F80L/F80L sample (“mutant specific”). Figures 8.4 B and C sum-
marize the total number of peaks identified in each of the 3 categories, and the number and percentage of
these peaks that are located close to a TSS (+/- 250 bp). It shows that more than half of common peaks
are located close to a TSS, while only a third of WT-specific ones are. Interestingly, only 3 peaks close to
a TSS were identified as specific to the THAP11F80L/F80L sample. Visualization of these peaks using the
UCSC genome browser showed that the 3 mutant-specific TSS-associated peaks are actually very low peaks
that can be considered as background (Figure 8.5). Thus, the THAP11F80L/F80L mutant protein remains
bound to only a subset of its promoter targets, and does not exhibit any evident de novo promoter binding
compared to the WT protein. For the rest of the study, I thus focus only on the common and WT-specific
peak categories.
The effect of the THAP11 p.F80L mutation is DNA-site specific. For instance, THAP11 is located at
the MMACHC promoter in WT cells, but absent in the THAP11F80L/F80L mutant cells (Figure 8.6 A).
As a reminder, the associated MMACHC protein is an essential enzyme in the cobalamin pathway, and
90% of cobalamin disorders result from mutations in the MMACHC gene. The loss of MMACHC -promoter
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Figure 8.3: Visualization of the sequencing duplicates at three ChIP-seq peaks. Peaks were vi-
sualized using the UCSC genome browser, all tracks being set with the same vertical viewing range (1 to
600).
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Figure 8.4: Number of identified peaks after THAP11 ChIP-seq in WT and THAP11F80L/F80L
cells. Total number of peaks, number and percentage of peaks close to a TSS (250 kb on each side) in
each cell type (A) or in each of the three peak categories (B). Venn diagrams visually showing the overlap
of all peaks (C) or TSS-close peaks (D) between the two different cell lines. Red, WT cells; light orange,
THAP11F80L/F80L cells.
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Figure 8.5: Visualization of the 3 TSS-associated mutant-specific peaks. Peaks were visualized using
the UCSC genome browser, all tracks being set with the same vertical viewing range (1 to 600).
binding by THAP11 in THAP11F80L/F80L cells is thus particularly interesting regarding the pathogenicity
of the THAP11 p.F80L mutation [75]. Examining a larger segment of the MMACHC genomic region reveals
additional THAP11-binding sites, that are differentially affected by the p.F80L mutation. THAP11 binding
at the TOE1 / MUTYH bidirectional promoter (left peak) is also lost, while retained at the TMEM69 /
GPBP1L1 one (right peak) (Figure 8.6 B).
Thus, we considered the peaks falling into two simplistic categories, depending on whether the peak is
retained or not in the THAP11F80L/F80L sample: common versus WT specific peaks. Importantly, the
common-peak classification does not discriminate between the peaks that are relatively similar between the
two samples, and the ones that, although present in both samples, exhibit a notable change in the peak level
between the samples. In a more developed analysis, additional peak categories may be created to take into
account the more subtle changes between the WT and mutant samples.
In conclusion, the THAP11 p.F80L mutation results in a selective disruption of THAP11 DNA binding at
specific genomic locations. While some DNA sites remain unaffected by the mutation, other sites suffer from
a partial to complete loss of THAP11 DNA binding. Also, the THAP11 p.F80L mutation does not create
de-novo THAP11 promoter-binding sites.
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Figure 8.6: THAP11F80L mutant protein selectively dissociate from a subset of DNA sites.
MMACHC -promoter region (A) and 100-time zoom out (B). Peaks were visualized using the UCSC genome
browser, all tracks being set with the same vertical viewing range (1 to 600).
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8.2.2 Why is the THAP11F80L mutant protein not bound to some specific DNA
sites?
It is intringuing that some genomic locations are dramatically affected, whereas others are not. To understand
differences that may exist between the DNA sites that remain bound by the THAP11F80L mutant protein
(common peaks) and the ones lost upon THAP11 p.F80L mutation (WT-specific peaks), Dr. Viviane Praz
performed different motifs analyses of the DNA sequence below the peaks.
To begin, we looked for recurrent motifs in the DNA sequences underlying the THAP11 peaks, separately
for each peak category. We used CentriMo [116], a tool for sequence comparison with known motifs, to
search for motifs within 1000 bp on each side of the peak middle. Interestingly, the results were extremely
similar for both sets of peaks. For both peak categories, CentriMo revealed several enriched motifs that
are actually simply different versions of the same motif. Figure 8.7 shows the top three motif hits found
for each peak category with their respective E-value (A), and the probability of each motif relative to the
peak center (B). The two first ones, named as ETS1 and SMARCC2 and 21-bp long, are just the reverse
complement of each other (Figure 8.7 C, compare the two top motifs). The third one, called ZNF143 and 15-
bp long, is a 5’ truncation of the two former motifs (Figure 8.7 C, compare the first and last motifs). Further
down in the motif list output, alternate versions of the ZNF143 motif come up, being 15 to 22-bp long.
All of the motifs listed in the CentriMo output actually end up being the same ones, or truncated versions,
or reverse complements, of the aforementioned ETS1 and SMARCC2 motifs. In conclusion, the CentriMo
analysis revealed that a single motif is associated to the THAP11 peaks, irrespective of the THAP11 p.F80L
mutation. The motif identified here, called as ETS1, SMARCC2 or ZNF143 in the CentriMo motif database,
is also the same as identified as the THAP11 motif or Ronin-binding motif [43, 70]. For the remainder of
this thesis, it will be referred to as the THAP11-associated motif (TAM). These results led to think that the
difference between the common and WT-specific peak sets is probably more subtle than a complete difference
in the underlying DNA sequence.
To assess whether this difference is due to subtle variations among TAMs, Dr. Viviane Praz created a
pipeline to generate, separately for each peak category, a consensus sequence (for more details, see the
explained procedure in the Chapter 2). Figure 8.8 B and C display the consensus sequences obtained for each
of the common and WT-specific peak category, respectively. The consensus sequence is extremely similar,
but weaker for the WT-specific peaks. A part of the weakness of the consensus sequence of WT-specific peaks
might be explained by the smaller number of motif-containing sequences used to build the consensus of the
WT-specific peak category, compared to the number for the common category (561 versus 1159 sequence,
respectively). This, however, is not likely to account for the whole difference of consensus strength. Notably,
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Figure 8.7: Motif analysis of DNA sequences underlying each category of peaks using Centrimo.
(A) Top three hits found for each peak category with their respective E-values. (B) Motif-probability graph
showing the probability of finding the given motif at a specific distance of the peak center. (C) Motif logo
of each of the 3 hits provided by Centrimo, with their respective ID.
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if the guanine nucleotides are taken as reference, the thymidine in position 17 is severely diminished in the
WT-specific peak consensus sequence compared to the common-peak one. More generally, the 3 thymidines
in position 15, 17 and 20, as well as the 2 adenines in positions 12 and 18 have a diminished strength in the
WT-specific peak consensus sequence compared to the common-peak one, if taking the neighboring guanine as
references. Other less important nucleotides also show a diminution in the WT-specific peak motif. Overall,
the two consensus motifs are relatively similar regarding their key features (such as the guanine triplet in
position 9 to 11 and the 2 guanines in position 16 and 19), but secondary nucleotide positions appear to be
weaker in the motif generated with the sequences underlying WT-specific peaks compared to common ones.
Actually, the weakness of the TAM under WT-specific peaks was already suggested by the lower E-values
obtained in the CentriMo output for the WT-specific set compared to the common one (Figure 8.7 A). Thus,
the fact that the mutant THAP11F80L protein still binds, or not, to DNA locations likely depends on the
strength of the underlying motif: if the DNA motif is strong enough, the mutant THAP11F80L protein will
still be able to bind this genomic location, while it will not bind if the motif is weaker. This would explain
the selective disappearance of binding sites bearing a weaker motif.
In the previous analysis, we only considered a single motif per peak — the one closest to the peak summit
— whereas many THAP11-bound DNA sites actually exhibit several TAMs. We also counted all the TAMs
found within 1000 bp on each side of the peak maximum. Figure 8.9 shows for each of the two groups
of peaks the number and percentage of peaks with (one or more) and without a motif (A) as well as the
distribution of motif number per peak (B). The results demonstrate that most common peaks (92%) have
at least one TAM (dark-green bar). In constrast, almost half of WT-specific peaks (48%) do not have any
evident TAM, as shown on Figure 8.9 B (light-red bars). Regarding the peaks having at least one TAM,
there is not much difference between the common and WT-specific peak categories regarding the distribution
of the motif number per peak, as shown by the peak distribution (Figure 8.9 B, compare the dark-red and
red bars for motif numbers from 1). Interestingly, for both categories, a large proportion of peaks exhibits
between 2 to 4 motifs per peak.
These different analyses strongly suggest that with the p.F80L mutation THAP11 retains some DNA-
binding ability. The resulting mutant protein does not have any de-novo binding activity but rather remains
bound to its strongest DNA locations. These are the ones that have at least one TAM, the latter being the
strongest possible. Thus, the criterion that determines whether the mutant THAP11F80L protein is still able
or not to bind a specific DNA location is its apparent affinity for the associated DNA sequence.
153
CHAPTER 8. ROLE OF THAP11 ON GENE TRANSCRIPTION
Figure 8.8: TAM consensus sequence in common and WT-specific peak categories. (A) 22-bp
long ZNF143 motif logo from Hocomoco (ZN143 HUMAN.H11MO.0.A) used as a reference, the consensus
sequence being depicted below. (B) and (C) Logo of consensus sequences obtained for common and WT-
specific peaks, respectively.
8.2.3 The THAP11 F80L mutation affects a specific subset of THAP11-bound
promoters
THAP11 regulates transcription, and has been previously shown to be tightly associated to TSSs [43, 70].
I already mentioned that one half of THAP11 binding sites lies close to an annotated TSS, both in WT
and THAP11F80L/F80L mutant cells (Figures 8.4 A). This finding is even better illustrated by the genomic
distribution charts in Figure 8.10. Indeed, half of both WT and THAP11F80L protein DNA association
happens in a 500 bp-window (+/- 250bp) around an annotated TSS (TSS PROX). The association of THAP11
to TSSs is even more prominent than what the pie charts visually suggests at first sight, as the TSS PROX
category is much more restrictive than the other ones that encompass much larger regions of the genome.
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Figure 8.9: Percentage of peaks with a THAP11-associated motif. The number and percentage of
peaks with a TAM was calculated separately for each peak category. (A) Percentage of peaks with (regardless
of the motif number), and without, a motif, the raw numbers being written above the bars. (B) Distribution
of the motif number per peak. Only peaks with a number of motifs up to 10 were shown, but some rare
peaks have a higher TAM number, up to 18.
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For instance, a remarkably higher proportion of THAP11 peaks is located in the TSS PROX category, which
is 500-bp wide, compared to the 1500-bp wide TSS DIST category.
As both the WT and the p.F80L mutant THAP11 proteins associate preferentially to TSSs, Dr. Viviane
Praz prepared a composite plot showing the THAP11 occupancy in a window of +/- 1 kb around TSSs. For
this, peaks in the TSS PROX category were considered and pilled up using the TSS as a reference. Figure
8.11 shows that both WT and mutant THAP11 proteins preferentially associate 50 bp upstream to TSSs, on
average. This observation is in agreement with the average 77-bp distance to TSSs that have been already
proposed [70]. The THAP11F80L/F80L-cell curve (dark-blue line) is less high than the WT curve (dark-red
line) due to the fewer number of peaks in the mutant sample and to the fact that the WT-specific peaks tend
to be lower (see Figure 8.13 later).
In conclusion, I demonstrate that THAP11 prefentially associates just upstream to TSSs, this feature
being unaffected by the THAP11 p.F80L mutation. As I am particularly interested in the role of THAP11
in gene transcription, the rest of the study focuses on the TSS-related peaks — meaning, THAP11 peaks
for which at least one bp is located within a -250 to +250 bp window of an annotated TSS (TSS PROX
category).
So far, I have shown that the THAP11 p.F80L mutation induces a selective THAP11 DNA dissociation at
genomic sites for which THAP11 has a lower apparent affinity. This selective modification of THAP11 DNA-
binding pattern thus likely affects gene transcription as both WT and mutant THAP11 proteins are associated
with TSSs. Indeed, it has been previously shown that fibroblasts from the THAP11F80L/F80L patient exhibit
a different transcriptome compared to fibroblasts from healthy patients. We thus analyzed the genes for which
THAP11 promoter binding has been altered by the p.F80L mutation. For each THAP11 TSS-associated peak
as defined above, scores were calculated by normalizing the tag counts in the ChIP sample by the tag counts
in the input sample and the peak width. When the peak is present in both replicates — which is the case for
most of the peaks — the mean score between the two replicates is considered. The dot plot in Figure 8.12
shows the distribution of TSS-associated common (dark-red dots) and WT-specific (light-red dots) peaks
according to their WT score (X axis) and the fold change between the WT and THAP11F80L/F80L samples
(Y axis, a positive fold change meaning that the score is higher in the WT sample compared to the mutant
one).
This plot revealed an impressive segregation between common (dark-red dots) and WT-specific (light-red
dots) peaks. First, the red cloud of WT-specific peaks is above the dark-red one of the common peaks. This
confirms the previously-made segregation of peaks between the common and WT-specific categories: the
WT-specific peaks are the ones present in the WT sample but disappearing in the mutant one, thus logically
have an higher fold change between the two samples. Not surprinsingly, the two distributions are not exactly
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Figure 8.10: Genomic-distribution chart of THAP11 DNA association in WT and
THAP11F80L/F80L cells. The proportion and number of peaks in each of the genomic category are dis-
played for WT (A) and THAP11F80L/F80L cells (B). TSS PROX, peaks for which at least one bp is located
within a -250 to +250 bp window of an annotated TSS; TSS DIST, peaks which at least one bp is located
within a -1 to +1 kp window of an annotated TSS, but not included in the TSS PROX category; intergenic,
peaks found in repeats and between genes; intragenic, peaks found in exons and introns.
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Figure 8.11: THAP11 occupancy around transcription start sites in WT and THAP11F80L/F80L
cells. Composite plot showing the THAP11 occupancy (Y axis) in a +/- 1kb window around TSSs for each
WT (A) and THAP11F80L/F80L cells (B). Only peaks categorized as TSS PROX were considered (+/- 250
bp window). Dashed-grey line, TSS position; solid-purple line, average position of peaks.
on the top of each other horizontally fashion, but rather diagonally, as the fold change increases with the WT
score. Of note, the dot labelled as (a) represents a peak categorized in the common category, but bearing
a log2 fold-change of 2.5. It may thus seem mislabelled. It has, however, a very low WT score, suggesting
that it may be simply background. Indeed, the peak comes from the repeated RNA5S genes genomic region,
in which input and IP samples diplay the same signal strength. In addition, WT and THAP11F80L/F80L
samples are similar at this genomic region. Consequently, this peak is not mislabelled, it is simply not a real
peak and has been identified as such due to the nature of its associated genomic sequence.
Second, the dot plot shows that the peaks in the dark-red cloud (common peaks) are shifted to the right of
the plot, thus have overall higher WT scores than the light-red cloud ones (WT-specific peaks). This is even
better shown by the distribution of WT scores for each peak category, displayed in Figure 8.13. This means
that the peaks that remain bound by the THAP11F80L mutant protein are the ones with a higher score, thus
the strongest peaks. It nicely fits the model that I am so far elaborating in which the THAP11F80L mutant
protein remains only bound to the genomic sites for which it has the higher affinity.
Interestingly, the top hit regarding the fold change (labelled as (b) on 8.12) is the peak associated to
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Figure 8.12: Distribution of peaks according to their score in the WT sample and the fold change
between the WT and THAP11F80L/F80L sample scores. Each dot represents a peak colored according
to its category: dark-red dots, common peaks; light red dots: WT-specific peaks. The X axis represents
the score of the peak in the WT sample (the mean between the two replicates, if applicable). The Y axis
represents the fold change between the WT and THAP11F80L/F80L samples, meaning the difference between
the respective (log2) scores. Specific peaks of interest discussed in the text are labelled with letters.
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Figure 8.13: Distribution of WT scores for each peak category.
the DPF1 gene. Its associated protein is a neurospecific transcription factor essential for proper neuronal
development. It belongs to the nBAF neuron-specific chromatin remodeling complex which regulates the
transition from proliferating neural progenitors to differentiated neurons [128]. It is particularly intringuing
as the cobalamin disorder is associated with neurodevelopmental abnormalities. Furthermore, the MMACHC
gene promoter is among the top peak hits with the higher fold change between the WT and mutant samples
(Figure 8.12, peak labelled as (c)). Indeed, THAP11 DNA binding is completely lost upon the THAP11
p.F80L mutation, as seen in Figure 8.6 A. Thus, MMACHC gene expression is likely to be affected by the
loss of THAP11 binding. More generally, the selective modification of THAP11 promoter-binding pattern is
thus likely to affect the expression of various genes.
8.2.4 Overview of differential gene expression due to the THAP11F80L mutation
We then submitted the WT and mutant cells to a large-scale transcriptomic analysis by RNA extraction and
sequencing to analyze the change in gene expression due to the THAP11 p.F80L mutation. Thanks to the ease
of the RNAseq procedure, we performed, as for the proliferation assays, the experiment at both 37 ◦C and
39.5 ◦C, for the WT and both the homozygous THAP11F80L/F80L and the heterozygous THAP11F80L/+ cell
lines. Indeed, I previously showed that the heterozygous cells exhibit an intermediate behavior between the
WT and the homozygous mutant cells, and thus it is interesting to examine these cells in parallel. Also, even
if there is no temperature-specific effect in the proliferation impairment, I still demonstrated that increasing
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the temperature reinforces the proliferation phenotype, and thus may facilitate the interpretation of the
results. Cells were grown for 3 days in duplicate for each condition, either at 37 ◦C, or at 39.5 ◦C for the
two last days. RNA was extracted and subsequently sequenced to probe the whole transcriptomic changes
between the WT and the mutant cells.
As done previously, Dr. Viviane Praz summarized the normalized data using a PCA, as shown in Figure
8.14. First, there is a general temperature effect. Indeed, each cell line is displaced in the same direction
(and magnitude) by the increase of temperature. Again, no temperature-specific effect was observed for the
mutation. This PCA plot also discriminates the samples by their genotype. Curiously, the heterozygous
mutation implies a deplacement similar to the temperature shift. In contrast, the homozygous mutation
displaces the samples on the PCA in a perpendicular direction of the PCA plot. This demonstrates that the
heterozygous THAP11F80L/+ cells are more similar to the WT cells, compared to the homozygous mutant
ones.
Then, Dr. Viviane Praz performed several differential analyses on the RNA-seq data, to understand which
genes are differentially expressed between the different samples. Here, only data from cells grown at 37 ◦C
were used as I have just shown that there is no temperature-specific effect. For each comparison, she
subsequently submitted the list of upregulated and downregulated genes for a Gene Ontology (GO) analysis.
In the homozygous THAP11F80L/F80L cells, 346 genes were upregulated and 669 downregulated, compared
to the WT cells. When sujected to GO analysis, upregulated genes in the homozygous mutant cells reveal
pathways largely related to transcription, DNA binding and chromatin (Supplemental Table S9, orange dots),
and a pathway related to neuronal development (dendritic spine development, purple dot). In addition,
genes downregulated in the homozygous mutant cells are associated to mitochondria (Supplemental Table
S10, green dots), and also reveal transcription and development-associated GO terms (orange and purple
dots, respectively). Conversely, many fewer genes were differentially expressed when THAP11 is mutated
in an heterozygous fashion: only 171 genes were upregulated and 142 downregulated, in the heterozygous
mutant cells compared to the WT ones. When these lists of differentially expressed genes were submitted
for GO analysis, no particular pathway stood out for genes upregulated in the heterozygous mutant cells
(Supplemental Tables S11), while some development and proliferation-associated GO terms are revealed
by downregulated genes (S12, purple and blue dots, respectively). Interestingly, the comparison of the
homozygous THAP11F80L/F80L cells with the heterozygous ones leads to results similar to the comparison
with the WT cells. Indeed, 479 genes were upregulated and 925 downregulated, in the homozygous mutant
cells compared to the heterozygous THAP11F80L/+ cells. GO analysis revealed, as for the comparison
with the WT cells, pathways related to transcription (upregulated genes, orange dots) and to development
(downregulated genes, purple dots) as well as association with mitochondria (downregulated genes, green
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Figure 8.14: Principal component analysis of RNA-seq data from WT, THAP11F80L/F80L and
THAP11F80L/+ cell lines. PCA1 and 2 resulting from RNA-seq data of WT (red), THAP11F80L/F80L
(homozygous, blue) and THAP11F80L/+ (heterozygous, purple) cells, cultivated for 3 days at 37 ◦C or for
1 day at 37 ◦C and the 2 following days at 39.5 ◦C. The triangles and squares represent the mean of the
2 technical replicates with the dashed-line circle representing the standard error. Triangles represent cells
grown at 37 ◦C while diamonds represent cells grown at 39.5 ◦C.
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dots) (Supplemental Tables S13 and S14, respectively). The two latter comparisons between the homozygous
and heterozygous clones confirm again the fact that the heterozygous THAP11F80L/+ cells are more similar
to WT cells than to homozygous mutant cells, as was already seen in the proliferation assays (at least at
37 ◦C) and with the PCA plot.
I looked closer at the top differentially expressed genes (in terms of p value) between the WT and the
homozygous THAP11F80L/F80L cells at 37 ◦C (Figure 8.15). The first hit is HIST1H1D, which encodes
for the linker histone H1.3 involved in the condensation of chromatin into higher-order structures. Second
and third are the TMOD2 (tropomodulin 2) and the MMACHC genes, respectively. Indeed, HIST1H1D is
more than 10-time less expressed, TMOD2 is completely absent (almost 6-time lower), and MMACHC is
more than 4-times less expressed in the homozygous mutant cells compared to the WT cells (Figure 8.15 A,
compare the solid blue and red bars; please note that the data are expressed in log2 of normalized expression
values, so a change of 1 unit means a 2-fold change in the expression of the gene). As mentioned above,
THAP11 DNA binding is lost upon p.F80L mutation at the MMACHC promoter (Figure 8.6). Similarly,
the THAP11F80L mutant protein also dissociates from the TMOD2 promoter in the homozygous mutant
cells (Figure 8.15 B and Figure 8.12, peak labelled as (d)). Thus, the selective dissociation of THAP11
from a subset of promoters due to the mutation results in a severe impairment in the expression of the
corresponding genes. In contrast, no THAP11 occupancy was observed at the HIST1H1D promoter. While
a portion of affected genes are likely to be primary targets of THAP11 affected by the mutation, others
may conversely represent downstream effectors. Also, the mRNA levels of the three top hits are similar
in cells grown at 37 ◦C and 39.5 ◦C (Figure 8.15, compare solid and hatched bars). This suggests again
that there is no temperature-specific effect on these cells: the increase of temperature does not reinforce the
disease mechanism, but rather adds an unrelated constraint to the cells. It thereby explains the behavior
of homozygous THAP11F80L/F80L cells at elevated temperature that we have seen both on proliferation
assays and on the previous PCA plot. Interestingly, heterozygous cells exhibit similar expression levels of
these three genes at both temperatures (solid and hatched-purple bars). It thereby suggests once again that
the heterozygous cells are not much affected by the heterozygous presence of the mutation. Furthermore,
Quintana and colleagues have also previously demonstrated that both TMOD2 and MMACHC mRNA
levels are dramatically reduced in THAP11F80L/F80L patient-derived fibroblasts compared to healthy-patients
fibroblasts [75]. As in their study, we did not identify any genes involved in cobalamin metabolism other than
MMACHC, being differentially expressed between the HEK-293 WT and homozygous THAP11F80L/F80L
cells. Thus, the dysregulation of MMACHC gene expression resulting from the loss of promoter binding
is likely to account for a sizeable part of the disease phenotype, which is tightly linked to the cobalamin
pathway.
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Figure 8.15: Top-three differentially expressed genes between WT and THAP11F80L/F80L mutant
cells. The genes differentially expressed between the WT cells and THAP11F80L/F80L mutant cells were
ranked by their p value and the top three genes were selected. (A) Normalized log2(RPKM) expression values
of the three top gene hits, in WT, THAP11F80L/F80L and THAP11F80L/+ cells, at both temperatures, shown
as the mean +/- standard deviation of the two technical replicates. (B) Visualization of THAP11 occupancy
at the TMOD2 promoter in WT cells and THAP11F80L/F80L mutant cells using the UCSC genome browser,
all tracks being set with the same vertical viewing range (1 to 600).
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To summarize, the results presented here support the idea that the THAP11 p.F80L mutation leads to a
loss of THAP11 binding to specific promoters, which in turn alters the expression of the corresponding genes
and subsequent downstream targets.
8.2.5 Its THAP11 gene expression affected by the p.F80L mutation?
I previously demonstrated that the level of THAP11 protein is diminished in THAP11F80L/F80L cells com-
pared to WT cells (see Chapter 6). Thus, I wondered whether this would be the result of a decrease of
THAP11 gene transcription. Indeed, one could imagine that the WT THAP11 protein may regulate the
expression of its own gene, and that the p.F80L mutation could disrupt its binding to its own promoter,
leading to an impaired THAP11 gene expression. The RNA-seq and ChIP-seq experiments described above
allow to test this hypothesis.
As shown on Figure 8.16 A, THAP11 protein is indeed bound to its own promoter. In addition, there
are two very strong TAMs under this peak, which are likely to be responsible for THAP11 recruitement
(black triangles). THAP11 thus has the potential to regulate the expression of its own gene. The mutant
THAP11F80L protein, however, still binds the THAP11 promoter, even though the peak is slightly lower
in the THAP11F80L/F80L sample compared to the WT one (Figure 8.16 A, and peak labelled (e) in Figure
8.12). In addition, THAP11 gene expression is not affected by the THAP11 p.F80L mutation, as seen by
the similar mRNA levels in the WT and mutant cells (Figure 8.16 B).
To summarize, although THAP11 has the potential to regulate the expression of its own, the THAP11
p.F80L mutation does not affect THAP11 gene expression. Consequently, the diminished level of mutant
THAP11 protein in the THAP11F80L/F80L cells is not due to a decrease in THAP11 mRNA levels.
8.3 Discussion
In this chapter, I discussed high-throughput analyses performed to understand how THAP11 controls gene
transcription and cell proliferation. I was very lucky to benefit from help for these analyses, both on the
experimental side and on the computational side.
First, we compared gene expression between parental cells and stable cells expressing an ectopic THAP11
protein, either WT or HBM mutant. In agreement with previous studies [29, 39, 54, 68–77], we revealed
that THAP11 is involved in gene transcription, development and cell proliferation. For instance, heart
development is a developmental pathway that particularly stands out in our GO analysis, and Fujita and
colleagues have suggested that Ronin (the mouse Thap11) governs early heart development [71]. In addition,
THAP11 is associated with genes involved in mitochondrial function, which is in agreement with a previous
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Figure 8.16: THAP11 binding to its own promoter and effect of the THAP11F80L mutation.
(A) Visualization of THAP11 recruitment to its own promoter, in WT and THAP11F80L/F80L mutant cells,
using the UCSC genome browser, all tracks being set with the same vertical viewing range (1 to 600). The
two black triangles represent the two strong TAMs. (B) Normalized log2(RPKM) expression values of the
THAP11 gene, in WT and THAP11F80L/+ mutant cells, shown as the mean +/- standard deviation of the
two technical replicates.
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study showing that Ronin is essential for mitochondrial function in the developing retina [74]. Interestingly,
we showed that THAP11 functions are HBM dependent, as mutation of the HBM sequence in the ectopic
THAP11 construct severely attenuates the gene expression changes implied by THAP11 ectopic synthesis.
This is also in accordance with previous publications [29,39,43,54,70,71,75].
Probing the gene-expression changes between WT and THAP11F80L/F80L mutant cells also revealed
an association to mitochondria, and pathways linked to transcription and development. Thus, the two
experiments, ectopically expressing or mutating THAP11, respectively, are in agreement by revealing the
same regulated pathways. Not surprisingly, the effect in the THAP11F80L/F80L mutant cells is milder and
pathways are less standing out compared to the ectopic-synthesis experiment. Indeed, this is expected because
the mutation has a more subtle effect than the forced expression, as it affects only a subset of THAP11-bound
promoters. Notably, proliferation-associated pathways do not stand out in the GO analyses of mutant cells,
while showing up in the stable-cell experiments and that proliferation assays demontrated a strong impact of
the mutation on cell proliferation (Chapter 7). In addition, the direction of gene-expression changes in the
two set ups are the same: upregulated genes in the stable or mutant cells point towards transcription and
development, while downregulated genes point towards mitochondria, when compared to the WT or parental
cells. This observation meets with the proliferation experiments in which THAP11 ectopic synthesis had a
similar impact on cell proliferation than the p.F80L mutation (Chapter 7). This strenghtens the previous
hypothesis which suggested that THAP11 increased level has a dominant-negative effect.
As mentioned, both THAP11 stable and mutant cells revealed GO cellular components associated to
mitochondria. This is particularly interesting as the cobalamin disorders have been associated with alteration
of mitochondria [129,130]. Also, cells bearing different HCF-1 cblX -causing mutations exhibit a morphological
change of their mitochondria (Laura Sposito, personal communication).
Second, I focused on the human THAP11 cblX -associated mutation and we performed a genome-wide
analysis of THAP11 DNA association, in both WT and THAP11F80L/F80L cells. It revealed a selective
dissociation of the mutant THAP11 protein from a subset of DNA sites. On the other hand, the THAP11
p.F80L mutation does not enable THAP11 to bind additional promoters compared to the WT protein. We
thus investigated the reason behind the selective DNA dissociation, meaning the difference between the
DNA locations that remain bound by the mutant protein, compared to the ones that are still bound despite
the mutation. While both categories of peaks reveal the same underlying motif — referred as THAP11-
associated motif (TAM) — it is stronger for the peaks that remain bound despite the THAP11 p.F80L
mutation compared to the ones that disappear. Also, most of peaks still present in THAP11F80L/F80L
cells have at least an underlying TAM, and they exhibit a high score in the WT sample. By contrast, the
disappearing peaks have lower WT scores, and only half of them have a TAM. These conclusions led me to
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build the following model: upon p.F80L mutation, THAP11 protein selectively dissociates from its weakest
DNA sites, which are the ones that have a weaker, if any, TAM. This results in a selective dissociation of
THAP11 from specific promoters, the associated genes likely being affected.
Indeed, a transcriptomic analysis comparing the gene expression profiles of WT and THAP11F80L/F80L
cells revealed, as already mentioned, differentially expressed genes associated with transcription and mito-
chondria. The third most affected gene is actually MMACHC, the associated protein being a key enzyme in
the cobalamin pathway. Most of cobalamin-disorder forms are due to mutations in the MMACHC gene. It
has already been suggested that THAP11, together with HCF-1, regulates MMACHC transcription [75]. I
have demonstrated here that the mutant THAP11F80L protein dissociates from the MMACHC promoter, re-
sulting in a marked decrease in gene transcription. This specific change in DNA binding and subsequent gene
transcription is likely to be responsible of a large part of the mutation pathogenicity. It is thus not surprising
that THAP11 and HCF-1 mutations fall into the same group of cobalamin disorders. As it has been suggested
that they would inter-dependently regulate MMACHC expression, the dissociation of any of the two from
the MMACHC promoter would result in a similar phenotype, accounting mainly for the dramatic decrease
in MMACHC gene expression. Nevertheless, I suspect that other affected genes — primarily downstream
targets — also play a role in the pathogenicity and the specificity of the cblX cobalamin-disorder type. For
instance, the cblX group of cobalamin-disorder is distinct from cblC one, which is due to mutations in the
MMACHC gene. Biochemical characteristics of cblC and cblX are similar, though milder in cblX patients,
but the two disorders are clinically distinct, cblX exhibiting a more severe neurologic phenotype [126].
The gene ontology analyses did not identify any cobalamin-related pathway. This is actually expected:
even though MMACHC dysregulation is likely to account for the majority of the mutation pathogenicity, it
is the sole cobalamin-related gene affected by the mutation. The MMACHC protein is an enzyme and thus
will not have any downstream transcriptional effect. Thus, it is not surprising that the cobalamin pathway
was not identified by the ontology analyses as it concerns a single gene. Curiously, however, GO analyses
revealed the KEGG pathway associated to lupus (systemic lupus erythematosus), which is an auto-immune
disease. The putative association between lupus and THAP11 is thus worth being investigated, as the cause
of this disease remains unknown, the cure non-existant and the treatments not very effective.
Third, I also investigated whether the THAP11 p.F80L mutation affects the expression of its own gene.
I showed that THAP11 has the potential to regulate THAP11 gene expression because it binds its own
promoter. This binding is not greatly affected in the presence of the p.F80L mutation. Also, in agreement with
what has been published [75], I showed that THAP11 gene expression is not affected in THAP11F80L/F80L
mutant cells. Thus, the decreased level of THAP11 mutant protein observed in the THAP11F80L/F80L cells
(Figure 6.9) in not a consequence of a lack of THAP11-promoter self recruitement and subsequent decrease
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in gene expression. Alternatively, it can be due to a decrease in mRNA translation or to an increased
degradation of the mutant protein. As THAP11 p.F80L is suspected to affect the folding of its THAP
domain, a degradation mechanism is more likely responsible for the lower level of THAP11 mutant protein.
Fourth, the analysis of the heterozygous THAP11F80L/+ mutant cells is contradictory with the prolif-
eration results (Chapter 7). Indeed, I showed that despite a small delay in cell proliferation at specific
time points, heterozygous cells grown at 37 ◦C end up behaving similarly to WT cells. On the other hand,
when grown at 39.5 ◦C, heterozygous cells display a sizeable impairment in cell proliferation. Transcrip-
tomic analyses demonstrated that, overall, these cells have a transcriptome more similar to WT cells than
to homozygous mutant cells, both at 37 ◦C and at 39.5 ◦C. Particularly, they do not exhibit any change in
MMACHC expression. The discrepancy may come from the fact that RNA was extracted from cells only
2 days after the temperature switch. Indeed, when looking at Figure 7.7, the impairment of cell prolifer-
ation in heterozygous THAP11F80L/+ mutant cells compared to WT ones observed at day 3 (2 days post
temperature switch), when grown at 39.5 ◦C, is less pronounced that at the end time points. Thus, an
hypothesis is that, at 39.5 ◦C, heterozygous cells are initially able to compensate for the hemizygous loss of
the WT THAP11 protein, but eventually fail to compensate and exhibit defects. To probe this hypothesis,
it would be interesting to repeat the transcriptomic analyses at later times after the temperature switch. It
is unlikely, however, that the compensation would be mediated by THAP11 auto-regulation to increase the
expression of its own gene, as RNA-seq data of heterozygous cells show no variation in the THAP11 mRNA
levels in the heterozygous cells grown at 37 ◦C or 39.5 ◦C. Whatever the case, the heterozygous THAP11
p.F80L mutation does not causes any significant defect when grown at 37 ◦C. It would be interesting to know
whether the siblings of the THAP11F80L/F80L cblX -like patient are asymptomatic carriers of the mutation
in an heterozygous state. These data, however, are unavalaible as the parents of the patient declined any
genetic testing on themselves and their four other healthy children. Thus, it is not possible to know whether
the p.F80L mutation has appeared spontaneously, in an homozygous fashion, in the patient, or whether it
has been transmitted from the parents to their son. Due to the low likelihood of a spontaneous homozygous
mutation, it is more probable that the parents are heterozygous carriers of the mutation. This variant must
be extremely rare, as it was not found in public databases.
Overall, these results lead me to propose a model for the mechanism and pathogenicity of the THAP11
p.F80L mutation associated with cobalamin disorder. On a whole, I suggest that the effects of the THAP11
p.F80L mutation are not due to a change in THAP11 DNA-binding ability, but rather simply due to a
decrease level of the protein, which then becomes a limiting factor. I propose that, upon mutation, the
resulting THAP11F80L protein is unstable — probably because of folding issues of the THAP domain —
leading to its increased degradation. As the protein level is much lower, it is limited for binding to DNA
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and probably in too small quantity to bind to all the promoter sites normally occupied by the WT protein.
Consequently, the limited amount of THAP11F80L mutant protein will preferentially bind to the DNA sites
for which it has the strongest affinity, which are the ones that display at least one underlying TAM and
the strongest one. Then, a subset of THAP11-regulated genes is lacking the THAP11-promoter binding
and are thus misregulated. Among them, MMACHC is strongly downregulated in the mutant cells, which
probably accounts for a large part of the pathogenicity. As HCF-1 and THAP11 co-regulate MMACHC gene
expression, it is thus not surprising that mutations in both protein resulting in DNA-binding impairments
lead to extremely similar diseases that are classified together (cblX ). Other misregulated genes are likely to
also play some role in the disease pathogenicity and to account for the specificity of the cblX disease group.
Thus, a decrease in THAP11 protein level such as the one observed in THAP11F80L/F80L cells has
dramatic consequences. Indeed, it induces broad changes in the transcriptional program. As already shown
in Figure 4.1, THAP11 is evenly expressed in the different human tissues. In addition, the Human Protein
Atlas [131] references that, despite differential levels of mRNA, THAP11 protein is present at similar levels in
the different human tissues. Thus, THAP11-mediated transcription in the different organs is likely to trigger
similar transcriptional programs. Particularly, it probably triggers MMACHC expression in all the tissues,
which is reassuring as the latter enzyme is necessary for cell metabolism.
It is important here to point out again that this analysis has been done on a single clone per cell type.
Thus, the results, even if they are in agreement with the disease pathogenicity and previous analysis of the
patients fibroblasts [75], will need to be confirmed with additional independent cell clones.
Future studies on THAP11F80L/F80L cells will work to correlate ChIP-seq and RNA-seq data to unravel
the primary gene targets, besides MMACHC, affected by the THAP11 p.F80L mutation. It would also clarify
downstream target genes and pathways. This will probably help to highlight the mechanisms underlying
the mutation pathogenicity, particularly the difference between the cblX and the cblC groups, and the
neurological involvement in the cblX type. Indeed, cobalamin-metabolism impairment causes neurological
disorders by itself, as vitamin B12 is particularly important for the normal functioning of the brain and the
nervous system. The cblX disease group, however, exhibit a more severe neurological trouble compared to
the cblC one caused by the sole MMACHC mutation, suggesting that additional neurological mechanisms
take place in the THAP11F80L/F80L patient and other cblX ones.
170
Chapter 9
Concluding thoughts
When starting my PhD work, I reviewed the literature regarding HCF-1, which is the main research topic
of the Herr laboratory. Doing so, I encountered the THAP11 protein presented as an important co-factor
for HCF-1. Digging into the subject, I realized that THAP11 belongs to a family of related proteins, some
of them having already been suggested to interact and collaborate with HCF-1 at the onset of my work.
First, I was extremely interested by these proteins and their interplay with HCF-1. While some of them were
largely understudied at that time, some have already been proved to bear exciting properties, such as their
transcriptional role in cell proliferation. Second, I rapidly realized that a global analysis of these different
proteins as a family, and not as separate entities, was lacking from the published reports. I thus felt that the
study of these proteins as an entire family may provide an interesting research opportunity. In particular,
studying a family of related factors enables me to compare and to contrast their respective properties. Third,
as their importance was still emerging, tools to study them were often lacking. Nevertheless, this last point
did not discourage me given my enthusiasm of studying this family of proteins. Thus, I decided to study
the THAP family of proteins and to try to understand how they regulate transcription and subsequently cell
proliferation.
Thanks to the power of bioinformatics, publicly-available bio-databases and recent state-of-the-art high-
throughput technologies, I was able to study in parallel all the different human THAP proteins, and to shed
light on their structure, their evolution among animals and their pattern of expression in mice and human
(Chapters 3 and 4). I showed that, despite sharing similarities such as their defining THAP domain, the
THAP proteins are also notably diverse regarding their sequence and structure. Also, examining human
and mouse gene expression revealed that each THAP gene has a specific expression pattern. Furthermore, I
demonstrated that the HBM sequence and coiled-coil domain in THAP proteins are under positive selective
pressure, indicating the importance of their interaction with HCF-1 and with themselves. Subsequently,
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biochemistry analysis of selected THAP proteins (Chapter 5) showed that each of them possesses differing
capacities for self binding — homo- and heterodimerization — and for interaction with HCF-1. These
various results led to the conclusion that the different THAP proteins display similarities and differences,
which can lead to both shared and specialized partners, functions and outcomes. At a certain point in my
research, I realized that my analysis was limited by the available experimental tools, such as antibodies or
engineered cells. While the generation of an antibody directed to the THAP7 protein was not successful, I
managed to engineer several custom cell lines — with site-specific genomic mutations or stably transfected
— to study further the two THAP7 and THAP11 proteins (Chapter 6). The phenotypic study of these
different cell lines demonstrated that both THAP7 and THAP11 are required for proper cell proliferation
(Chapter 7). Finally, I worked further on THAP11 and showed that it associates with DNA to regulate
genes involved in development, cell proliferation and transcription (Chapter 8). Doing so, I also clarified
the molecular mechanisms underlying the THAP11 cobalamin disorder-associated mutation. I proposed a
model in which the THAP11 p.F80L mutation induces the destabilization of the THAP11 protein leading to
its subsequent degradation. This results in a pronounced decrease of THAP11 protein level, THAP11 then
probably becoming a limiting factor for DNA binding. I thus further hypothesize that THAP becomes limiting
for binding to gene promoters and consequently associates with DNA sites for which it has the highest affinity,
causing a selective dissociation of the mutant THAP11 protein from a subset of promoter sites, leading to
a misregulation of the corresponding genes. The MMACHC gene being the sole misregulated gene linked
to the cobalamin pathway, it likely accounts for a large part of the mutation pathogenicity (Chapter 8).
In summary, the results presented in this thesis implicate the THAP transcriptional factors as important
regulators of development, and cell proliferation and metabolism that happen to be associated to a variety
of diseases.
I have already extensively discussed the described results at the end of each chapter and suggested many
follow-up research directions. Here, I rather illuminate some more general considerations related to my thesis
work. In particular, my thesis makes me dive into the field of human genetics, which was relatively new for
me. Subsequent to the completion of this work, I realize how powerful this field has become, notably thanks
to the development of state-of-the-art techniques in the past decade.
First, DNA sequencing has been a revolution in the field of human biology, but not exactly in the way
it was anticipated. Before the completion of the human-genome sequencing, people had tremendous hopes
on what it would bring. Particularly, it was often thought that the human genome would be quite easy to
read and that it would solve many things in and of itself, particularly diseases such as cancer. It became
rapidly clear, however, that knowing the sequence of the human genome was not going to give the magical
result. Indeed, the human genome is far more complex to decipher than anticipated and remains, even over
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15 years after the first completion of the Human Genome Project, in good part a mystery. Consequently,
people placing a lot of hope in the knowledge of the human-genome sequence were disappointed.
Nevertheless, the (near) completion of the human-genome sequence was a gigantic step forward in the
research in biology and medicine. It nevertheless provides the (near-complete) sequence of the human genome,
which, even if not as easy to read as initially expected, is a bottomless source of information and research.
In addition, it has been the starting point of the development of state-of-the-art high-throughput sequencing
technologies. The cost to sequence the human genome has been reduced by more that 2000-fold in a decade,
while the speed of sequencing increased considerably: it took almost 15 years to get the first sequence of the
human genome, while nowadays it is possible to fully sequence the genome of an individual within a day.
This revolution had enormous impacts on, among other fields, the identification, research and management
of rare genetic diseases. Indeed, the democratization of high-throughput sequencing techniques allowed to
understand disease genetics and this revolution has benefited most to the field of rare genetic diseases. The
identification of the genetic trait responsible for a particular disease not only allows to decipher the molecular
mechanisms but also has the potential to lead to its better clinical management. Furthermore, diseases are
an extremely valuable source of knowledge: they exhibit the malfunctions of the human body and thus
are a window onto how it works. Thus, integrating rare genetic diseases — which in an of themselves
are individually much more numerous than common ones — susbtantially enlarges the disease window and
provides many more opportunities to understand the human body.
Also, DNA sequencing has revolutionized the way of doing genetics as it does not only enable me to
study the genome of cells per se. Indeed, it also enables the study of the transcriptome (RNA-seq, thanks
to the reverse transcription of RNA into DNA). Furthermore, it allows the analysis of numerous aspects of
the chromatin, such as the proteins bound to it, directly or not (ChIP-seq and derived techniques, DNA ade-
nine methyltransferase identification DamID), its conformation and organization (chromosome-conformation
capture techniques(3C)-based methods or chromatin accessibility assays such as MNase-seq or DNase-seq) or
its composition (bisulfite sequencing for DNA methylation, modification-specific histone ChIPseq for histone
composition and modifications). Consequently, DNA sequencing is not only a poweful tool for genetic studies,
but also for epigenetics and gene-expression concerns.
Second, I used in my thesis research the state-of-the art CRISPR/Cas9 genome-editing technology. It
allowed me to create mutant cell lines, both functional mutants to decipher the mechanism of action of
my proteins of interest as well as disease-associated mutants. Here, I used a very simple application of
the CRISPR/Cas9 system, but it is much more powerful and can be used to create whole organisms with
the desired mutation. As a research point of view, this enables the recapitulation of a genetic disease in a
genetically homogenous context, having mutant samples (cells, tissues, animals) carrying the exact genetic
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modification as well as control (“healthy”) samples for comparison as opposed to “real life” where each patient
exhibits additional variability that is not linked to the disease. Thus, this technique is an incredibly powerful
research tool. Furthermore, in a therapeutic point of view, the CRISPR/Cas9 genome-editing technology has
the potential to precisely correct the genetic alteration responsible for a given genetic disease. CRISPR/Cas9-
mediated gene therapy is still at its infancy and different problems still need to be solved, such as accuracy
(off-target effects, raising safety issues), efficiency, and delivery methods [132, 133]. Nevertheless, this field
is rapidly progressing and an increasing number of pre-clinical and clinical gene-editing trials are currently
in progress [133]. Thus, one can have the optimistic hope that within a couple of decades, CRISPR/Cas9-
mediated gene therapy will allow the correction of the genetic cause underlying some diseases.
To conclude, I feel lucky to have been able to use these two incredibly powerful techniques that are DNA
sequencing and CRISPR/Cas9-mediated genome editing, and it taught me a lot. To finish with, I just want
to raise some considerations about the development of these amazing technologies, particularly ethically
speaking. Indeed, the development and democratization of these two techniques has raised important ethical
issues that researchers, politicians and even lay people are struggling with.
Regarding DNA sequencing, the possibility of sequencing, at low cost, the genome of any individual raises
questions about the use of these sequencing data. An example is the interpretations that can be inferred
with such data, for instance at the scale of a single individuals. Nowadays, more and more companies such as
23andMe R© or Pathway Genomics R© are bein established, providing a DNA-sequencing service to anybody
willing to pay for it, advertising the possibility to decipher the customer’s origins or his/her genetic features,
such as the explanation of his/her personality traits, or even the prediction of disease susceptibility. This last
service related to diseases is, in my opinion, the most problematic one as the information is released to the
customer without much background explanation, while the customer can be far from educated for properly
understanding such results. This can result in dramatic consequences for the customer and generating
aberrant behaviors, for example in the case he/she would understand that he/she would end up having
Alzheimer’s disease while his/her DNA simply contains alleles associated to an increased susceptibility to
develop this disease. In addition, this also raises the question of availability and privacy of such data.
Indeed, they could be for instance unfairly exploited by insurance companies (disease-associated data). Also,
pharaceutical companies nowadays pay a fortune to buy such bio-databases, such as what happened recently
(summer 2018) when 23andMe R© sold almost its entire set of data to the english pharmaceutical company
GSK (GlaxoSmithKline). I thus believe that DNA sequencing is an extremely valuable and powerful tool,
but its democratization now urgently requires the creation of regulations and ethical guidelines.
As far as the CRISPR/Cas9 technology, I would like to highlight that manipulation of the genome,
particularly the human one, is not without facing ethical issues. Indeed, mad scientists could envision to
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not only repair the genome in case of genetic disorders, but also to “improve” it. Thus, the extent and
circumstances to which the genome can be manipulated urgently needs to be defined by ethical advisory
commitees.
As a conclusion, I have shared in these few pages my amazement regarding the revolution that has
transformed (and is still transforming) the field of human genetics, and also my personal feeling that ethical
guidelines as well as regulations are urgently needed.
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Appendix
Supplemental Table S1: GO terms associated with upregulated genes in the Flp-In
TM
T-Rex
TM
THAP11WT cells compared to parental cells (DMSO treatment). GO terms related to development,
proliferation and transcription are highlighted by purple, blue and orange dots, respectively.
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Supplemental Table S2: GO terms associated with downregulated genes in the Flp-In
TM
T-Rex
TM
THAP11WT cells compared to parental cells (DMSO treatment). GO terms related to mitochondria
are highlighted by green dots.
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Supplemental Table S3: GO terms associated with upregulated genes in the Flp-In
TM
T-Rex
TM
THAP11WT cells compared to parental cells (doxycycline treatment). GO terms related to devel-
opment, proliferation and transcription are highlighted by purple, blue and orange dots, respectively.
180
Supplemental Table S4: GO terms associated with downregulated genes in the Flp-In
TM
T-Rex
TM
THAP11WT cells compared to parental cells (doxycycline treatment). GO terms related to mito-
chondria are highlighted by green dots.
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Supplemental Table S5: GO terms associated with differentially expressed genes between DMSO
and doxycycline treatment of Flp-In
TM
T-Rex
TM
THAP11WT cells. Genes upregulated (A) and
downregulated (B) in the Flp-In
TM
T-Rex
TM
THAP11WT cells treated with doxycycline compared to treated
with DMSO were submitted to Gene Ontology analysis.
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Supplemental Table S6: GO terms associated with differentially expressed genes in the Flp-In
TM
T-Rex
TM
THAP11HBM cells compared to parental cells (DMSO treatment). Genes upregulated
(A) and downregulated (B) in the Flp-In
TM
T-Rex
TM
THAP11HBM cells compared to parental cells (DMSO
treatment) were submitted to Gene Ontology analysis.
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Supplemental Table S7: GO terms associated with upregulated genes in the Flp-In
TM
T-Rex
TM
THAP11WT cells compared to Flp-In
TM
T-Rex
TM
THAP11HBM cells (DMSO treatment). GO
terms related to development, proliferation and transcription are highlighted by purple, blue and orange dots,
respectively.
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Supplemental Table S8: GO terms associated with downregulated genes in the Flp-In
TM
T-Rex
TM
THAP11WT cells compared to Flp-In
TM
T-Rex
TM
THAP11HMB cells (DMSO treatment). GO
terms related to mitochondria are highlighted by green dots.
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Supplemental Table S9: GO terms associated with upregulated genes in the THAP11F80L/F80L (ho-
moyzygous) cells compared to WT cells (37 ◦C). GO terms related to development and transcription
are highlighted by purple and orange dots, respectively.
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Supplemental Table S10: GO terms associated with downregulated genes in the THAP11F80L/F80L
(homozygous) cells compared to WT cells (37 ◦C). GO terms related to development, transcription
and mitochondria are highlighted by purple, orange and green dots, respectively.
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Supplemental Table S11: GO terms associated with upregulated genes in the THAP11F80L/+
(heterozygous) cells compared to WT cells (37 ◦C).
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Supplemental Table S12: GO terms associated with downregulated genes in the THAP11F80L/+
(heterozygous) cells compared to WT cells (37 ◦C). GO terms related to development and proliferation
are highlighted by purple and blue dots, respectively.
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Supplemental Table S13: GO terms associated with upregulated genes in the THAP11F80L/F80L
(homozygous) cells compared to THAP11F80L/+ (heterozygous) cells (37 ◦C). GO terms related
to transcription are highlighted by orange dots.
190
Supplemental Table S14: GO terms associated with downregulated genes in THAP11F80L/F80L
(homozygous) cells compared to THAP11F80L/+ (heterozygous) cells (37 ◦C). GO terms related
to development and mitochondria are highlighted by purple and green dots, respectively.
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